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INTRODUCTION 
ÁÕó¦¾É §Åñ¼¡Å¡õ Â¡ì¨¸ìÌ «Õó¾¢ÂÐ 
   «üÈÐ §À¡üÈ¢ Ô½¢ý. 
-ÌÈû. 
  
Siddha system of medicine is a traditional medicine of Tamilians. It is one of the 
most antiquated traditional medicine in the world. Siddha system was first described by 
lord Shiva to his wife Parvathi. She explore all these knowledge to her son lord Muruga. 
He taught all these knowledge to his disciple sage Agathiyar in Tamil language, so only 
lord Muruga is called as Thamizh Kadavul (God of Tamils). 
Siddhars were saints, doctors, alchemists and mysticists all at once. They wrote 
their findings, in the form of poems in Tamil language, on palm leaves. Sage Agathiyar is 
considered the guru of all Siddhars. He is the first Siddhar. His disciples and other 
siddhars contributed thousands of texts on Siddha literatures, including medicine and 
form the profounder of the system in this world. He is considered as the father of Tamil 
literature and compiled the first Tamil grammar called Agathiyam. It is believed that he 
has lived in the 6th or 7th century B.C and specialized in language, alchemy, medicine 
and spirituality (Yogam and Gnanam).  
Siddha is the science of life. According to Siddha philosophy the universe around 
us is the Macrocosm (Andam) and the human body is considered as the Microcosm 
(Pindam). Any change in the macrocosm will have its impact in the Microcosm i.e human 
body. Both are formed by the basic of five elements called as Pancha Boothangal 
(Panchabootha theory) i.e: Ahayam (Ether), Kattru (Air), Thee (fire), Neer (Water) and 
Nilam (Earth). These five elements combine to form the three Thathus (Vatha, Pitha, 
Kaba), the balance of which is very essential for the healthy life. 
This holistic ancient science has two objects, viz. to maintain the health of healthy 
person, and to treat the sick person. The diseases evolving recently in the modern system 
of medicine (Allopathy) have already been dealt by our tamil inventors, the great 
Siddhar’s. Many millennium backs one such clinical entity is “Mathumegam” which is 
described by “Yoogi Vaithiya chinthamani-800”. According to Siddha Maruthuvam 
Pothu the synonyms of Mathumegam are Neerizhivu, Enippu neer. 
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“Tamilians who know about its prominent manifestation of “persistent polyuria” 
named the disease Megam, Mathu means “honey” (sweetness)”.  
The term Mathumegam is indicating the idea of sweet substance similar to honey 
in reset of taste, odor, and color not in concentration, which is secrete profusely through 
the urinary system. 
Diabetes mellitus is recognized as one of the oldest known disease. Historical 
accounts revel that as early as 700-200 BC. Diabetes mellitus was a well-recognized 
disease in India. In modern science, Mathumegam is co-relating with Diabetes mellitus. 
Yoogimuni used the term “Mathumegam” for Diabetes mellitus. Yoogimuni, author of 
Yoogi Vaithiya Chinthamani-800 has described the signs and symptoms of Mathumegam 
as “Gunam and Avathaigal". They are may be correlated to sign and symptoms of 
Diabetes mellitus. 
Diabetes Mellitus is a heterogeneous group of metabolic disorder of multiple 
etiologies characterized by chronic hyperglycemia with the disturbance of carbohydrate, 
protein and fat metabolism resulting from defects in insulin secretion, action or both. 
Type 2 Diabetes is one of the major health problems all over the world. According to 
WHO recent estimates indicate there were 171 million people in the world with diabetes 
in the year 2000 and this is projected to increase to 366 million by 2030. There were 32 
million people with Diabetes in India in 2000, which is projected to rise to 80 million by 
the year 2030. Increase in prevalence is rapid in urban areas from 2% in 1970s to 12% in 
2000 and as well in rural areas. 
Diabetes mellitus is one of the cardinal problems in the medical profession 
because it cannot be cure but some extent controlled. Present days oral anti-diabetic drugs 
have prominent side effects like hypoglycemia at higher doses, liver problems, diarrhea 
etc. It is important that efforts are made to develop more efficacious agents with lesser 
side effects. 
The role of medicinal plants in ameliorating the problem of Diabetes is 
noteworthy because of their low cost, quick positive response and being safe on the body 
without apparent side effects. Therefore, investigations of these herbal agents for anti-
diabetic activity are an important area of research. 
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In Siddha system of medicine, various herbal, herbo-mineral and minerals are 
using popularly and very effectively in the treatment of Mathumegam with different 
disease conditions. Hunting of the Siddha treasures may give valuable information about 
prevention for the disease, as well as treatment of the disease. This system had got 
advantage over other medicines in many respects. It aims at treating the patient and the 
other system aims at treating the disease. 
. 
This study brings out the therapeutic efficacy of siddha polyherbal formulation 
Atthippattaiyathi   kasayam in the treatment of Mathumegam (type-2 Diabetes Mellitus) 
and to create awareness about the disease, its complications and managements. 
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AIM AND OBJECTIVE 
AIM 
The Purpose of this study is to evaluate the therapeutic efficacy of the Siddha   
polyherbal formulation ATTHIPPATTAIYATHI KASAYAM in the treatment of 
MATHUMEGAM as an open clinical trial. 
 
OBJECTIVES 
Primary objective: 
To evaluate the safety of the Siddha polyherbal formulation Atthippattaiyathi 
kasayam in the treatment of Mathumegam 
 
Secondary objective:   
1. To Botanical identification and authentication of the trial drug. 
2. To prepare the trial drug Atthippattaiyathi kasayam as per Siddha literature 
and analysis of qualitative and quantitative constituents present in the trial 
drug. 
3. To establish the toxicological profile by performing acute oral toxicity studies 
and sub acute toxicity studies on mice and rats following WHO guidelines. 
4. To Study the Safety and efficacy of the test drug through an open clinical trial. 
5. To analyze the prevalence of Mathumegam among the society through Age, 
Sex, Occupation, Distribution etc. 
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SIDDHA ASPECTS 
In siddha system of medicine diseases classified as 4448 types. According to 
Yoogi Vaithiya Chinthamani Meganoi is classified into 20 types, Mathumegam one 
among them under pitha type. 
¾ñ¨ÁÂ¡öî ºÄó¾¡Ûõ ÀÍôÒ Áïºû 
¾¡É¢ÈíÌ À£ºÓí§¸¡ ºÓí¸ ÎìÌõ 
«ñ¨ÁÂ¡ÂÊì ¸ÊìÌ ¿£Ã¢ÈíÌõ 
«Êì¸ÊìÌ «¨Ã¿¡Æ¢ ¾É¢§Ä ¸¡Ïõ 
¦Åñ¨ÁÂ¡ ÂÊ¾É¢ø ¾¡ý À¢ÊìÌõ 
Á¢ì¸¡É º¼õ¦ÅÙòÐ §ÁÉ¢ ¸ñÏõ 
Àñ¨ÁÂ¡öô ÀïºÅ¡ñ ¼¾É¢ü ¦¸¡øÖõ 
À¸÷¸¢ýÈ ÁÐÁ¢Âò¾¢ý À¡íÌ ¾¡§É. 
-ä¸¢¨Åò¾¢Â º¢ó¾¡Á½¢ 
Definition: 
 “Mathumegam is a clinical condition characterized by frequent passage of urine 
more than the normal resulting in deterioration and diminution of Seven Thathus.  
ºÃ¢Â¡É §Á¸ò¾¡ ÄÀ¡É Å¡Ô 
¾¡ýÒ¨¸ìÌ §Á§ÄÈ¢ì ¸À¡Äî Ý¼¡õ 
¦ÀÃ¢¾¡É §Á¸ò¾¡ Äò¾¢ ¦ÅóÐ 
§À¡ÁôÀ¡ ¾¨º¦ÅóÐ Ãò¾õ ÅüÈ¢ô 
ÀÃ¢Å¡¸¢ò ¾ºÅ¡öÅ¡ø Áó¾í ¦¸¡ñÎ 
¦ÀÕó¾£É¢ ÁÄÀó¾õ ¯¾¡É Å¡Ô 
ÅÃ¢Å¡¸¢ò §¾¸¦ÁÄ¡õ Å¢¼ ¿£Ã¡§Ä 
¦ÁöÂÆ¢óÐ §Á¸¦ÁýÈ ¾¢ÕÀ ¾¡î§º 
      - º¢ò¾÷ ¿¡Êáø 
 
“Tamilians who know about its prominent manifestation of persistent polyuria 
named the disease Megam, Mathu means honey (sweetness)”. 
The term Mathumegam is indicating the idea of sweet substance similar to honey 
in reset of taste, odour and colour not in concentration, which is excrete profusely through 
the urinary system.  
Synonyms of Madhumegam 
According to Siddha Maruthuvam the synonyms of Mathumegam are Enippu 
neer, Neerizhivu. 
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Etiology: 
The authentic etiological factors described by various siddhars are as follows. 
§¸¡¨¾Â÷ ¸ÄÅ¢ §À¡¨¾ ¦¸¡Øò¾Á£ É¢¨Èîº¢ §À¡¨¾ 
À¡ÐÅ¡ö ¦¿öÔõ À¡Öõ ÀÃ¢×¼ ÛñÀ£ Ã¡¸¢ø 
§º¡¾À¡ñ ÎÕÅ Á¢ì¸ Íì¸¢Ä À¢Ã§Á ¸ó¾¡ý 
µÐ¿£ Ã¢Æ¢× §ºÃ ×ñ¦¼É ÅÈ¢óÐ ¦¸¡û§Ç  
-«¸ò¾¢Â÷ 1200 
 
The above poem quotes that excessive intake of rich food like ghee, fish, milk, 
toddy and excessive indulgence in sex leads to Mathumegam. The same also discussed in 
below poem with increased body heat (Pitham) and excessive hunger also leads to 
Mathumegam. 
 
¯ðÊ½ §Ã¡¸ò ¾¡Öõ ÓÚõ¦ÀÕõ Àº¢Â¢É¡Öõ 
¸ð¼Å¢ú §¸¡¨¾Á¡¾÷ ¸ÄÅ¢ÁðÊÄ¡ ¨ÁÂÄ¡Ö 
Óð¼È¡ ¿¡ÖÁ¡Ú ÓõãýÚ ¦Á¡ýÚ ¦ÁýÚ 
¾¢ð¼Á¡ö ÅÕÅ¦¾ýÚ ¾¢ÕÁÓÉ¢ ÂÕÇ¢î ¦ºö¾¡÷ 
-«¸ò¾¢Â÷ 1200 
 
The same etiological factor discussed below in Yoogi Vaithiya Chinthamani. 
¯üÀÅ¢ìÌõ À¡ø¦¿öÂ¡ Ä¢¨Èîº¢ ¸ûÇ¡ø 
¯Ã¢¨ºÂ¡ö Á£ýÈýÉ¡ø ÅÕÅ¢ Õò¾ 
ÁüÀÅ¢ìÌõ À¾¡÷ò¾ò ¾¡øÁÐÃ ÅŠ¾¡ø 
Áó¾í¸û ¾É¢ü¦À¡º¢ò¾ø §Å¸¡ô Àñ¼õ 
ÌüÀÅ¢ìÌí ÌÇ¢ó¾ÅýÉ Áí¨¸ §¸¡ŒÊ 
ÌÈ¢ò¾¿¢ò ¾¢¨Ã¾Å¢÷¾ Äì¸¢É¢ Áó¾õ 
¾üÀÅ¢ìÌï ºÃ£Ãó¾¡ý Á¢¸ôÀ Õì¸ø 
ºïºÄó¾¡ý ÀÂýÀÎ¾ø ¾Ã¢ìÌõ §¿¡§Â  
 
þÂõÀ§Å ¬ÚÌÇõ À¢ýÉï ¦ºö¾ø 
²üÈÁ¡ö À¢Ã¡ÁŠ¾¢Ã£ ºí¸õ Àñ½ø 
ÀÂõÀ§Å À¡Ä¸÷¸Ùì ¦¸¡Ç¢òÐò ¾¢ýÉø 
ÀÆ¨ÁºÄõ §À¡ÈÅÆ¢ ¾¨Éò¾ Îò¾ø 
«ÂõÀ§Å ¬ÄÂò¾¢ü ºÄõÅ¢ð §¼¡÷ìÌõ 
¬¾¢Â¡õ §Å¾ò¨¾ òà‡¢ò §¾¡÷ìÌõ 
ÐÂõÀ§Å ÝÃ¢Â¨É Åñí¸¡ §¾¡÷Ìõ 
ÍÕì¸¡¸ §Á¸õÅó ÐüÀÅ¢ìÌó ¾¡§É    
- ä¸¢¨Åò¾¢Â º¢ó¾¡Á½¢ 
 
 
7 
 
Sexual indulgence: 
All Siddhars attribute Mathumegam mainly due to excessive indulgence in sex 
which results in depletion of total strength of body as a whole, making the individual 
susceptible to this disease. 
¸ýÉ¢ ÁÂì¸ò¾¡ø ¸ñÊÎõ §Á¸§Á  
-¿¡Êáø 
 
¸ð¼Å¢ú §¸¡¨¾Á¡¾÷ ¸ÄÅ¢ÁðÊÄ¡ ¨ÁÂÄ¡Ö 
-«¸ò¾¢Â÷ 1200 
 
Š¾¢Ã¢§À¡¸õ ¦ºö¾¾¢É¡ø §Å×¦¸¡ñÎ 
º¢ÃÍ ÁðÎõ ¦ÅóÐÕ¸¢ì ¸É§Ä Á£È¢ì 
ÌÈ¢Ô¼§É §Á¸ó¾¡ý ¦¸¡Î¨Á ¦ºöÐ 
Ì¨ÈóÐ ÅÕõ ¾¡Ð¦ÅøÄ¡õ ÌýÈ¢ô§À¡Ìõ  
-ÌÕ¿¡Ê 
 
¿¢¨È âò¾ ¦¸¡í¨¸Â¡û ¿¡Â¸ý §Á¸ò¾¡ø 
Á¨È §À¡üÚõ ¸ÕôÀò¾¢ø ÅÇ÷ó¾Ð §Á¸§Á  
-¾¢ÕãÄ÷ 
 
¸¢Ãó¾¢ Òñ½¢Ã½ §Á¸ì ¸£º¸ ¦ÉýÛó ÐýÁ¡÷ì¸ 
ÉÕó¾¾¢ ¦ÂýÛõ À¡ïº¡Ä¢ Âý¨É¨Âì ¸ñÏüÈ¡§É 
 
-§¾Ãý ÁÕòÐô À¡Ã¾õ 
 
Psychosomatic Factors: 
Yoogimuni and other Siddhars also said that, psychosomatic stress resulting 
in disease like Mathumegam, Gunmam and Kuruthi Azhal. 
 
þÂõÀ§Å ¬ÚÌÇõ À¢ýÉï ¦ºö¾ø 
«ÂõÀ§Å ¬ÄÂò¾¢ü ºÄõÅ¢ð §¼¡÷ìÌõ 
¬¾¢Â¡õ §Å¾ò¨¾ òà‡¢ò §¾¡÷ìÌõ 
ÐÂõÀ§Å ÝÃ¢Â¨É Å½í¸¡ §¾¡÷Ìõ 
ÍÕì¸¡¸ §Á¸õÅó ÐüÀÅ¢ìÌó ¾¡§É  
- ä¸¢¨Åò¾¢Â º¢ó¾¡Á½¢ 
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Kanma Noi 
In the views of Agathiar and Theraiyar, Mathumegam also occurs as a 
result of bad deeds committed in his or her past. Nowadays it is called as 
“Genetic factors”. 
 
 
¬ÁôÀ¡ ÁÉ¢¾÷ ¦ºö¾ ¸÷Áò¾¡§Ä 
«Ã¸Ã¡ §Á¸¦ÁýÈ Ã¡º¡Å¡§Ä 
¸¡ÁôÀ¡ Ä¾¢É¡ø Àº¢ÔôÀ ¿¡Ùí 
¨¸ì¸¼í¸¡ §¿¡ö¸û ÅÕõ ¸÷Áò¾§Ä 
-«¸ò¾¢ÂÓÉ¢Å÷ ¸ýÁ¸¡ñ¼õ 
 
¾¡§ÉâÕÅ Å¢¾¢Â¢É¡ø º¡Õõ À¢½¢¸¦ÇøÄ¡õ 
Á¡§É¡÷ Å¢Æ¢Â¡û §Åð¨¸Â¢É¡ø ÅÕóÐõ À¢ýÛõ Àº¢Â¡ø 
¾¡§É ¦À¡ÚòÐ ¯ñ¨¸Â¢É¡ø ¾¡¸ó¾ýÉ¡ø Á¢¸î§º¡÷óÐ 
¾¡§É ¸ÁÄõ Òñ½¡¸¢ ¦ºöÔõ À¢Ã§Á¸î ¦ºÂø¾¡§É 
-§¾¨ÃÂ÷ 
 
Classification 
Twenty types of Meganoi have been discussed by Yoogimuni, Agathiar and 
Theraiyar. 
 
ÅºÉ¢ò¾ §Á¸ÁÐ þÃñÎ ÀòÐ 
Å¡¾¾¢ü À¢Èó¾ºÄõ ¿¡§Ä Â¡Ìõ 
À¢ºÉ¢ò¾ À¢ò¾ò¾¢ ÖüÀ Å¢ò¾ 
§ÀÃ¡É ºÄó¾¡Û Á¡Ú Á¡Ìõ 
¦¾ºÉ¢ò¾ §ºðÎÁò¾¢ø ¯üÀ Å¢ò¾ 
º£Ã¡É ºÄó¾¡Ûõ Àò§¾ Â¡Ìõ 
þºÉ¢ò¾ þ¾¢Û¨¼Â Ì½¡Ì ½í¸û 
ÍÆ¢Å¡É ¯üÀò¾¢ Â¢ÂõÀì §¸§Ç 
 
Ó¨ÈÂ¡É À¢ò¾ºÄ Á¡Ú Á¡Ìõ 
Ó¾¢÷ó¾«ô À¢Â¦ÁýÚõ À¢ÃÁ¢Â ¦ÁýÚõ 
¾¨ÈÂ¡É º¡õÀ£÷½Á ÐÁ¢Â ¦ÁýÚõ 
º¡ò¾¢¸§Á Â¡ÚÅ¢¾ó ¾ýÉ¡¼¡Ú 
Á¨ÈÂ¡É Å¢ó¾¡Ú §Á¸ó ¾ý¨É 
Á¸§¾Å÷ ¦º¡øÄ¢¼§Å §¾Å¢ §¸ð¸ò 
Ð¨ÈÂ¡É Ì½¡Ì½ò¨¾ Å¢Ã¢òÐî ¦º¡øÄ 
ÍüÈÁ¡Âô À¢Âò¾¢ý ÍÕÀí §¸§Ç. 
- ä¸¢¨Åò¾¢Â º¢ó¾¡Á½¢ 
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¾ì¸ ¾¡ÃÉ¢ Á¡É¢¼ò§¾¡÷ §¸û 
Àì¸ Á¡ ºÄõ Å¨¸ÔÁ¡§Á 
¿ì¸ ¿¡Â¸ý ¿¡Â¸¢ì§¸ ¦º¡ø 
Á¢ì¸ ¿ó¾¢ Å¢ÇõÀ¢ Å¢¾¢ò¾§¾ 
 
¸Æ¢Ôõ Å¡¾õ ¿¡ý¸¡Öõ 
¸Âõ À¢ò¾ Á¡È¡Öõ 
¸Æ¢Ôõ §ºòÐÁõ Àò¾¡Öõ 
¦º¡øÖõ ¿¡Äïº¡ö §¾¡ýÚõ 
ÅÆ¢Ôõ Å¡¾õ ¿¡ý¸¡§Á 
Á¡Õ ¾Å¢ú¾ó ¾ýÉ¡§Ä 
-§¾¨ÃÂ÷ Å¡¸¼õ 
 
¯ðÊ½ §Ã¡¸ò ¾¡Öõ ÓÚõ¦ÀÕõ Àº¢Â¢É¡Öõ 
¸ð¼Å¢ú §¸¡¨¾Á¡¾÷ ¸ÄÅ¢ÁðÊÄ¡ ¨ÁÂÄ¡Ö 
Óð¼È¡ ¿¡ÖÁ¡Ú ÓýãýÚ ¦Á¡ýÚ ¦ÁýÚ 
¾¢ð¼Á¡ö ÅÕÅ¦¾ýÚ ¾¢ÕÁÓÉ¢ ÂÕÇ¢î ¦ºö¾¡÷ 
 
-«¸ò¾¢Â÷ 1200 
According to Yoogi Vaithiya Chinthamani “Meganoi” is classified into 20 types 
i.e Vatha meganeer- 4, Pitha meganeer - 6 and Kaba meganeer - 10 types. 
“Mathumegam” comes under Pitham type. Each author who have dealt Meganoi have 
differently classified them under three doshas and have given names according to their 
concept. But the number, signs and symptoms are almost identical. 
Clinical features 
Signs and Symptoms (Gunam and Avathaigal) 
Yoogimuni, author of Yoogi Vaithiya Chinthamani has described the signs and 
symptoms of Mathumegam as “Gunam and Avathaigal".  
Gunam 
¾ñ¨ÁÂ¡öî ºÄó¾¡Ûõ ÀÍôÒ Áïºû 
¾¡É¢ÈíÌ À£ºÓí§¸¡ ºÓí¸ ÎìÌõ 
«ñ¨ÁÂ¡ÂÊì ¸ÊìÌ ¿£Ã¢ÈíÌõ 
«Êì¸ÊìÌ «¨Ã¿¡Æ¢ ¾É¢§Ä ¸¡Ïõ 
¦Åñ¨ÁÂ¡ ÂÊ¾É¢ø ¾¡ý À¢ÊìÌõ 
Á¢ì¸¡É º¼õ¦ÅÙòÐ §ÁÉ¢ ¸ñÏõ 
Àñ¨ÁÂ¡öô ÀïºÅ¡ñ ¼¾É¢ü ¦¸¡øÖõ 
À¸÷¸¢ýÈ ÁÐÁ¢Âò¾¢ý À¡íÌ ¾¡§É. 
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ÜÈ¡É §Á¸ÁÐ þÕÀ ÐìÌõ 
Ì½ó¾¨É º¢Åý¦º¡øÄ §¾Å¢ §¸ð¸ 
¾¡È¡É ¾¡¸¦Á¡Î §º¡¸ §Á¸ó 
¾Ã¢Â¡Áø ¿£Ã¢Æ¢¾ Ä¢ÕÁø ãîÍ 
¬È¡É «Õº¢ºò¾¢ º¢ò¾ À¢Ã¨Á 
«Êì¸ÊìÌò ¾ñ½£÷¾¡ý ¬í§¸ §¸ð¸ø 
®È¡É þÎôÒìÌû ¸ÎôÒ ¸¡½ø 
±ÖõÒÆüÈ ÄÆüÈ§Ä¡ ¦¼Ã¢×ñ ¼¡§Á 
 
±Ã¢§Å¡Î ºÃ£Ã¦ÁøÄ¡ Á¨ÈÀð ¼¡ü§À¡ø 
±Æ¢Ö¼õÒ §¿¡¾ø¿¢ò ¾¢¨ÃÂ¢ø Ä¡¨Á 
ÅÃ¢§Å¡Î Å¡ö×¦Áò ¾×õÀ È¢¾ø 
ÁÉÐºï ºÄôÀÎ¾ø ¸¡üÚ §Åñ¼ø 
¦ÁÃ¢§Å¡Î §ÁøãîÍ Á¢¸×ñ ¼¡¾ø 
Å¢ì¸§Ä¡Î ÁÂì¸ó¾¡ý ¦Áò¾ì ¸¡½ø 
¦¾Ã¢§Å¡Î §¾¸¦ÁíÌõ ¦ÅÙÕñ ¼¡¾ø 
§¾¸¦Áò¾ Å¡§Ä¡Àô ÀÎ¾ø ¸¡§½. 
-ä¸¢¨Åò¾¢Â º¢ó¾¡Á½¢ 
 
Passing of urine in large quantity at frequent intervals, while passing urine the 
patient experience burning and spasmodic pain in the urethra and dull pain in the testis. 
The urine has yellow color, and produces white sediments which adhere to the bottom of 
the vessel in which it is collected. The skin is pale and there is generalized body pain. If it 
is not treated in time resulting in death within five years of period. 
þÉ¢ôÀ¡É þÉ¢ôÀøÄ ® Åó¾¡Îõ 
´Õ ÐÇ¢Å¡ö Å¢ð¼¡÷¨¸ô À¢½¢Â¡ö §¾¡ýÚõ  
-ÌÕ¿¡Ê 
 
The above description quotes that ant and flies are attracted to the site of voided 
urine and when the urine is heated it gives honey odour. 
Avathaigal 
¸¡½§Å Ó¾ÄÅò¨¾ ºÃ£Ãó ¾¡Ûõ 
¸ÉÁ¡¸ô ÀÕò¾¢ÚÌ ¿£÷òÐ Å¡Ãõ 
§Å½§Å ¦Åñ¼¡ì¸¢ Â¸Äõ ÀñÏõ 
Á¢ì¸Å¢Ãñ ¼¡ÁÅò¨¾ Å¢ÇõÀì §¸Ç¡ö 
ã½§Å ãò¾¢Ãô À£¨¼ÔÁ¡î Íì¸¢Ä 
Ó¸ÁØ¸¢ò §¾ƒÍ¾¡ý Á¢¸§Å ÌýÚõ 
¿¡½§Å ãýÈ¡Ì ÁÅò¨¾ì Ìó¾¡ý 
¿¡ÅÃÙõ Å¡ÔÅÐ Á£Úó ¾¡§É.  
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¾¡É¡É ¿¡ÄÅò¨¾ Âí¸ ¾¡¸õ 
ºýÉ¢ÂÐ À¡¾Óñ¼¡ ¨Áó¾ Åò¨¾ 
§¾É¡É ¿£÷¦ÀÕÌó ¾¡Ð ¿Œ¼õ 
¿¢¨ÄÂ¡È¡ ÁÅò¨¾Ô¼ü ¸¢¨¼¦¸¡û Ç¡Ð 
ãÉ¡É ã÷î¨ºÅÕ §ÁÆ Åò¨¾ 
Á¢ì¸Å§Ã¡ º¢¸ïÍÅ¡ºó §¾¸ º¡ðÂõ 
²É¡É ±ð¼¡Å ¾Åò¨¾ ¾¡§É 
±Ø¸¢Ãó¾¢ À¢Ç¨ÅÔó¾¡ý Á¢¸×ñ ¼¡§Á.  
 
¯ñ¼¡Ì ¦Á¡ýÀ¾¡ ÁÅò¨¾ §¸Ç¡ö 
´Øì¸¡É ¬º¡Ãí ¸¢ÕÁ¢ Ôñ¼¡õ 
Áñ¼¡É Àò¾¡ó¾¡ ÉÅò¨¾ §¸Ç¡ö 
À¡ÃÁ¡õ ‡Âí¸ñÎ ÀÃòÐì §¸Ìõ 
Å¢Çí¸¢Â§¾¡÷ ¾ºÅÅò¨¾ Å¢ÀÃï ¦º¡ý§É¡õ.  
-ä¸¢¨Åò¾¢Â º¢ó¾¡Á½¢ 
 
The below signs and symptoms are occurring in undiagnosed and improperly treated 
cases. 
1. First symptoms of Megam disease are obesity and dilation of urethral. 
2. Body becomes dry and loses its lusture due to excessive secretion and flow of 
urine mixed with vital fluid (semen). 
3. Dryness of the tongue and distension of abdomen due to formation and 
accumulation of excessive gas. 
4. Delirium (Toxic condition) supervenes following dehydration due to excessive 
elimination of tissue fluid. 
5. Restlessness due to loss of vital fluid in urine. 
6. Breathlessness and restlessness. 
7. Nausea, tastelessness, laboured breathing, exhaustion. 
8. Carbuncle and multiple abscess formation.  
9. Maggot formation and generalized emaciation.  
10. Intractable troublesome, cough with profuse expectoration leading to death. 
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PINIYARIMURAIMAI (Diagnosis) 
 It is very important part of the treatment. It is helpful to select the correct line of 
treatment and good prognosis. It is based upon the following diagnostic methods. 
· Poriaal therthal 
· Pulanaal arithal 
· Vinadhal 
· Envagai thervugal 
Poriaal therthal 
The physician should examine the patient’s porigal. 
· Mei: Feels all types of sensations 
· Vaai: For knowing taste 
· Kan: Meant for vision 
· Mooku: For knowing the smell 
· Sevi: For hearing 
Pulanaal Arithal: 
The physician should examine the patient’s pulangal (Functions of the sensory organs) 
· Oosai             - Perception of sound 
· Ooru   - Perception of sensation 
· Oli  - Perception of vision 
· Suvai  - Perception of taste 
· Nattram  - Perception of smell 
 
Vinadhal (Interrogation) 
 The physician should interrogate about the patient’s name, age, occupation, 
native, socio- economic status, dietetic habits, prone to any allergens, complaints, history 
of previous illness, history of past illness, family history and frequency of attacks. If the 
patient is unable to speak, or is a child physician should interrogate the details with his 
immediate relatives who are taking care of him. 
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Ennvagai thervugal 
 The prime method adopted to diagnose the disease is by means of “Ennvagai 
thervugal”. The value of ennvagai thervugal is very important for diagnosing purposes, 
which is the unique and special method described in siddha system of medicine. 
1. Naadi 
2. Sparisam 
3. Naa 
4. Niram 
5. Mozhi 
6. Vizhi 
7. Malam 
8. Moothiram 
 
Eight different kinds of tests to be applied or attended by a physician before 
arriving  a correct diagnosis. Envagai thervukal is considered as Physician's Instruments. 
 
“¿¡Ê ÀÃ¢ºõ ¿¡ ¿¢Èõ ¦Á¡Æ¢ Å¢Æ¢ 
ÁÄõ ãò¾¢Ãõ þ¨Å ÁÕòÐÅÃ¡Ô¾õ”  
-§¾¨ÃÂ÷ 
1. Naadi (Pulse) 
 Naadi is the vital force. Any change in the three dhoshas are best diagnosed by 
feeling the nadi. Naadi is an important observation for diagnosis and prognosis. Naadi is 
responsible for the existence of life and can be felt one inch below  the wrist on the radial 
side by means of palpation with the tips of index, middle and ringfinger corresponding to 
Vatham, Pitham and Kabam. 
 
Site and procedure to feel Naadi according to Agasthiyar  
“¸Ã¢Ó¸ ÉÊ¨Â Å¡úò¾¢ì 
¨¸¾É¢ø ¿¡Ê À¡÷ì¸¢ø 
¦ÀÕÅ¢ÃÄíÌÄò¾¢ø 
À¢Êò¾Ê ¿Î§Å ¦¾¡ð¼¡ø 
´ÕÅ¢Ã§Ä¡Êø Å¡¾õ 
¯Â÷ ¿ÎÅ¢ÃÄ¢ü À¢ò¾õ 
¾¢ÕÅ¢Ãø ãýÈ¢ §Ä¡Êø 
º¢§ÄòÐÁ ¿¡Ê ¾¡§É”. 
-«¸ò¾¢Â÷ ¿¡Ê 
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According to Thirumoolar, the ten sites for feeling Naadi  
 
¾¡Ð Ó¨È§¸û ¾É¢ò ¾Ì¾¢î ºó§¾¡Î 
µÐÚ ¸¡Á¢Â Óó¾¢¦¿Î Á¡÷Ò 
¸¡Ð ¦¿ÎãìÌ ¸ñ¼õ ¸ÃõÒÕÅõ 
§À¡ÐÚÓîº¢ Ò¸ú ÀòÐõ À¡÷ò¾¢§¼ 
-¾¢ÕãÄ÷ ¿¡Ê 
 
Formation of Naadi 
 Naadi  + Vayu  = Uyir Thathu 
 Idakalai + Abanan = Vatham 
 Pinkalai + Pranan  = Pitham 
 Suzhumunai + Samanan = Kabam 
  
Normally the three humors Vatham, Pitham and Kabam exist in the ratio 1: ½ : ¼ 
The derangement in these ratio leads to various disease entities and is best diagnosed by 
feeling the Naadi. 
 
Naadi in Madhumegam 
 
“þÕÁ¢§Â À¢ò¾Óõ Å¡¾Óõ ÜÊø 
ÁÕ×ºÄ §Á¸õ Å¡Õ¾¢ §À¡Ä¡Ìõ 
¯ÕÅõ §ÅÈ¡Ì Óñ¼×¼ü ¸¡öó¾¢Îõ 
¯Õ¸§Å ç§É¡Î ¯È¢ïº¢ þÉ¢ìÌ§Á” 
 -¾¢ÕãÄ÷ ¿¡Ê 
 
 The above stanza describes that excessive elimination of urine containing sugar 
are always primarily due to combined vitiation of Vatha, and Pitha  functional factors in 
the body. The pitha and vatha vitiation is indicated  clinically by excessive hunger, thirst, 
over-eating, emaciation and passing of large quantities of urine. 
 
“þÉ¢ì¸¢ýÈ Å¡òò¾¢¨¼ §ºÃ¢ø ³Âó¾¡ý 
ÀÉ¢ì¸¢ýÈ ¸ûÙô À¾É¢§À¡ø ¿£§Ã¡Îõ 
¸Éì¸¢ýÈ §ÁÉ¢¸¨ÃóÐ ¦ÅÙô§ÀÚõ 
¸É¢ìÌÁÐ §Á¸ó ¾ôÀ¡§¾ ³ÂÓõ”  
-¾¢ÕãÄ÷ ¿¡Ê 
 
The above poem indicates that initially vatha and kabam get deranged leading to 
vitiation of pitha thathu finally. When the aggravated vatha naadi combines with 
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aggravated kaba naadi, there is genesis of megam disease in the body. The meganeer thus 
formed and eliminated has the consistency and appearance of toddy. The affected 
individual's body is pale and emaciated. This is the typical clinical picture of 
Mathumegam. 
 
“ÐÃ½Ó¼ý ¿£÷ôÀ¡Î ¦¸÷ôÀô À¡¼¡É¡ü 
¦º¡øÖ¸¢§Èý ¿¡Ê¦ÂøÄ¡í ¸ÆýÚ ¸¡Ïõ” 
-ÀÃ¢âÃ½ ¿¡Ê 
In the above lines, it is said that all the three naadi are feeble and weak in 
Mathumegam. 
 
“ÀüÀ¢Êò¾ §Á¸õ ±ýÈ¡ø À¢ò¾Á£Úõ 
À¡Ä¸§É ¸¡í¨¸ ¦¸¡ñÎ ¿£Ã¡õ À¡§Ã” 
-ÀÃ¢âÃ½ ¿¡Ê 
By the above lines it is clearly stated that aggravation of pitha naadi results in 
increased udal kaangai. Eventually this leads to emaciation of seven udalthathus resulting 
in Meganeer. 
 
“¿£÷§Á¸Á¡ÉÅ÷ìÌ ¿¡Ê ¸¡Ïõ 
¿¢÷½ÂÁ¡ö ¿¡Ê¦ÂøÄ¡õ ¦ÀÄ§Á ¦¸ðÎì 
¸¡÷§Á¸õ §À¡Ä Åó¾ ±Ã¢Â¢ý §Á§Ä 
¸ñÎ Å¢Øõ ÒØô§À¡Ä§Å ÒÃñÎ ¸¡Ïõ”  
-ÀÃ¢âÃ½ ¿¡Ê 
All the three naadi are felt feeble in those suffering from Neerizhivu Noi. The 
character of the pulse is compared to that of wriggling movements of a worm that has 
fallen into the fire. 
 
2. Sparisam (Palpation) 
 The following points are elicited by Sparisam, the temparatue of skin (heat or 
cold), smoothness, roughness, softness, sweat, dryness. 
3. Malam (Faeces) 
 In the examination of Malam, Niram (Colour), Nurai (Froth), Erugal (Solid), 
Elagal (Semisolid or liquid), quantity (increased or decreased) and smell can be noted. 
Other quantitative analysis such as, presence of blood, mucus, undigested matter in the 
stools and odour can also be studied. 
4.  Moothiram (Urine) 
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 In the examination of urine, colour, odour, quantity of urine, the presence of froth, 
deposits, blood, pus, inorganic sediments, abnormal constituents such as sugar, protein 
etc, and the frequency of micturition, flow pattern, burning sensation if any while passing 
urine are to be noted. 
The diagnosis and prognosis are usually arrived at by methods of urine examinations as 
follows, 
i) Neerkuri 
ii) Neikuri 
 
Collection of Urine 
“«ÕóÐÁ¡È¢Ã¾Óõ «Å¢§Ã¡¾Á¾¡ö 
«·¸ø «Ä÷¾ø «¸¡Äçñ ¾Å¢÷ó¾Æü 
ÌüÈÇ ÅÕó¾¢ ¯Èí¸¢ ¨Å¸¨È 
¬Êì ¸Äºò ¾¡Å¢§Â ¸¡Ð ¦À¡ö 
¦¾¡Õ ÓÜ÷ò òì¸¨Ä ÌðÀÎ ¿£Ã¢ý 
¿¢ÈìÌÈ¢ ¦¿öìÌÈ¢ ¿¢ÕÁ¢ò¾ø ¸¼§É” 
- §¾Ã÷ ¿£÷ÌÈ¢ ¦¿öÌÈ¢ 
 
 Prior to the day of urine examination, the patient should be advised to take a 
balanced diet and should have good rest. The first voided urine of the patient is collected 
in a glass container. The collected urine is subjected into neerkuri and neikuri 
examination within1½ hours and the following are to be observed colour, smell, frothy, 
volume, specific gravity and sedimentation and the shape of the oil spread in the urine. 
i) Neerkuri 
“Åó¾ ¿£÷ì¸Ã¢ ±¨¼ Á½õ Ñ¨Ã ±ïº¦Äý 
¨Èó¾¢ÂÖÇÅ¨Å Â¨ÈÌÐ Ó¨È§Â” 
      - º¢ò¾ÁÕòÐÅ¡í¸ ÍÕì¸õ, À.±ñ:510 
  
In Neerkuri Niram, Edai, Manam, Nurai and Enjal of the urine voided is noted. 
This has been already mentioned in Envagai thervugal. The urine should be examined 
only according to the rules and regulations but at time of emergency they can be relaxed. 
 
Niram  : It indicates the colour of urine voided. 
Edai  : It indicates the specific gravity of urine (increased or decreased  
quantity). 
Manam : In indicates the smell of urine voided. 
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Nurai  : It indicates the frothy nature of urine voided. 
Enjal  : It indicates the quantity of urine. 
 
Neerkuri of Mathumegam is studied as follows: 
 
Niram : Clear and white. This is due to Kaba vitiation and it is not amenable to  
treatment. 
Edai : Urine is thick and its consistency is like honey. 
Manam: Smells like honey. Ants and flies are attracted towards the voided urine. It 
indicates that it contains some sweet substances which attract the ants and 
flies. 
Nurai : It is frothy at the time of urination. 
Enjal : Large quantity of urine is passed. This will result in the loss of large  
Volume of water and life sustaining minerals resulting in fatigue, 
exhaustion and weakness. 
 
If the urine is lightly transparent, it indicates the vitiation of kaba in which the 
prognosis is said to be very bad. The above findings of Neerkuri in Madhumegam is 
described in Siddha texts are as follows. 
 
“¾ñ¨ÁÂ¡öî ºÄó¾¡Ûõ ÀÍôÒ Áïºû 
¾¡É¢ÈíÌ À£ºÓí§¸¡ ºÓí¸ ÎìÌõ 
«ñ¨ÁÂ¡ÂÊì ¸ÊìÌ ¿£Ã¢ÈíÌõ 
«Êì¸ÊìÌ «¨Ã¿¡Æ¢ ¾É¢§Ä ¸¡Ïõ 
¦Åñ¨ÁÂ¡ ÂÊ¾É¢ø ¾¡ý À¢ÊìÌõ 
Á¢ì¸¡É º¼õ¦ÅÙòÐ §ÁÉ¢ ¸ñÏõ 
Àñ¨ÁÂ¡öô ÀïºÅ¡ñ ¼¾É¢ü ¦¸¡øÖõ 
À¸÷¸¢ýÈ ÁÐÁ¢Âò¾¢ý À¡íÌ ¾¡§É”. 
-ä¸¢¨Åò¾¢Â º¢ó¾¡Á½¢ 
 
The description of the physical feature of the Mathumegam urine in siddha system 
agree with the description of the physical feature of  diabetic urine by modern science. 
The name of the disease itself indicates that the urine passed contains a substance which 
is not only sweet but also emanates the odour of honey. 
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Neikuri 
 A drop of gingely oil is dropped into a wide vessel containing the urine to be 
tested and kept  under the sunlight in a silent place and observed for one minute. The 
variations of the three thathus in the disease condition studied and the prognosis of the 
disease can be observed from the  spreading  pattern of gingely oil in the urine surface. 
“«Ã¦ÅÉ ¿£ñÊÉ·§¾ Å¡¾õ” 
-§¿¡ö¿¡¼ø §¿¡öÓ¾ø ¿¡¼ø ¾¢ÃðÎ 
 
The drop of oil lengthening like a snake indicates Vatham. 
 
“¬Æ¢§À¡ü ÀÃÅ¢ý «·§¾ À¢ò¾õ” 
-§¿¡ö¿¡¼ø §¿¡öÓ¾ø ¿¡¼ø ¾¢ÃðÎ 
 
The drop of oil spreading like a ring it indicates Pitham. 
 
“Óò¦¾¡òÐ ¿¢ü¸¢ý ¦Á¡Æ¢Å¾ý ¸À§Á” 
-§¿¡ö¿¡¼ø §¿¡öÓ¾ø ¿¡¼ø ¾¢ÃðÎ 
 
The drop of oil look like a pearl shape it indicates kabam. 
 
 
Thinai (Land or Place) 
Nilam is classified into five types depending on the flora and fauna, landscape and 
ecology study of  five places is very much necessary as some of the diseases are more 
prevalent in a particular land. 
· Kurinji: Mountain and its surroundings. Liver diseases are common. 
· Mullai: Forest and its surroundings Pittha diseases, Vadha diseases are common. 
· Marutham: Paddy field and its surroundings. This is the ideal place for healthy 
living. 
· Neithal: Sea and seashore. Liver diseases occuring in combination with other 
diseases. 
· Palai: Desert and its surroundings. Vatha, Pittha and Kabha diseases occur  
 
Nowadays Mathumegam is prevalent in all five types of lands due to sedentary lifestyle. 
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Paruvakalam (Season) 
 In siddha system of medicine Siddhars have classified the seasons into six each 
comprising of two months. 
Sl.No. Kalam Kuttram State of Kuttram 
1 
 
Kar kalam 
(Avani & Purattasi) 
(Aug. 17 - Oct 17) 
Vatham 
Pitham 
Vettrunilai 
Valarchi 
Thannilai 
valarchi 
2 Koothir Kalam 
(Iypasi & Karthigai) 
(Oct. 18 - Dec. 15) 
Vatham 
Pitham 
Thannilai 
Valarchi 
Vettrunilai 
valarchi 
3 Munpani Kalam 
(Maragazhi & Thai) 
(Dec. 16 - Feb. 12) 
 
Pitham Thannilai 
Adaithal 
4 Pinpani Kalam 
(Masi & Panguni) 
(Feb.13 - Aprl. 13) 
 
Kapham Thannilai 
valarchi 
5. Elavenir kalam 
(Chithirai & Vaikasi) 
(Aprl. 14 - June 14) 
Kapham Vettrunilai 
valarchi 
6. Mudhu venir Kalam 
(Aani & Aadi) 
(June 15 - Aug. 16) 
Vatham 
Kapam 
Thannilai 
Valarchi 
Thannilai 
adaithal 
 
Mukkuttram 
1. Vatham 
2. Pitham 
3. Kabam 
I. Vatham 
 Vatham is the kinetic energy which influences all motions. It denotes Vayu 
dryness, pain, flatulence. It is classified into 10 types based on functions. 
 
Location of Vatham in our body 
 Vatham is located in abanan, Faeces, Idakalai, Spermatic cord, Nerve plexus, 
Joints, Hair follicles and Muscles, Bones  and Thigh. Increase or decrease of Vatham can 
cause some standing symptoms which are below, 
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Increase 
Pain in the body, twitching & piercing pain, inflammation, reddish complexion, 
roughness of skin, hardness of limbs, astringent sense of taste in the mouth, taste not 
palatable, sweating during sleep, traumatic pain, constipation, oliguria, blackish 
discolouration of skin,stool, urine and muddy conjuctiva, tremors, abdomen distention, 
insomnia, and  breathlessness. 
Decrease 
 Body pain, feeble voice, diminished competence of intellectual functions and 
syncope etc. 
 
Types of Vatham 
1. Piranan (Uyir Kaal) 
 It is mainly responsible for respiration and it is necessary for proper digestion and 
control knowledge. 
2. Abanan (Keezhnokku Kaal) 
 It is responsible for voiding of urine, stools, semen and menstrual flow. 
3. Viyanan (Paruvkaal) 
 It is used to feel all types of Sensations. It carries nutrients to all over the body 
flexes and extends the movable joints. 
4. Uthanan (Maelnokku kaal) 
 Responsible for all kinds of upward motion such as nausea, vomiting and 
eruption. 
5. Samanan (Nadukkaal) 
 Considered essential for proper digestion assimilation and carries the digested 
nutrients to each and every organ. 
6. Nagan  Helps in opening and closing of the eyes. 
 
7. Koorman  Responsible for yawning, vision and lacrimation. 
8. Kirugaran  Responsible for salivation, nasal secretion and appetite. 
9. Dhevathathan 
 Induces and stimulates a person to become alert, get anger, to quarrel, to sleep, to 
become lazy etc. 
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10. Dhananjeyan 
 Resides in the cranial cavity and produces bloating of the body after death. This 
leaves from the body after 3 days forming a way through the skull bone. 
In case of Madhumegam 
 1.Abanan - Affected ( increased volume and frequency of micturation). 
 2.Viyanan - Affected  (altered sensation). 
 3.Udhanan - Affected  (nausea, vomiting). 
 4.Koorman - Affected  (Blurring of vision) 
 5.Kirugaran - Affected  (Polydipsia). 
The above mentioned types of vatham are affected in mathumegam.    
 
II. Pitham  
It is the thermal life force of the body. Pitha in the body is followed by  
the derangement of metabolic energy caused by the involvement of Vatha. 
 
Location of Pitham in our body  
Pingalai, Piranan, Urinary bladder, Heart, Moolakkini, Head, Abdomen, Sweat, 
Blood, Saliva and Digested material etc. 
Increase or decrease of Pitham can cause some standing symptoms which are below   
 
Features of increased pitham: 
Yellowish discolouration of eyes, skin, urine and motion. Polyphagia, polydipsia, 
burning sensation all over the body, sleeplessness, acidity, profuse sweating and dizziness 
etc. 
 
Features of decreased pitham: 
Loss of appetite, cold, pallor, symptoms associated with defective growth of 
Kapham. 
 
Types of Pitham 
1. Anar Pitham  
It peps up the appetite aids in digestion. 
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2. Ranjaga Pitham  
It is responsible for the colour and contents of the blood. 
3. Pirasaga Pitham 
It gives Complexion of the Skin. 
4. Sathaga Pitham  
It is Necessary to carry out regular works properly. 
5. Aalosaga Pitham  
It is responsible for the perception of Vision. 
 
In case of Mathumegam 
1. Anar Pitham  
Affected – Polyphagia 
2. Alosaga Pitham :  
Affected - Blurring of Vision. 
 
 III. Kabam 
It is responsible for the stream lined functions of the body and body's defence 
mechanism to be intact. 
Location of Kabam in our body  
Samanan, Suzhumunai, Vinthu, Head, Fat, Marrow, Nose, Colon,Joints etc. 
Increase or decrease of Kabam can cause some standing symptoms which are below, 
 
Features of increased kabam: 
Loss of appetite, excessive salivation, heaviness, excessive musculature, 
dyspnoea, excessive sleepiness, fair complexion, itching, dullness, cold, loss of sensation, 
sweetness in mouth and indigestion etc., 
 
Features of decreased kabam: 
Prominence of bony edges, dry cough, lightness, profuse sweating  and 
palpitation. 
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Types of Kabam 
1. Avalambagam 
Lies in the respiratory organs, exercises authority over other Kabams and controls  
heart and circulatory system. 
2. Kilethagam 
It is found in stomach as its seat moistens the food, softens and helps it for 
digestion. 
3. Pothagam 
Tongue is the centre for pothagam, it is responsible for the sense of taste. 
4. Tharpagam 
Head is the centre for tharpagam, it gives cooling to the eyes. 
5. Santhigam 
It lies in the joints and is responsible for the lubrication and true movements of 
joints. 
 
In the case of Mathumegam 
1. Kilethagam - Gets affected due to increased appetite. 
 
Udal Kattugal 
These are seven basic principles which constitute the entire body. There are seven 
Udal Kattugal described in Siddha text. 
 
1. Saram  
It strengthens the body and mind. 
2. Senneer   
It is responsible for the nourishment, Strength, Vigour and healthy complexion. 
3. Oon   
It gives structure and shape of the body and is responsible for the movement of the 
body. 
4. Kozhuppu 
It helps for lubrication of joints and other parts of the body to facilitate their 
functions. 
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5. Enbu  
It supports the body structure and protects the organs. It is responsible for the 
posture and movement of the body. 
6. Moozhai  
It nourishes the bone marrow. 
 
7. Sukkilam/ Suronitham 
It is responsible for reproduction. 
  
 
 
Udal Kattugal 
                               
Increased features 
   
Decreased features 
1)  Saaram Leads to a disease identical 
to the increase in kabam 
like  loss of appetite 
,profuse salivation, 
depression etc., 
Dryness of  the skin 
diminished  activity of the 
sense organs, lassitude,  
Loss of weight, Intolerance 
to sounds.  
 
2)  Senneer Increased blood  pressure, 
boils in eye brow, scalp  
neck, lips and legs, skin 
jaundice, haemaeturia, 
Colic pain 
Eagerness to sore an foods. 
Tiredness, lassitude,d cold 
anaemia. 
3)  Oon Deposition of fat around the 
neck, face, abdomen, thigh, 
genitalia, etc., 
Muscle wasting, tiredness. 
 
4)  Kozhuppu Identical feature of 
increased oon  associated 
with dyspnoea on exertion 
Loin pain, emaciation 
splenomegaly 
 
 
 
 
5)  Enbu 
 
Excessive ossification and 
dentition 
Pain in joints, loss of hair, 
extraction of foot, weak 
bone and nail. 
6) Moozhai Weariness of the body and 
eye, swollen 
interphalangeal joints, 
oliguria  and non healing 
ulcer. 
Osteporosis and 
shunken eyes 
7)  Sukkilam (or) 
Suronitham 
Increased sexual activity 
urinary calculi etc 
Pain in the genitalia, failure  
to production. 
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In case of Mathumegam all seven thathus are affected. 
1. Saram-  Tiredness 
2. Senneer- Reduced Strength 
3. Oon-  Weight loss 
4. Kozhuppu- Weight loss (or) obese 
5. Enbu - Joint pain 
6. Moolai - Affected   
7. Sukkilam- Body becomes dry and loses its lusture due to excessive flow of 
urine mixed with vital fluid. 
 
In the case of Mathumegam frequent passage of increased amount of urine results in 
gradual diminition of seven thathus. 
 
“ºÃ¢Â¡É §Á¸ò¾¡ ÄÀ¡É Å¡Ô 
¾¡ýÒ¨¸ìÌ §Á§ÄÈ¢ì ¸À¡Äî Ý¼¡õ 
¦ÀÃ¢¾¡É §Á¸ò¾¡ Äò¾¢ ¦ÅóÐ 
§À¡ÁôÀ¡ ¾¨º¦ÅóÐ Ãò¾õ ÅüÈ¢ô 
ÀÃ¢Å¡¸¢ò ¾ºÅ¡öÅ¡ø Áó¾í ¦¸¡ñÎ 
¦ÀÕó¾£É¢ ÁÄÀó¾õ ¯¾¡É Å¡Ô 
ÅÃ¢Å¡¸¢ò §¾¸¦ÁÄ¡õ Å¢¼ ¿£Ã¡§Ä 
¦ÁöÂÆ¢óÐ §Á¸¦ÁýÈ ¾¢ÕÀ ¾¡î§º” 
      - º¢ò¾÷ ¿¡Êáø 
 
In this poem Oon and Senneer were  affected. 
 
Noi Kanippu Vivaadham (Differential Diagnosis): 
 
· Thelineer 
The signs and symptoms of the thelineer were polyuria (voided urine is clear and 
snow like appearence), polydypsia, loss of appetite, loss of body weight, dryrness of skin, 
constipation or diarrhoea, muscle cramps. Due to the presence of loss of appetite and 
absence of excessive sugar in blood and urine sample, this disease can be differentiated 
from mathumegam. 
· Due to prolonged intake of diuretics 
 Due to the history of prolonged intake of diuretics the patient may have symptoms 
of polyuria. But due to the absence of excesssive sugar in blood and urine sample the 
symptoms can be differentiated from mathumegam. 
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Noinidhanam (Prognosis): 
As per Siddha system four types of Meganeer formed as a result of Vatham is 
incurable. The six types arising due to the vitiation of pitham could be cured with 
difficulty. But then ten types of meganeer arising due to Iyyam are curable by proper 
treatment. 
Line of Treatment: 
The aim of Noi Neekkam is based on 
1. Treatment of the disease by internal medicines  
2. Diet and advices 
3. Yoga therapy 
 
The line of treatment is described as follows, 
In Theran Maruthuva bharatham, it is said that the disease has been caused by 
excessive sexual indulgence. Excessive sexual indulgence leads to the formation of 
Megam which gradually affect all the seven thathus and finally sets in the genitourinary 
system resulting in excessive excretion of urine, tasting sweet as honey. 
“¸¢Ãó¾¢ Òñ½¢Ã½ §Á¸ì ¸£º¸ ¦ÉýÛó ÐýÁ¡÷ì¸ 
ÉÕó¾¾¢ ¦ÂýÛõ À¡ïº¡Ä¢ Âý¨É¨Âì ¸ñÏüÈ¡§É” 
-§¾Ãý ÁÕòÐô À¡Ã¾õ 
 
In Theran Maruthuva bharatham, Megam is alluded to Keesagan and 
Mathumegam is alluded to Sainthavan, are also alluded to certain metals namely 
Bheeman for Rasam (Mercury), Dharmar for Ayam (Iron) and other brothers for Steel, 
Silver, Gold, Lead and Copper. 
So, Parpam and chendooram of above metals should be used one by one with 
suitable Anubanam for the treatment of Meganeer especially Mathumegam. 
Treatment: 
Siddhars aimed at bringing the three doshas in equilibrium in the treatment of 
disease. Siddhars prescribed  a minimum dosage initially and then increased the dose 
gradually. 
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“§Å÷À¡Õ ¾¨ÆÀ¡Õ Á¢ïº¢Éì¸¡ø ¦ÁøÄ ¦ÁøÄ 
ÀüÀ ¦ºóàÃõ À¡§Ã” 
 
So, metal and mineral preparations like Parpam and Chendooram are followed by 
Herbal preparations like Kudineer, Chooranam and Ilagam. There are thousands of 
preparations for Mathumegam and its complications found in various Siddha text books 
like Kudineer, Chooranam, Ilagam, Parpam and Chendooram, etc. 
 
Diet and advices: 
¾Å¢ì¸ §ÅñÊÂ¨Å: 
 
· º÷¸¨Ã, §¾ý, À¨É¦ÅøÄõ, þÉ¢ôÒ Å¨¸¸û, Á¢Ì þÉ¢ôÀ¡É ÀÆí¸û, 
ÀÆîº¡Ú Å¨¸¸û, ¸¢ÆíÌ Å¨¸¸û, ¦¿ö, À¡ø, ¾Â¢÷, ±ñ¦½ö 
ÀÄ¸¡Ãí¸û, §¸¡Æ¢, ¬Î, Óð¨¼ Áïºû¸Õ ¬¸¢ÂÅü¨È ¾Å¢÷¸×õ. 
· ÁÐ, Ò¨¸, ¦ÅüÈ¢¨Ä, À¡ìÌ þÅü¨È ¾Å¢÷¸×õ. 
 
§º÷ì¸ §ÅñÊÂ¨Å: 
 
· ¾¡É¢Â ¸Ä¨Å, Ó¨Æ¸ðÊÂ ¾É¢Âõ, ÀÕôÒ Å¨¸¸û, ÀîºÊ Å¨¸, 
§º¡Â¡À£ý ¬¸¢Â¨Å Óì¸¢Â ¯½×¸û ¬Ìõ. 
· Àî¨º þÇõ¸¡ö¸û, ¿¡÷ºòÐì ¸¡ö¸û, ¸£¨Ã¸û ÁüÚõ §Á¡÷, ¸¼øÁ£ý, 
¦¸¡ØôÀüÈ Á¡Á¢ºõ ¬¸¢ÂÅüÈ¢Ä¢ÕóÐ ÒÃ¾í¸¨Ç ¦ÀÚÅÐ ¿ýÚ. 
· ÓØ¾¡É¢Âí¸û, ÓØÀÕôÒ Å¨¸¸û, §º¡Â¡À£ý, Àî¨º þ¨Äì¸¡ö¸È¢¸û 
ÁüÚõ ¦Åó¾Âõ ¬¸¢Â¨Å ¿¡÷ºòÐÁ¢ì¸ ¯½×¸û. 
· ¸¼¨Ä ±ñ¦½ö, ¿ø¦Äñ¦½ö, ÀÕò¾¢Å¢¨¾ ±ñ¦½ö, ¨ÃŠÀ¢Ãý 
±ñ¦½ö, º¡À¢Ç¡÷ ±ñ¦½ö ¬¸¢Â ±ñ¦½ö Å¨¸¸¨Ç ÀÂýÀÎò¾×õ. 
· ¾¢ÉºÃ¢ 6¸¢ ¯ôÒ ÁðÎ§Á ±ÎòÐì¦¸¡ûÇ×õ, °Ú¸¡ö, «ôÀÇõ, ºðÊÉ¢ 
ÁüÚõ ¯ôÀ¢ø °È¢Â ¾Â¡Ã¢ôÒ ¯½×¸¨Ç ¾Å¢÷¸×õ. 
· ¾¢ÉºÃ¢ 45 ¿¢Á¢¼õ §Å¸ ¿¨¼ ¿¼ôÀÐ ¿ýÚ. 
 
Yoga Theraphy 
 Yoga is India’s unique contribution to the world. The word “Yoga” is derived 
from the Sanskrit word “yuj” which means bind, join, or attach. Yoga therefore is an art 
which brings an incoherent and scattered mind to a reflective and coherent state. 
Yogasanaas are nothing but a kind of Yogic exercises. There are innumerable 
types of Aasanaas. According to Thirumoolar, 
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“þÂÁ É¢ÂÁ§Á ±ñ½¢Ä¡ ¬¾Éõ 
¿ÂÓÚ À¢Ã¡½Â¡Áõ À¢ÃòÂ¡¸¡Ã 
ºÂÁ¢¸ ¾¡Ã¨½ ¾¢Â¡ÉºÁ¡¾¢ 
«ÂÓÚõ «ð¼¡í¸ Á¡ÅÐ Á¡§Á” 
-¾¢ÕãÄ÷ 
 
Each Yogasanam is indicated for a definite effect in a particular region of the 
system by stimulating the internal organs to function in a normal way and to co-ordinate 
bodily functions. Villaasanam and Mayuraasanam are specifically helps in the treatment 
of Mathumegam.  
· In Mayuraasanam the presence of conjoined elbow against umbilicus 
region activates the pancreas to work more.  
· In Villaasanam the whole abdominal organs including the pancreas are 
properly tuned and stimulated well by the increase of intra abdominal 
pressure motivated towards pancreas. 
 It has been proved that Aasanaas are useful in regulating the pancreas, but in 
practice the physician should bear in his mind whether in a particular case Yoga alone can 
be useful or a combined drug administration is also essential. 
The following Aasanas are advised for controlling Madhumegam  
· Chakkaraasanam 
· Mathsyaasanam 
· Pachimothaasanam 
· Pujangaasanam 
· Padmaasanam 
· Sarvaangaasanam 
All these Aasanas should be practiced daily and regularly which can be of immense 
value to patients of Madhumegam. All these Aasanas activate the pancreatic cells and 
have a curative value. These help in restoring cellular function of the pancreas and 
activate them to work more. 
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MODERN ASPECTS 
Definition 
 Diabetes mellitus is a metabolic-cum-vascular syndrome of multiple etiologies 
characterized by chronic hyperglycemia with disturbance of carbohydrate, fat and protein 
metabolism resulting from defects in insulin, insulin action or both. This disorder is 
frequently associated with long term damage, which can lead to failure of organs like 
eyes, kidneys, nerves, heart and blood vessels.  
Epidemiology 
In recent years, India has witnessed a rapid exploding epidemic of diabetes. 
Indeed, India today leads the world with its largest number of diabetic people in any 
given country. WHO estimates that there are 32 million people with Diabetes in India in 
2000, which is projected to rise to 80 million by the year 2030. Increase in prevalence is 
rapid in urban areas from 2% in 1970s to 12% in 2000 and in rural areas also it is now 
beginning to increase. 
Epidemic of Type 2 Diabetes 
 There are two main form of diabetes. Type 1 diabetes (insulin dependent) is 
primarily due to autoimmune-mediated destruction of pancreatic beta cells, resulting in 
absolute insulin deficiency. While type 1 diabetes is also on the increase the actual 
numbers of people with type 1 diabetes in india is relatively speaking still small. Type 2 
diabetes (non-insulin dependent) on the other hand accounts for over 90-95% of all 
diabetic people and is characterized by insulin resistance and/or abnormal insulin 
secretion, either of which may predominate. The diabetes epidemic particularly to type 2 
diabetes and is taking place both in developed and developing nations with particular 
reference to India and is predominantly due to the changing demography and increased 
longevity. 
ANATOMY OF THE PANCREAS: 
The pancreas is a compound racemose gland, analogous in its structures to the 
salivary glands, though softer and less compactly arranged than those organs. Its 
secretion, the pancreatic juice, carried by the pancreatic duct to the duodenum, is an 
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important digestive fluid. In addition the pancreas has an important internal secretion, 
probably elaborated by the cells of Langerhans, which is taken up by the blood stream 
and is concerned with sugar metabolism. It is long and irregularly prismatic in shape; its 
right extremity, being broad, is called the head, and is connected to the main portion of 
the organ, or body, by a slight constriction, the neck; while its left extremity gradually 
tapers to form the tail. It is situated transversely across the posterior wall of the abdomen, 
at the back of the epigastric and left hypochondriac regions. Its length varies from 12.5 to 
15 cm, and its weight from 60 to 100 gm. 
Microscopic anatomy of islets of Langerhans 
They are found more in the tail of the pancreas than in the other parts. They form 
about 1 – 2% of pancreatic weight.  There are about 2 millions of islets in human 
pancreas.  Each islet has an epithelial mass, tunneled by labyrinthine capillaries.  The 
position of the islets is mostly within the lobules, rather than between them.  Each 
spheroid islet is surrounded by reticular membrane.  Islet tissue is arranged in irregular 
anastomosing cellular plates.  Their epithelial cords are separated by blood vessels.  A 
sphincter controls the blood supply.  The histological structure of the islets shows Alpha, 
Beta and Delta cells. 
Beta cells are the source of insulin hormone.  The cells are polyhedral, the nuclei 
are centrally or eccentrically placed, the cytoplasm is grannular, filled with prominent 
secretary vacuoles containing few ribosomes.  The secretory granules show species 
variations.  In man they are spherical or elongated crystalline body.   
Insulin  
Biosynthesis 
Insulin is produced in the beta cells of the pancreatic islets. It is initially 
synthesized as a single-chain 86-amino-acid precursor polypeptide, preproinsulin. 
Subsequent proteolytic processing removes the aminoterminal signal peptide, giving rise 
to proinsulin. Proinsulin is structurally related to insulin-like growth factors I and II, 
which bind weakly to the insulin receptor. Cleavage of an internal 31-residue fragment 
from proinsulin generates the C peptide and the A (21 amino acids) and B (30 amino 
acids) chains of insulin, which are connected by disulfide bonds. The mature insulin 
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molecule and C peptide are stored together and cosecreted from secretory granules in the 
beta cells. Because the C peptide is cleared more slowly than insulin, it is a useful marker 
of insulin secretion and allows discrimination of endogenous and exogenous sources of 
insulin in the evaluation of hypoglycemia. Pancreatic beta cells cosecrete islet amyloid 
polypeptide (IAPP) or amylin, a 37-amino-acid peptide, along with insulin. The role of 
IAPP in normal physiology is unclear, but it is the major component of the amyloid fibrils 
found in the islets of patients with type 2 diabetes, and an analogue is sometimes used in 
treating both type 1 and type 2 DM. Human insulin is now produced by recombinant 
DNA technology; structural alterations at one or more residues are useful for modifying 
its physical and pharmacologic characteristics. 
Secretion 
Glucose is the key regulator of insulin secretion by the pancreatic beta cell, 
although amino acids, ketones, various nutrients, gastrointestinal peptides, and 
neurotransmitters also influence insulin secretion. Glucose levels > 3.9 mmol/L (70 
mg/dL) stimulate insulin synthesis, primarily by enhancing protein translation and 
processing. Glucose stimulation of insulin secretion begins with its transport into the beta 
cell by the GLUT2 glucose transporter. Glucose phosphorylation by glucokinase is the 
rate-limiting step that controls glucose-regulated insulin secretion. Further metabolism of 
glucose-6-phosphate via glycolysis generates ATP, which inhibits the activity of an ATP-
sensitive K+ channel. This channel consists of two separate proteins: one is the binding 
site for certain oral hypoglycemics (e.g., sulfonylureas, meglitinides); the other is an 
inwardly rectifying K+ channel protein. Inhibition of this K+ channel induces beta cell 
membrane depolarization, which opens voltage-dependent calcium channels (leading to 
an influx of calcium), and stimulates insulin secretion. Insulin secretory profiles reveal a 
pulsatile pattern of hormone release, with small secretory bursts occurring about every 10 
min, superimposed upon greater amplitude oscillations of about 80–150 min. Incretins are 
released from neuroendocrine cells of the gastrointestinal tract following food ingestion 
and amplify glucose-stimulated insulin secretion and suppress glucagon secretion. 
Glucagon-like peptide 1 (GLP-1), the most potent incretin, is released from L cells in the 
small intestine and stimulates insulin secretion only when the blood glucose is above the 
fasting level. Incretin analogues, such as exena-tide, are being used to enhance 
endogenous insulin secretion. 
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Action 
Once insulin is secreted into the portal venous system, ~50% is degraded by the 
liver. Unextracted insulin enters the systemic circulation where it binds to receptors in 
target sites. Insulin binding to its receptor stimulates intrinsic tyrosine kinase activity, 
leading to receptor autophosphorylation and the recruitment of intracellular signaling 
molecules, such as insulin receptor substrates (IRS) IRS and other adaptor proteins 
initiate a complex cascade of phosphorylation and dephosphorylation reactions, resulting 
in the widespread metabolic and mitogenic effects of insulin. As an example, activation 
of the phosphatidylinositol-3'-kinase (PI-3-kinase) pathway stimulates translocation of 
glucose transporters (e.g., GLUT4) to the cell surface, an event that is crucial for glucose 
uptake by skeletal muscle and fat. Activation of other insulin receptor signaling pathways 
induces glycogen synthesis, protein synthesis, lipogenesis, and regulation of various 
genes in insulin-responsive cells. 
Glucose homeostasis reflects a balance between hepatic glucose production and 
peripheral glucose uptake and utilization. Insulin is the most important regulator of this 
metabolic equilibrium, but neural input, metabolic signals, and other hormones (e.g., 
glucagon) result in integrated control of glucose supply and utilization. In the fasting 
state, low insulin levels increase glucose production by promoting hepatic 
gluconeogenesis and glycogenolysis and reduce glucose uptake in insulin-sensitive 
tissues (skeletal muscle and fat), thereby promoting mobilization of stored precursors 
such as amino acids and free fatty acids (lipolysis). Glucagon, secreted by pancreatic 
alpha cells when blood glucose or insulin levels are low, stimulates glycogenolysis and 
gluconeogenesis by the liver and renal medulla. Postprandially, the glucose load elicits a 
rise in insulin and fall in glucagon, leading to a reversal of these processes. Insulin, an 
anabolic hormone, promotes the storage of carbohydrate and fat and protein synthesis. 
The major portion of postprandial glucose is utilized by skeletal muscle, an effect of 
insulin-stimulated glucose uptake. Other tissues, most notably the brain, utilize glucose in 
an insulin-independent fashion [Harrison's Principle of Internal Medicine 17 Ed. 2008]. 
 
 
 
33 
 
General symptoms Diabetes mellitus 
· Increased thirst 
· Frequent urination, passing large quantities of urine, hence dehydration 
· Increased hunger 
· Feeling very tired without any particular reason 
· Blurred vision due to dehydration of eye lens 
· Continuous ache, pain in legs and feet including numbness, burning sensation, or 
no sensation 
· No healing of cuts, wounds, boils and sores 
· Skin infection, especially around genital area, vaginal infection in women, urinary 
tract infection 
· Impotence 
· Weight loss 
Types of Diabetes 
Diabetes basically can be categorized into two types (WHO, 1985). Diabetes insipides 
and Diabetes mellitus. 
Types of Diabetes mellitus 
 There are several types of diabetes mellitus. The following classification system 
for diabetes was endoned by the board of directors of the American Diabetes Association 
at its 1979 annual meeting and also by the World Health Organization (1994). 
I. Type 1 diabetes (-cell destruction, usually leading to absolute insulin deficiency) 
A. Immune-mediated 
B. Idiopathic 
II. Type 2 diabetes (may range from predominantly insulin resistance with relative 
insulin deficiency to a predominantly insulin secretary defect with insulin resistance) 
Other specific types of diabetes 
 A. Genetic defects of -cell function characterized by mutations in: 
· Hepatocyte nuclear transcription factor (HNF) 4 (MODY 1) 
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· Glucokinase (MODY 2) 
· HNF-1 (MODY 3) 
· Insulin promoter factor (IPF) 1 (MODY 4) 
· HNF-1 (MODY 5) 
· Mitochondrial DNA 
· Proinsulin or insulin conversion 
 B. Genetic defects in insulin action 
§ Type A insulin resistance 
§ Leprechaunism 
§ Rabson-Mendenhall syndrome 
§ Lipoatrophic diabetes 
 C. Diseases of the exocrine pancreas-pancreatitis, pancreatectomy,  
 neoplasia, cystic fibrosis, hemochromatosis, fibrocalculous  pancreatopathy 
D. Endocrinopathies acromegaly, Cushing’s syndrome, glucagonoma  
pheochromocytoma, hyperthyroidism, somatostatinoma, aldosteronoma 
 E. Drug- or chemical-induced Vacor, pentamidine, nicotinic acid,   
 glucocorticoids, thyroid hormone, diazoxide, -adrenergic agonists,   
 thiazides, phenytoin, interferon, protease inhibitors, clozapine, beta   
 blockers 
 F. Infections: congenital rubella, cytomegalovirus, coxsackie 
 G. Uncommon forms of immune-mediated diabetes:  
“stiff-man” syndrome, anti-insulin receptor antibodies. 
 H. Other genetic syndromes sometimes associated with diabetes:  
Down’s syndrome, Klinefelter’s syndrome, Turner’s syndrome, Wolfram’s  
 syndrome, Friedreich’s ataxia, Huntington’s chorea, Laurence-Moon-Biedl  
 syndrome, myotonic dystrophy, porphyria, Prader-Willi syndrome 
I. Gestational diabetes mellitus (GDM) 
J. MODY: Maturity onset of diabetes of the young. 
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TYPE-I DIABETES MELLITUS 
(INSULIN DEPENDENT DIABETES MELLITUS) 
Genetics 
               The genetic contributions to type 1 DM involve multiple genes. The 
development of the disease appears to require inheritance of a sufficient complement of 
genes to confer susceptibility to the disorder. The concordance of type 1 DM in identical 
twins ranges between 30 and 70%, indicating that additional modifying factors must be 
involved in determining whether diabetes develops. 
 The major susceptibility gene for type 1 DM is located in the HLA region on 
chromosome 6. Polymorphisms in the HLA complex appear to account for 40 to 50% of 
the genetic risk of developing type 1 DM. 
 Most individuals with type 1 DM have the HLA DR3 and/or DR4 haplotype. 
Genes that confer protection against the development of the disease also exist. For 
example, the haplotype DQA1*0102, DQB1*0602 is present in 20% of the U.S. 
population but is extremely rare in individuals with type 1DM (<1%). 
Environmental Factors 
 It has been proposed that lack of exposure to pathogenic organisms in early 
childhood limits maturation of the immune system and increases susceptibility to 
autoimmune disease (‘the hygiene hypothesis’), Viruses, Diet, Stress, Immunological 
factors 
Viruses 
     The evidence that viral infection might cause some forms of type 1 diabetes is derived 
from studies where virus particles known to cause cytopathic or autoimmune damage to 
beta cells. The viruses have been isolated from the pancreas.Viruses that causes type 1 
diabetes include Mumps, Coxsackie B4, retroviruses, rubella (in utero), cytomegalovirus 
and Epstein-Barr virus. 
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Diet 
   Dietary factors may influence the development of type 1 diabetes.  Bovine serum 
albumin (BSA), a major constituent of cow’s milk, has been implicated in triggering type 
1 diabetes. It has been shown that children who are given cow’s milk early in infancy are 
more likely to develop type 1 diabetes than those who are breastfed.  BSA may cross the 
neonatal gut and raise antibodies which, because of the close homology between BSA, 
the Beta chain of HLA class II antigens and a heat-shock protein expressed by beta cells, 
could cross-react with and cause damage to beta cell components.Various nitrosamines  
and coffee have been proposed as potentially diabetogenic factors. 
Stress 
       Stress may progress the development of type 1 diabetes by stimulating the secretion 
of counter-regulatory hormones and possibly by modulating immune activity. 
Immunological Factors 
      Type 1 diabetes is a slow T cell-mediated autoimmune disease.  Family studies have 
produced evidence that destruction of the insulin-secreting cells in the pancreatic islets 
takes place over many years.  Hyperglycaemia accompanied by the classical symptoms of 
diabetes occurs only when 70-90% of beta cells have been destroyed. In humans and 
animals with spontaneous type 1 diabetes the immune system retains the capacity to 
recognize and destroy transplanted pancreatic beta cells indefinitely. 
 
TYPE-II DIABETES MELLITUS 
(NON INSULIN DEPENDENT DIABETES MELLITUS) 
 Type 2 diabetes commonly occurs in subjects who are obese and insulin-resistant, 
but these two factors alone are insufficient to cause diabetes unless accompanied by 
impaired beta cell function. 
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Genetics 
        Type 2 DM has a strong genetic component. Although the major genes that 
predispose to this disorder have yet to be identified, it is clear that the disease is polygenic 
and multifactorial. 
  Various genetic loci contribute to susceptibility, and environmental factors (such 
as nutrition and physical activity) further modulate phenotypic expression of the disease. 
The concordance of type 2 DM in identical twins is between 70 and 90%. Individuals 
with a parent with type 2 DM have an increased risk of diabetes; if both parents have type 
2 DM, the risk in offspring may reach 40%. Insulin resistance, as demonstrated by 
reduced glucose utilization in skeletal muscle, is present in many nondiabetic, first-degree 
relatives of individuals with type 2 DM. However, definition of the genetic abnormalities 
of type 2 DM remains a challenge because the genetic defect in insulin secretion or action 
may not manifest itself unless an environmental event or another genetic defect, such as 
obesity, is superimposed. 
Environmental Factors 
1. Life Style 
Epidemiological studies of  type 2 diabetes provide evidence that over eating, 
especially when combined with obesity, middle-aged people with diabetes eat 
significantly more and are fatter and less active than their non-diabetic siblings. Obesity 
probably acts as a diabetogenic factor (through increasing resistance to the action of 
insulin) in those genetically predisposed to develop type 2 diabetes.  
2. Malnutrition in utero 
     Retrospective analysis of the birth weight of males has born an inverse relationship 
between weight at birth and at 1 year, and the development of type 2 diabetes in late 
adulthood. It is proposed (but not yet proven) that malnutrition in utero may programme 
beta cell development and metabolic functions at a critical period, so predisposing to type 
2 diabetes later in life. Smoking during pregnancy has also been implicated. 
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3. Age 
     Age is an important risk factor for type 2 diabetes. Over 70% of all cases of diabetes 
occur after the age of 50 years.  Type 2 diabetes is principally a disease of the middle 
aged and elderly, affecting 10% of the population over the age of 65. 
4. Pregnancy 
     During normal pregnancy, insulin sensitivity is reduced through the action of placental 
hormones and this affects glucose tolerance. The term ‘gestational diabetes’ refers to 
hyperglycaemia occuring for the first time during pregnancy.  Repeated pregnancy may 
increase the likelihood of developing irreversible diabetes, particularly in obese women; 
80% of women with gestational diabetes ultimately develop permanent clinical diabetes 
requiring treatment. 
Pathogenesis of type 2 diabetes 
Insulin resistance 
 Increased hepatic production of glucose and resistance to the action of insulin in 
muscle  are invariable in both obese and non-obese patients with type2 diabetes. Insulin 
resistance may be due to any one of three general causes: an abnormal insulin molecule, 
an excessive amount of circulating antagonists, or target tissue defects. The last is the 
most common cause of insulin resistance in type 2 diabetes and seems to be the 
predominant abnormality in those with more severe hyperglycaemia. 
 A characteristic feature of type 2 diabetes is that it is often associated with other 
medical disorders including obesity, hypertension and hyperlipidaemia. It has been 
suggested that this cluster of conditions, all of which predispose to cardiovascular disease, 
is a specific entity (the ‘insulin resistance syndrome’ or ‘metabolic syndrome’), with 
insulin resistance being the primary defect. 
Pancreatic beta cell failure 
                  In type 2 diabetes there is only moderate reduction in the total mass of 
pancreatic islet tissue which is consistent with a measurable fall in plasma insulin 
concentration when related to the blood glucose level. However, some pathological 
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changes are typical of type 2 diabetes, the most consistent of which is deposition of 
amyloid. This is accompanied by atrophy of the normal tissue, particularly islet epithelial 
cells. Islet amyloid is composed of insoluble fibrils formed from islet amyloid 
polypeptide  (also known as amylin). Small quantities of islet amyloid are very common 
in elderly non-diabetic patients, and the role of islet amyloid in the pathogenesis of type 2 
diabetes is uncertain. Deposition of amyloid is probably not a cause of diabetes but rather 
reflects a pathological process which is increased in type 2 diabetes. More extensive 
amyloidosis is, however, found in patients who have progressed to insulin replacement 
therapy, suggesting that islet function may become compromised by amyloid deposition. 
 While beta cell numbers are reduced by 20-30% in type 2 diabetes, alpha cell 
mass is unchanged and glucagons secretion is increased, which may contribute to the 
hyperglycaemia. Insulin resistance tends to raise blood glucose and this stimulates insulin 
secretion to prevent hyperglycaemia . when the maximal insulin secretory capacity has 
been exceeded, any further increase in fasting blood glucose levels causes a decline in 
insulin generation. Possible mechanisms for beta cell decompensation include 
glucotoxicity, an intrinsic failure of insulin production, a switch to abnormal processing 
pathways producing biologically inactive products and chronic degranulation of the beta 
cell. 
GESTATIONAL DIABETES 
         Gestational diabetes, defined as hyperglycaemia diagnosed for the first time in 
pregnancy, is a common problem.  It occurs in individuals who have an inherited 
predisposition to develop diabetes and may take the form of either type I or type II 
diabetes.  The hyperglycaemia may not disappear after delivery.  It is associated not only 
with increased rates of perinatal mortality and neonatal morbidity but also with a high 
incidence (possibly as great as 80% at 25 years postpartum) of subsequent clinical 
diabetes (both type I and type II) in the mother. Normalisation of metabolism, whether by 
treatment with dietary measures alone or, more commonly, with additional treatment in 
the form of insulin, undoubtedly reduces the fetal risk; its effect on diminishing the 
maternal risk of subsequent diabetes is less certain. 
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MAJOR  MANIFESTATIONS  OF  DISEASE 
Hyper Glycaemia: 
 Hyperglycaemia is a very common biochemical abnormality. It is frequently 
detected on routine biochemical analysis of asymptomatic patients, and is found during 
conditions which impose a burden on pancreatic beta cells, such as pregnancy, severe 
illness or treatment with drugs such as corticosteriods(‘stress hyperglycaemia’). 
Symptoms of Hyperglycemia Associated With Diabetes 
§ Thirst, dry mouth. 
§ Poly uria. 
§ Nocturia. 
§ Tiredness, fatigue, irritability. 
§ Recent change in weight. 
§ Blurring of vision. 
§ Pruritus vulvae, balanitis(genital condidiasis) 
§ Nausea; headache 
§ Hyperphagia; predilection for sweet foods 
Diabetic Ketoacidosis: 
 Keto acidosis is caused by insulin deficiency and an increase in catabolic 
hormones, leading to hepatic over-production of glucose and ketone bodies. The cardinal 
biochemical features of diabetic ketoacidosis are 
§ Hyperglycaemia 
§ Hyperketonaemia 
§ Metabolic acidosis 
COMPLICATIONS OF DIABETES MELLITUS 
1. Acute Complications 
§ Diabetic ketoacidosis (DKA) 
§ Nonketotic hyperosmolar state(NKHS) 
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Diabetic Ketoacidosis: 
                       Diabetic ketoacidosis is a major medical emergency and remains a serious 
cause of morbidity, principally in people with type 1 diabetes. The average mortality in 
developed countries is 5-10% and is higher in the elderly. 
 A clear understanding of the biochemical basis and pathophysiology of this 
problem is essential for its efficient treatment. 
Ketoacidosis is caused by insulin deficiency and an increase in catabolic 
hormones, leading to hepatic over-production of glucose and ketone bodies. 
The cardinal biochemical features of diabetic ketoacidosis are: 
§ hyperglycaemia 
§ hyperketonaemia 
§ metabolic acidosis. 
         Hyperglycaemia causes a profound osmotic diuresis leading to dehydration and 
electrolyte loss, particularly of sodium and potassium. The metabolic acidosis forces 
hydrogen ions into cells, displacing potassium ions, which may be lost in urine or through 
vomiting. 
 About half the deficit of total body water is derived from the intracellular 
compartment and occurs comparatively early in the development of acidosis with 
relatively few clinical features; the remainder represents loss of extra cellular fluid 
sustained largely in the later stages. It is at this time that marked contraction of the size of 
the extra cellular space occurs, with haemoconcentration, a decreased blood volume, and 
finally a fall in blood pressure with associated renal ischaemia and oliguria. 
           Every patient in diabetic ketoacidosis is potassium-depleted, but the plasma 
concentration of potassium gives very little indication of the total body deficit. Plasma 
potassium may even be raised initially due to disproportionate loss of water and 
catabolism of protein and glycogen.  
 However, soon after insulin treatment is started there is likely to be precipitous 
fall in the plasma potassium due to dilution of extra cellular potassium by administration 
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of intravenous fluids, the movement of potassium into cells as a result of treatment with 
insulin, and the continuing renal loss of potassium. 
 The severity of ketoacidosis can be assessed rapidly by measuring the plasma 
bicarbonate; less than 12 mmol/l indicates severe acidosis. 
Clinical features: 
a.Symptoms -  Nausea,vomitingThirst,polyuria,Abdominal pain,Altered mental function 
and Shortness of breath 
b.Physical findings - Tachycardia,Dry mucous membranes, reduced skin 
turgor,Dehydration, hypotension,Tachypnea, Kussmaul respirations, respiratory 
distress,Abdominal tenderness, (may resemble acute pancreatitis or surgical 
abdomen)FeverLethargy ,obtundation , cerebral edema and possibly comac.  
c.Precipitating events - Inadequate insulin administration, infection (pneumonia/ UTI/ 
gastroenteritis / sepsis), Infarction (cerebral, coronary, mesenteric, peripheral) and drugs 
(cocaine) 
Nonketotic Hyperosmolar State 
 Clinical Features - NKHS is most commonly seen in elderly individuals with 
type 2 DM. Its most prominent features include polyuria; orthostatic hypotension; and a 
variety of neurologic symptoms that include altered mental status, lethargy, obtundation, 
seizure, and possibly coma.  
 The prototypical patient is a mildly diabetic, elderly individual with a several 
week history of polyuria, weight loss, and diminished oral intake that culminates in 
mental confusion, lethargy, or coma. The physical examination reflects profound 
dehydration and hyperosmolality and reveals hypotension, tachycardia, and altered 
mental status 
 NKHS is often precipitated by a serious, concurrent illness such as myocardial 
infarction or stroke. Sepsis, pneumonia, and other serious infections are frequent 
precipitants and should be sought thoroughly. In addition, a debilitating condition (prior 
stroke or dementia) or social situation that compromises water intake may contribute to 
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the development of the disorder. Finally, the development of NKHS can be associated 
with the use of certain medications (thiazide diuretics, glucocorticoids, phenytoin). 
2. Chronic Complications of Diabetes Mellitus  
a. Microvascular  
§ Eye disease 
§ Retinopathy(nonproliferative/proliferative) 
§ Macular edema 
§ Cataracts 
§ Glaucoma 
§ Neuropathy 
§ Sensory and motor (mono- and polyneuropathy) 
§ Nephropathy.  
b. Macrovascular 
§ Coronary artery disease 
§ Peripheral vascular disease 
§ Cerebrovascular disease  
c. Other 
§ Gastrointestinal (gastroparesis, diarrhea) 
§ Genitourinary (uropathy/sexual dysfunction) 
§ Dermatologic 
DIABETIC RETINOPATHY 
         Diabetic retinopathy is the most common cause of blindness in adults between 30 
and 65 years of age in developed countries. 
Pathogenesis 
     Hyperglycaemia increases retinal blood flow and metabolism and has direct 
effects on retinal endothelial cells and pericytes, loss of which impairs vascular 
autoregulation.    
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 The resulting uncontrolled blood flow increases production of vasoactive 
substances and endothelial cell proliferation, resulting in capillary closure. This causes 
chronic retinal hypoxia and stimulated production of growth factors, including vascular 
endothelial growth factor (VEGF). VEGF acts via protein kinase C to stimulate 
endothelial cell growth (causing new vessel formation) and increased vascular 
permeability (causing exudative damage). 
Clinical Features Of Diabetic Retinopathy 
§ Microaneurysms 
§ Retinal haemorrhages 
§ Exudates 
§ Cotton wool spots 
§ Venous changes 
§ No vascularisation 
§ Pre-retinal haemorrhage 
§ Vitreous haemorrhage 
§ Fibrosis 
Microaneurysms 
 In most cases these are the earliest clinical abnormality detected. They appear as 
tiny, discrete, circular, dark red spots near to, but apparently separate from, the retinal 
vessels.  They look like tiny haemorrhages but photographs of injected preparations of 
retina show that they are in fact minute aneurysms arising mainly from the venous end of 
capillaries near areas of capillary closure. 
Haemorrhages 
 These most characteristically occur in the deeper layers of the retina and hence are 
round and regular in shape and described as ‘blot’ haemorrhages.  The smaller ones may 
be difficult to differentiate from microaneurysms and the two are often grouped together 
as ‘dots and blots’.  Superficial flame-shaped haemorrhages may also occur, particularly 
if the patient is hypertensive. 
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Exudates 
      These are characteristic of diabetic retinopathy.  They vary in size from tiny 
specks to large confluent patches and tend to occur particularly in the perimacular area.  
They result from leakage of plasma from abnormal retinal capillaries and overlie areas of 
neuronal degeneration. 
Cotton Wool Spots 
 These are similar to those seen in hypertension, and also occur particularly within 
five disc diameters of the optic disc. They represent arteriolar occlusions causing retinal 
ischaemia and hence are a feature of  pre-proliferative diabetic retinopathy; they are most 
often seen in rapidly advancing retinopathy or in association with uncontrolled 
hypertension. 
Intraretinal microvascular abnormalities 
 Intraretinal microvascular abnormalities (IRMA) are dilated, tortuous capillaries 
which represent the remaining patent capillaries in an area where most have been 
occluded. 
Neovascularisation 
 This may arise from the venous circulation on the optic disc or the retina in 
response to areas of ischaemic retina.  The earliest appearance is that of fine tufts of 
delicate vessels forming arcades on the surface of the retina.  As they grow, they may 
extend forwards towards the vitreous. 
 This first appears as a white, cloudy haze among the network of new vessels.  As 
it extends, the new vessels may be obliterated and the surrounding retina covered by a 
dense white sheet.  At this stage, bleeding is less common but retinal detachment can 
occur due to contraction of adhesions between the vitreous and the retina. 
Venous Changes 
      These include venous dilatation (an early feature probably representing increased 
blood flow), ‘beading’ (sausage-like changes in calibre) and increased tortuosity 
including ‘oxbow lakes’ or loops.   
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 These latter changes indicate widespread capillary non-perfusion and are a feature 
of advanced pre-proliferative retinopathy. 
Cataract 
       Cataract is permanent lens opacity and is the most common cause of visual 
deterioration in the elderly population. 
 The lens thickens and pacifies with age, and the increased metabolic insult to the 
lens in people with diabetes causes these changes to accelerate and occur prematurely. 
Very rarely, a type of cataract specific to diabetes occurs in young patients with poorly 
controlled diabetes, called a ‘snow-flake’ cataract. This does not usually affect vision but 
tens to make fundal examination difficult. 
Renal Complications of Diabetes Mellitus 
 Diabetic nephropathy is the leading cause of ESRD in the United States and a 
leading cause of DM-related morbidity and mortality. Proteinuria in individuals with DM 
is associated with markedly reduced survival and increased risk of cardiovascular disease. 
Individuals with diabetic nephropathy almost always have diabetic retinopathy also. 
Like other microvascular complications, the pathogenesis of diabetic nephropathy 
is related to chronic hyperglycemia. The mechanisms by which chronic hyperglycemia 
leads to ESRD, though incompletely defined, involve the following: interaction of soluble 
factors (growth factors, angiotensin II, endothelin, AGEs), hemodynamic alterations in 
the renal microcirculation (glomerular hyperfiltration, increased glomerular capillary 
pressure), and structural changes in the glomerulus (increased extracellular matrix, 
basement membrane thickening, mesangial expansion, fibrosis). Some of these effects 
may be mediated through angiotensin receptors. Smoking accelerates the decline in renal 
function. 
The natural history of diabetic nephropathy is shown schematically in and is 
characterized by a fairly predictable pattern of events. Although this sequence of events 
was defined for individuals with type 1 DM, a similar pattern is also likely in type 2 DM. 
Glomerular hyperfusion and renal hypertrophy occur in the first years after the onset of 
DM and are reflected by an increased glomerular filtration rate (GFR).  
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During the first 5 years of DM, thickening of the glomerular basement membrane, 
glomerular hypertrophy, and mesangial volume expansion occur as the GFR returns to 
normal. After 5 to 10 years of type 1 DM, ~40% of individuals begin to excrete small 
amounts of albumin in the urine (microalbuminuria). Microalbuminuria is defined as 30 
to 300 mg/d in a 24-h collection or 30 to 300 ug/mg creatinine in a spot collection.  
 The appearance of microalbuminuria (incipient nephropathy) in type 1 DM is a 
very important predictor of progression to overt proteinuria (>300 mg/d). Blood pressure 
may rise slightly at this point but usually remains in the normal range. Once overt 
proteinuria is present, there is a steady decline in GFR, and ~50% of individuals reach 
ESRD in 7 to 10 years. The early pathologic changes and albumin excretion abnormalities 
are reversible with normalization of plasma glucose. However, once nephropathy 
becomes overt, the pathologic changes are likely irreversible. 
 The nephropathy that develops in type 2 DM differs from that of type 1 DM in 
the following respects: 
§ Microalbuminuria or over nephropathy may be present when type 2 DM is 
diagnosed, reflecting its long asymptomatic period;  
§ Hypertension more commonly accompanies microalbuminuria or overt 
nephropathy in type 2 DM; and  
§ Microalbuminuria may be less predictive of progression to overt nephropathy in 
type 2 DM. Finally, it should be noted that albuminuria in type 2 DM may be 
secondary to factors unrelated to DM, such as hypertension, congestive heart 
failure, prostate disease, or infection. 
Other renal problems may also occur in individuals with DM. Type IV renal tubular 
acidosis (hyporeninemic hypoaldosteronism) occurs in many individuals with DM. 
NEUROPATHY AND DIABETES MELLITUS 
              Diabetic neuropathy occurs in approximately 50% of individuals with long-
standing type 1 and type 2 DM. It may manifest as polyneuropathy, mononeuropathy, 
and/or autonomic neuropathy. 
Polyneuropathy / Mononeuropathy: The most common form of diabetic neuropathy is 
distal symmetric polyneuropathy. It most frequently presents with distal sensory loss. 
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Hyperesthesia, parathesia, and pain also occur. Any combination of these symptoms may 
develop as neuropathy progresses. Physical examination reveals sensory loss, loss of 
ankle reflexes, and abnormal position sense. 
Diabetic polyradiculopathy is a syndrome characterized by severe disabling pain in the 
distribution of one or more nerve roots. It may be accompanied by motor weakness. 
Intercostal or truncal radiculopathy causes pain over the thorax or abdomen. Involvement 
of the lumbar plexus or femoral nerve may cause pain in the thigh or hip and may be 
associated with muscle weakness in the hip flexors or extensors (diabetic amyotrophy). 
Fortunately, diabetic polyradiculopathies are usually self-limited and resolve over 6 to 12 
months. 
Mononeuropathy (dysfunction of isolated cranial or peripheral nerves) is less common 
than polyneuropathy in DM and presents with pain and motor weakness in the 
distribution of a single nerve. A vascular etiology is favored, but the pathogenesis is 
unknown. Involvement of the third cranial nerve is most common and is heralded by 
diplopia. 
Autonomic Neuropathy Individuals with long-standing type 1 or 2 DM may develop 
signs of autonomic dysfunction involving the cholinergic, noradrenergic, and peptidergic 
(peptides such as pancreatic polypeptide, substance P, etc.) systems. DM-related 
autonomic neuropathy can involve multiple systems including: the cardiovascular, 
gastrointestinal, genitourinary, sudomotor, and metabolic systems. 
 Autonomic neuropathies affecting the cardiovascular system cause a resting 
tachycardia and orthostatic hypotension. Reports of sudden death have also been 
attributed to autonomic neuropathy. Gastroparesis and bladder-emptying abnormalities 
are also likely related to the autonomic neuropathy seen in DM (discussed below). 
Hyperhidrosis of the upper extremities and anhidrosis of the lower extremities result from 
sympathetic nervous system dysfunction. Anhidrosis of the feet can promote dry skin 
with cracking, which increases the risk of skin ulceration. 
  Autonomic neuropathy may reduce counterregulatory hormone release, leading to 
an inability to sense hypoglycemia appropriately hypoglycemia unawareness;  thereby 
subjecting the patient to the risk of severe hypoglycemia and complicating efforts to 
improve glycemic control. 
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Cardiovascular Morbidity and Mortality 
 Cardiovascular disease is increased in individuals with type 1 or type 2 DM. The 
Framingham Heart Study revealed a marked increase in several cardiovascular diseases in 
DM including peripheral vascular disease, congestive heart failure, coronary artery 
disease, myocardial infarction, and sudden death (risk increase from one- to fivefold). 
  The extremely high frequency of underlying cardiovascular disease in individuals 
with diabetes (especially in type 2 DM).The absence of chest pain (“silent ischemia”) is 
common in individuals with diabetes. 
Cardiovascular Risk Factors 
 Dyslipidemia  Individuals with DM may have several forms of dyslipidemia. 
Because of the additive cardiovascular risk of hyperglycemia and hyperlipidemia, lipid 
abnormalities should be aggressively detected and treated as part of comprehensive 
diabetes care. The most common pattern of dyslipidemia is hypertriglyceridemia and 
reduced HDL cholesterol levels. DM itself does not increase levels of LDL, but the small 
dense LDL particles found in type 2 DM are more atherogenic because they are more 
easily glycated and susceptible to oxidation.   
 Hypertension: Hypertension can accelerate other complications of DM, 
particularly cardiovascular disease and nephropathy. Hypertension therapy should first 
emphasize life-style modifications such as weight loss, exercise, stress management, and 
sodium restriction.  
DIABETIC FOOT 
The foot is a frequent site for complication in patients with diabetes and for this reason 
foot care is particularly important. Tissue necrosis in the feet is a common reason for 
hospital admission in diabetic patient. Such admission tend to be prolonged and often end 
with amputation. The clinical features are listed below 
Symptoms 
§ Paresthesia   
§ Pain     
§ Numbness  
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Structural Damage   
§ Ulcer     
§ Sepsis    
§ Abscess                                   
§ Osteomyelitis 
§ Digital gangrene 
§ Charcot joint 
Management of Diabetic Foot Ulcers 
 Remove callus skin, treat infection, avoid weight-bearing, ensure good diabetic 
control, control oedema, undertake angiogram to assess feasibility of vascular 
reconstruction where indicated. 
Clinical examination of the patient with diabetes 
1. Examination Of The Hands 
§ Limited joint mobility (sometimes called cheirorthropathy) may be present; 
this is the inability to extend (to 180) the metacarpophalangeal or 
interphalangeal joints of at least one finger bilaterally.  The effect can be 
demonstrated in the prayer sign.  It causes painless stiffness in the hands, and 
occasionally affects the wrists and shoulders.  
§ Dupuytren’s contracture   is common in diabetes and may include nodules or 
thickening of the skin  and knuckle pads.  
§ Carpal tunnel syndrome  is common in diabetes and presents with wrist pain 
radiating into the hand. 
§ Trigger finger (flexor tenosynovitis)  may be present in people with diabetes. 
§ Muscle-wasting/sensory changes may be present as features of a peripheral 
sensorimotor neuropathy, although this is more common in the lower limbs. 
2.Abdomen 
                 Hepatomegaly 
3.Blood Pressure 
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4.Axilla 
               Acanthosis nigricans 
5.Neck 
  Carotid pulses,  Bruits and thyroid enlargement 
6.Head 
  Xanthelasma, Cranial nerve palsy and eye movements/ptosis 
7.Examination Of The Eyes 
§ Visual acuity 
§ Distance vision using Snellen's chart at 6 metres. 
§ Near vision using standard reading chart. 
Impaired visual acuity may indicate the presence of diabetic eye disease, and serial 
decline may suggest development or progression in severity. Lens opacification, look for 
the red reflex using the ophthalmoscope held 30 cm from the eye. The presence of lens 
opacities or cataract should be noted. 
Fundus examination  
                 The pupils must be dilated with a mydriatic and examined in a darkened room. 
Features of diabetic retinopathy should be noted, including evidence of previous laser 
treatment which leaves photocoagulation scars. 
8.Insulin Injection Sites 
Main areas used are 
Ø Anterior abdominal wall 
Ø Upper thighs/buttocks 
Ø Upper outer arms 
Inspection 
Ø Bruising 
Ø Lumps (lipodystrophy)  
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Ø Subcutaneous fat loss  (lipoatrophy; associated with injection of unpurified animal 
insulins-now rare) 
Ø Erythema, infection (rare) 
9.Legs 
Ø Muscle-wasting 
Ø Sensory abnormality 
Ø Granuloma annulare 
Ø Hair loss 
Ø Tendon reflexes 
Ø Necrobiosis lipoidica 
Ø Neuropathic foot ulcer 
10.Examination Of The Feet 
Inspection 
         Look for evidence of callus formation on weight-bearing areas, clawing of the toes 
(a feature of neuropathy, loss of the plantar arch, discoloration of the skin,ischaemia), 
localised infection and the presence of ulcers. Deformity of the feet may be present, 
especially in charcot neuroarthropathy.Fungal infection may affect skin between toes, and 
nails. 
Circulation 
 Peripheral pulses, skin temperature and capillary refill should be tested. 
Sensation 
§ Light touch: use monofilaments. 
§ Vibration sense: use 128Hz  tuning fork over big toe/malleoli. 
§ Pin-prick:  Use pin 
§ Pain: pressure over Achilles tendon. 
§ Proprioception test: 
Position of big toe  
Test for distal anaesthesia/hyperaesthesia in stocking distribution. 
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Reflexes 
 Test plantar and ankle reflexes 
Management 
Aims of treatment 
§ Adequate control of hyperglycemia and glycosuria 
§ Prevention of complications 
§ Disappearance of diabetic symptoms 
§ Maintenance the appropriate body weight 
All of these, the first two are very important. 
Treatments 
There  are 4  methods of treatments  available for diabetic patients 
§ Ladder diet regime 
§ Diet and oral hypoglycemic agents 
§ Diet and insulin 
§ Special treatment for complications 
DIETARY MANAGEMENT 
Aims of Dietary Management 
· Abolish symptoms of hyperglycaemia 
· Reduce overall blood glucose and minimise fluctuations 
· Achieve weight reduction in obese patients to reduce insulin resistance, 
hyperglycaemia and dyslipidaemia 
· Avoid hypoglycaemia associated with therapeutic agents (insulin, sulphonylureas) 
· Avoid weight gain associated with therapeutic agents (insulin, sulphonylureas, 
thiazolidinediones) 
· Avoid ‘atherogenic’ diets or those which may aggravate diabetic complications 
(e.g. high protein intake in nephropathy) 
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General Principles of Diet for Diabetes: 
 Direction sugar intake in the form of refined carbohydrates should be totally 
avoided.  This includes table sugar, sweets, and jaggery. The total quantity of food must 
be restricted. 
 There is no need to change over from rice to wheat or ragi as the carbohydrate 
content of these different cereals is not significantly different. Green leafy vegetables and 
other low calorie foods can be taken in unlimited quantities. 
Addition of vegetable proteins in the form of bengal gram, green gram, have multiple 
benefits as they: 
a).Increase the protein content 
b).Increase the fibre content 
c).Help to flatten sudden urges of blood sugar after a meal 
d).Help to reduce serum lipid (fat) levels 
e).The diet should help to maintain ideal body weight. 
f).The diet should also help bring down the cholesterol triglyceride levels 
Types of Diabetic Diet 
 The basis types of diet are used in the treatment of diabetes;  
1. Low energy, weight-reducing diets 
2. Weight maintenance diets 
3. Diets for insulin-treated diabetes 
Low-energy, weight-reducing diets 
Dietary prescriptions which cause a daily deficit of 500 kcal provide a realistic diet and 
induce a weekly weight loss of around 0.5 kg.  Rapid weight reduction may provoke loss 
of lean body tissue, and care must be taken in the elderly to avoid the omission of 
essential nutrients, vitamins and minerals. Caloric restriction is essential for the obese 
diabetic patient treated with insulin and most oral agents, to try to minimise the weight 
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gain which these can promote.  In such individuals, the omission of snacks between meals 
is often necessary. 
Weight maintenance diets 
These are necessary for individuals with a normal body mass index  and ideally should be 
high in carbohydrate and low in fat, with particular attention being paid to the type of fat 
ingested.  
Diets for Insulin-Treated Diabetes 
           A regular pattern of meals (and snacks) is important to maintain a constant daily 
intake of carbohydrate, and protects against hypoglycaemia. Simple information on the 
relative carbohydrate content of foods can be provided where appropriate.  Carbohydrate 
exchanges (10 g portions) are currently not advocated as a method of controlling 
carbohydrate intake, as the exchange system makes no allowance for the glycaemic effect 
or for the fat content of foods.  However, a good working knowledge of the carbohydrate 
content of foods is essential for practical management.  An insufficient dose of insulin for 
a meal with a large carbohydrate content leads to post-prandial hyperglycaemia, while 
inadequate carbohydrate consumption risks hypoglycaemia. 
Diabetic Foods and Sweeteners 
 Low-calorie and sugar-free drinks are useful for patients with diabetes.  These 
drinks usually contain non-nutritive sweeteners.  Many ‘diabetic foods’ contain sorbitol 
or fructose which are relatively high in energy, may be expensive and may have 
gastrointestinal side-effects.  They are not recommended as part of the diabetic diet. 
 The non-nutritive sweeteners saccharin, aspartame, sucramate and acesulphame K 
are the most widely used and provide means for reducing energy intake without loss of 
palatability. 
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TRIAL DRUG 
ATTHIPPATTAIYATHI   KASAYAM 
“«ò¾¢ÁÃô Àð¨¼ ¿ýÉ¡Ã¢ ¬Å¡¨Ã ¸¼Ä¢Èïº¢ 
Â¢òÐ¼ý ÁÕ¾¢Öô¨À þ¨ºó¾¿£÷ô âÄ¡ì¦¸¡ý¨È 
¯ò¾§¾¡÷ ÒÇ¢ÂõÀð¨¼ º¢Ú¸£¨Ã º£ó¾¢øÓò¾ 
¿ò¨¾îÝÃ¢ §Å÷¸üÈ¡¨Æ ¿¡Ãò¨¾ §ÅÕ¼íÜð§¼ 
           
¦¸¡ûÇ¡ö ¾¡Ç¢ºÀò¾¢Ã¢ ¾¢Ã¢¸ÎÌ ÌÄ×ÀÄí¸ Ç¢Ãñ¼¡¸ 
Å¢ûÇ¡ö º¡¾¢ôÀò¾¢Ã¢ ¸¡Âõ Á¢Ìò¾ ¸¢Ã¡õÒ ÅÃ¡¸¦É¨¼ 
¦ÁûÇ¡ö ÝÃ½ Á¡öôÀñ½¢ ¦ÅÕ¸Ê¿¡Æ¢ ¿£ÕÆì¸¡öì 
¦¸¡ûÇ¡ö ¸º¡Â Á¢ÕÀÐ¿¡û Üð¼¡¦ÂÕ¨Á §Á¡÷¾Â¢÷” 
      -«¸ò¾¢Â÷ þÃñ¼¡Â¢Ãõ. 
 
INGREDIDENTS: 
Required raw drugs: 
1. Ficus recemosa,Linn     -Atthi  - bark -70gm 
2. Cassia fistula,Linn    -Kontrai - bark -70gm 
3. Cassia auriculata,Linn    -Aavaram - bark -70gm 
4. Salacia reticulate,Wight    -Kadalalinjil - bark -70gm 
5. Madhuca longifolia (Koenig) J. F. Macbr  -Iluppai - bark -70gm 
6. Tamarindus indica,Linn   -Puli  - bark -70gm 
7. Terminalia arjuna (Roxb)    -Maruthu - bark -70gm 
8. Spermacoce hispida,Linn    -Nathaisoori - root -70gm 
9. Citrus medica,Linn     -Naarathai - root -70gm 
10. Hemidesmus indicus,Linn R.Br  -Nannaari - root -70gm 
11. Amaranthus tricolor,Linn   -Sirukeerai - root -70gm 
12. Phyllanthus reticulates,Poir    -Neerpoola - root -70gm 
13. Aloe barbadensis,Miller   -Kattralai - root -70gm 
14. Cyperus rotundus,Linn    -Korai  - root -70gm 
15. Tinospora cordifolia (Willd)   -Seenthil  -stem -70gm 
16. Zingiber officinale,Rosc   -Sukku  -rhizome-70gm 
17. Piper nigrum,Linn     -Milaku -fruit -70gm 
18. Piper longum,Linn    -Thippili -fruit -70gm 
19. Abies spectabilis (D.Don) Mirb   -Thalisa pathri -leaf -70gm 
20. Myristica fragrans,Houtt    -Saathi pathri - aril -4.2gm 
21. Syzygium aromaticum,(Linn) Merrill & Perry -Kirambu -bud -4.2gm 
22. Ferula asafoetida, Linn   -Perungaayam -gum resin-4.2gm 
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PROPERTIES OF THE TRIAL DRUGS 
1.«ò¾¢ôÀð¨¼ 
Å£Ú ¸ÎôÀ¢Ãò¾õ ¦Åñº£¾ Ãò¾¦Á¡Î 
¿¡ÚÅ¢Ã ½í¸¦ÇÄ¡õ ¿¡¼¡Å¡õ- ÜÚí¸¡ø 
«ò¾¢¾Õ §Á¸õ§À¡õ ¬Â¢¨Æ§Â! ±ï»¡ýÚõ 
«ò¾¢ôÀ¡ü Àð¨¼ì ¸È¢. 
      -«.Ì. 
Botanical Name            :  Ficus racemosa, Linn 
Family             :  Moraceae 
Suvai     :  Thuvarppu 
Thanmai    :  Thatpam 
Pirivu    :  Enippu 
Part Used    : Bark 
Properties   :  Astringent 
 
2.¬Å¡¨Ã Àð¨¼ 
¦º¡øÖ¾üÌ Áð§¼¡ ¦¾¡¨ÄÂ¾¡ §Á¸¿£÷ 
±øÄ¡ ¦ÁÆ¢ìÌ ¦ÁÃ¢Å¸üÚ- ¦ÁøÄÅº 
Á¡Å¡¨Ãô ÀõÀÃõ§À¡ Ä¡ðÎó ¦¾¡Æ¢Ä½í§¸! 
ÂÅ¡¨Ã ãÄ¢ ÂÐ. 
      -«.Ì. 
Botanical Name            :  Cassia auriculata, Linn 
Family             :  Caesalpiniaceae 
Suvai     :  Thuvarppu 
Thanmai    :  Thatpam 
Pirivu    :  Enippu 
Part Used    : Bark 
Properties   : Astringent, Tonic 
 
3.þÖô¨ÀôÀð¨¼ 
ÒñÏõ Ò¨ÃÔÁÚõ §À¡¾ò ÐÅ÷ôÀ¡Ìõ 
±ñÏÁ¸ì¸ÎôÀ¢ ÕìÌ§Á¡- ¦Àñ§½ §¸û 
¿£Ã¢Æ¢× §ÁÌõ ¦¿Î§Á¡¨Á ãÄò¾¡û 
§À¡Ã¼÷¸ ÎôÀ¢Ãò¾õ §À¡õ. 
 
Áó¾ Á§Ã¡º¢Á ¸¡Ý¨Ä º÷ÅÍÃõ 
Å¢óÐ¿ð¼ó ¾¡¸¦Á¡Î ¦ÁöÂ¢¨ÇôÒõ- Óó¾ 
«Öô¨Àô¦Àü §ÈÌ ÁÇ¸ò¾¢ü ¸¡¸¡ 
þÖô¨ÀìÌî Ý¼¾¢¸ ¦Áñ. 
      -«.Ì. 
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Botanical Name            :  Madhuca longifolia (Koenig) J. F. Macbr 
Family             :  Sapotaceae 
Suvai     :  Thuvarppuy 
Thanmai    :  Thatpam 
Pirivu    :  Karppu 
Part Used    : Bark 
Properties    : Alterative, stimulant, astringent, tonic, stomachic 
 
4.¸¼ÄÆ¢ïº¢ø Àð¨¼ 
 
¾£¾¢ø ¯¼ÄÆ¢ïº¢ø ¦ºöÔí Ì½í§¸Ç¡ö 
µÐÁÐ §Á¸ ¦Á¡Æ¢ôÀ¾øÄ¡ø- Å¾ò¾¢ø 
Åó¾ºÄõ À¢ò¾ºÄ Á¡¸Àîº Äó¾¡¸ò 
¦¾¡ó¾ºÄ Óõ§À¡ìÌï ¦º¡ø. 
 
¸ÁÄ Å¢Ã½í ¸º¢¿£ Ã¸üÚõ 
¿¢ÁÄ ÍÃõÅ¢ÄìÌ §¿§Ã- ¸ÁÄÓ 
Á¡§¾! ¸¼ÄÆ¢ïº¢ø ÅýÀð¨¼ §À¾¢¸ðÎï 
º£¾¡§Á ¸õ§À¡ìÌó §¾÷. 
      -«.Ì. 
Botanical Name            :  Salacia oblonga, wall 
Family             :  Celastraceae   
Suvai     :   Thuvarppu 
Thanmai    :  Thatpam 
Pirivu    :  Karppu 
Part Used    :  Root bark 
Properties    : Demulcent, astringent 
 
5.¦¸¡ý¨Èô Àð¨¼ 
 
À¡ñ¼Ãí¸÷ â½¡öô ÀÈì¸ÊòÐ §Á¸ò¨¾ 
Â¡ñ¼¡í¸ì ¨¸ìÌûÅº Á¡ìÌ§Á- ¸¡ñ¼ü 
Ì¾Å¢º¢Ä ¦ºöÐ¼¨Ä §Â¡õÒÁ¢Ð ¿£À¡÷ 
þ¾Æ¢¦ÂÛí ¦¸¡ý¨ÈÒÅ¢ Â¢ø. 
      -§¾.¦ÅñÀ¡. 
Ìð¼í ¸¢ÕÁ¢ ¦¸¡ÎïÝ¨Ä Å¡¾¨ÁÂõ 
Ðð¼ ÁÄÁÕº¢ àÃô§À¡õ- ¾ðÊî 
ÍÃì¸¢ýÈ §À¾¢Ôñ¼¡õ Ðöì¸ò ÐÅ÷Ìõ  
ºÃì¦¸¡ý¨Èì ¸¡Ã½í§¸! º¡üÚ. 
      -«.Ì. 
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Botanical Name            :  Cassia fistula, Linn 
Family             : Caesalpiniaceae  
Suvai     :   Kaippu, thuvarppu 
Thanmai    :  Veppam 
Pirivu    :  Karppu 
Part Used    : Bark 
Properties    : Laxative, astringent. 
6.ÁÕ¾õ Àð¨¼ 
µ¾¦ÁÛ ¿£Ã¢Æ¢¨Å §Â¡ðÎõ À¢Ã§Á¸í 
¸¡¾¦ÁÛ §Å¡¼ì ¸¼òÐí¸¡ñ- §À¡¾ 
ÁÂì¸ ¦Á¡Î¾¡¸ Á¡È¡î ÍÃò¾¢ý 
¾Âì¸ÁÚì Ìõ ÁÕ¾ï º¡üÚ. 
 
Ìð¼§Ã¡¸ ¸í¸¢ÕÁ¢ §¸¡Ã ÅÂ¢üÚÅÄ¢ 
Ðð¼ÅÈð Ý¨Ä ¦¾¡¨ÄÔí¸¡ñ- º¢ðÊô 
¦À¡Õ¾õÀ¡ ¦ÁýÛ Å¢Æ¢ô â¨ÅÂ§Ã! ¿¡Ù 
ÁÕ¾õÀ¡ ¦ÃýÈÇÅ¢ø Á¡öóÐ. 
      -«.Ì. 
Botanical Name            :  Terminalia arjuna (Roxb) 
Family             :  Combretaceae 
Suvai     :   Thuvarppu 
Thanmai    :  Thatpam 
Pirivu    :  Karppu 
Part Used    : Bark 
Properties    : Tonic, Cardiac stimulant. 
7.ÒÇ¢Âõ Àð¨¼ 
ÒÇ¢Â ÁÃò¾¢ý ÒÃ½¢¾¨Éì ¸ñ¼¡ø 
¯¨ÇÁ¡ó¨¾ ÌýÁÅÄ¢ §Â¡Îõ- ÅÇ¢Â¡÷ó¾ 
§À¾¢¸ð ÎõÍÃõ§À¡õ À¢ò¾ÓÚó ¾£ÀÉÁ¡õ 
´¾« º£Ã½§Á ÐýÛ. 
      -À.Ì.º¢(149) 
Botanical Name            :  Tamarindus indica, Linn 
Family             :  Caesalpiniaceae 
Suvai     :   Thuvarppu 
Thanmai    :  Veppam 
Pirivu    :  Karppu 
Part Used    : Bark 
Properties   : Mild astringent, tonic. 
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8.º£ó¾¢ø ¦¸¡Ê 
 
«Ó¾Åø Ä¢ì¦¸¡Ê Âì¸¡Ã ÓñÊ¼ì 
¾¢Á¢ÕÚ §Á¸§¿¡öò ¾£¦ÂÄ¡ Á¡Ú§Á. 
 
§Á¸¦ÁÛ Á¡¾Àò¾¡ø ¦Åó¾ ×Â¢÷ôÀÂ¢¨Ãò 
¾¡¸ Á¼í¸ò ¾½¢ò¾Ä¡ø- ¬¸õ 
«ÁÃ ¦ÃÉÄ¢Õì¸ Å¡¾Ã¢ò¾ Ä¡§Ä 
«Ó¾ÅøÄ¢ ºïº£Å¢ Â¡õ. 
      -§¾Ãý ¦ÅñÀ¡. 
Botanical Name            :  Tinospora cordifolia (Willd) 
Family             :  Menispermaceae 
Suvai     :   Kasappu 
Thanmai    :  Veppam 
Pirivu    :  Kaarppu 
Part Used    : Stem 
Properties    : Alterative, anti periodic, aphrodisiac, demulcent, 
stimulant, 
Stomachic, tonic, mild diuretic 
 
9.¸üÈ¡¨Æ §Å÷ 
¦À¡øÄ¡§Á ¸í¸ÀõÒ ØîÝ¨Ä Ìð¼õÃºõ 
«øÄ¡÷Áò ¾õÀ¸ó¾ ÃíÌýÁõ ±øÄ¡õÅ¢ð 
§¼Ì ÁÃ¢ìÌ ¦ÁÃ¢îºü ¸¢Ã¢îºÃÓ 
Á¡Ì ÁÃ¢ìÌ ÁÕñÎ. 
      -«.Ì. 
Botanical Name            :  Aloe barbadensis, Miller 
Family             :  Liliaceae 
Suvai     :   Siru kasappu 
Thanmai    :  Thatpam 
Pirivu    :  Enippu 
Part Used    : Root 
Properties    : Tonic, alterative, purgative, emmenagogue 
 
10.¿£÷ôâÄ¡ §Å÷ 
Á¡ó¾í¸ ½õ¦À¡ÕÁø Á¡È¡î ºÄòÐ¼§É 
§º÷ó¾ ¦º¡È¢º¢ÃíÌó ¾£Õí¸¡ñ- ²ó¾Æ¢¨Äî 
§º÷ôÀ¡¸ ¦¸¡ñ¼ ¦ºØó¾¢Õ§Å! âÅ¢Ö¨È 
¿£÷ôâÄ¡ô âñ¨¼ ¿¢¨É. 
      -«.Ì. 
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Botanical Name            :  Phyllanthus reticulates, Poir 
Family             :  Euphorbiaceae 
Suvai     :   Enippu, thuvarppu 
Thanmai    :  Thatpam 
Pirivu    :  Enippu 
Part Used    : Root 
Properties    : Alterative, refrigerant, diuretic. 
 
11.¿¡Ãò¨¾ §Å÷ 
 
¿ýÈ¢ ÔÈ×Ä¸¢ø ¿¡Ãò¾í¸¡ö «Õó¾ 
¦ÅýÈ¢ ¾ÕõÒÇ¢ôÀ¡ø ¦ÁöîÍò¾õ- «ýÈ¢Ô§Á¡ 
Å¡¾¦Á¡Î ÌýÁÁÚõ Å¡ü¸¢ÕÁ¢ Ôõ§À¡Ìõ 
¸¡¾ÖÚ ¾£ÀÉÁ¡í ¸¡ñ. 
      -À.Ì.º¢(202) 
Botanical Name            :  Citrus medica, Linn 
Family             :  Rutaceae 
Suvai     :   Thuvarppu 
Thanmai    :  Thatpam 
Pirivu    :  Kaarppu 
Part Used    : Root 
Properties    : Astringent 
 
12.¿ýÉ¡Ã¢ §Å÷ 
 
ºÄ§¾¡¼õ À¢ò¾Á¾¢ ¾¡¸õ ¯Æ¨Ä 
ºÄ§ÁÚ º£¾Á¢ýÉ¡÷ ¾ïÝ- ÎÄ¸Á¾¢ü 
¦º¡ýÉÁÐ §Á¸õÒñ ÍÃÁ¢¨Å¦Â Ä¡¦Á¡Æ¢ìÌõ 
¦ÁýÁÐÃ ¿ýÉ¡Ã¢ §Å÷. 
      -§¾.Ì 
Botanical Name            :  Hemidesmus indicus, Linn R.Br 
Family             :  Periplocaceae 
Suvai     :   Enippu, siru kasappu 
Thanmai    :  Thatpam 
Pirivu    :  Enippu 
Part Used    : Root 
Properties    : Alterative, tonic, demulcent, diuretic, diaphoretic. 
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13.¿ò¨¾îÝÃ¢ (ÌÆ¢Á£ð¼¡ý) §Å÷ 
¸½ò¾¢¦ÄØ Á¡ó¾ò¨¾ì ¸¡½¡×ð Ýð¨¼ì 
¸½ò¾¢§Ä §Å¨Ãì ¸¨ÇÔõ- ÁÉ¢ò¾Ó¨Äô 
À¡¨Äî ÍÃôÀ¢ìÌõ À¡Ã¢ü ÌÆ¢Á£ð¼¡ý 
¸¡¨Äò ¦¾¡ØÐñÏí ¸¡ø. 
      -À.Ì.º¢. 
Botanical Name            :  Spermacose hispida, Linn 
Family             :  Rubiaceae 
Suvai     :   Enippu, thuvarppu 
Thanmai    :  Thatpam 
Pirivu    :  Enippu 
Part Used    : Root 
Properties    : Alterative, tonic 
14.º¢Ú¸£¨Ã §Å÷ 
¸ñÒ¨¸îº §¿ò¾¢Ã§¿¡ö ¸¡ºõ À¼Äõ 
Òñ¸¢Ã¢îº Ãï§º¡¨À ¦À¡íÌÀ¢ò¾- ÁñÀÃ× 
¾¡ÅÃÅ¢¼í¸Ùõ §À¡õ ¾¡Æ¡ò ¾¢Õ×Óñ¼¡õ 
ÜÚº¢Ú ¸£¨Ã¾¨Éì ¦¸¡û. 
      -«.Ì. 
Botanical Name            :  Amaranthus tricolor, Linn 
Family             :  Amaranthaceae 
Suvai     :   Enippu 
Thanmai    :  Thatpam 
Pirivu    :  Enippu 
Part Used    : Root 
Properties    : Diuretic, refrigerant, laxative 
15.¾¡Ç¢ºÀò¾¢Ã¢ 
¿¡º¢ ¸ÇôÀ¢½¢¸û ¿¡ðÀð¼ ¸¡ºïÍ 
Å¡ºõ «Õº¢ ÅÁÉõ¸¡ø- Å£º¢ÅÕ 
§Á¸Áó¾õ «ò¾¢º¢Ãõ Å¢ð§¼Ìó ¾¡Ç¢îºò¾¡ø 
¬Ìï Í¸ôÀ¢Ãº Åõ. 
      -«.Ì. 
Botanical Name            :  Taxus baccata, Linn 
Family             :  Taxaceae 
Suvai     :   Kaarppu 
Thanmai    :  Veppam 
Pirivu    :  Kaarppu 
Part Used    : Leaf 
Properties    : Stomachic, carminative, expectorant, tonic. 
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16.ÍìÌ 
Ý¨ÄÁó¾õ ¦¿ï¦ºÃ¢ôÒ §¾¡¼§Áô ÀõÁÆ¨Ä 
ãÄõ þ¨ÃôÀ¢ÕÁø ãìÌ¿£÷- Å¡Ä¸À 
§¾¡¼Á¾¢ º¡Ãó ¦¾¡¼÷Å¡¾ ÌýÁ¿£÷ò 
§¾¡¼õ¬ Áõ§À¡ìÌï ÍìÌ. 
      -«.Ì 
Botanical Name            :  Zingiber officinale, Rosc 
Family             :  Zingiberaceae 
Suvai     :   Kaarppu 
Thanmai    :  Veppam 
Pirivu    :  Kaarppu 
Part Used    : Rhizome 
Properties    : Stimulant, stomachic, carminative. 
 
17.Á¢ÇÌ 
º£¾ÍÃõ À¡ñÎ º¢§ÄòÁí ¸¢Ã¡½¢ÌýÁõ 
Å¡¾õ «Õº¢À¢ò¾õ Á¡ãÄõ- µÐºýÉ¢ 
Â¡ºÁÀŠ Á¡Ãõ «¼ý§Á¸õ ¸¡ºÁ¢¨Å 
¿¡ºí ¸È¢Á¢Ç¸¢É¡ø. 
      -«.Ì. 
§¸¡Ï¸¢ýÈ Àì¸ÅÄ¢ ÌöÂ×§Ã¡ ¸õÅ¡¾ 
§º¡½¢¾í¸ Øò¾¢üÌû §¾¡ýÚ§¿¡ö- ¸¡½Ã¢Â 
¸¡Ð§¿¡ö Á¡¾÷ÌýÁí ¸¡Á¡¨Ä Áó¾¦ÁýÈ£÷ 
²Ð§¿¡ö ¸¡Â¢Õì¸¢ø ®íÌ. 
      -§¾.Ì. 
¾£Â¡¸¢ ¦ÂíÌõ ¾¢Ã¢ÔÁ¨¾ Â¡ÅòÐ 
§Á¡Â¡Á ¦ÄôÀÊÔ Óñ¼¡ì¸¡ü- À¡Â¡Ð 
§À¡ó¾¢Á¢÷Å¡ ¾í¸¢Ãó¾¢ Òñ½£Õõ Áñ½Å÷Ìõ 
¸¡ó¾¢¦ÁöÅ¡ ¾îºÖô¨Àì ¸¡ö. 
      -§¾Ãñ ¦ÅñÀ¡. 
Botanical Name            : Piper nigrum, Linn 
Family             :  Piperaceae 
Suvai     :   Kasappu, kaarppu 
Thanmai    :  Veppam 
Pirivu    :  Kaarppu 
Part Used    : Dried fruit 
Properties    : Acrid, carminative, anti periodic, rubefacient,  
     stimulant, resolvent, antidote, antivatha. 
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18.¾¢ôÀ¢Ä¢ 
þÕÁø ÌýÁõ þ¨ÃôÒ ¸ÂôÀ¢½¢ 
®¨Ç À¡ñÎ ºóÂ¡ºõ «§Ã¡º¸õ 
¦À¡ÕÁø °¨¾ º¢ÃôÀ¢½¢ ã÷î¨º§¿¡ö 
âÃ¢ì ÌïºÄ §¾¡¼õ À¢Ä£¸Óõ 
ÅÕÁ Äô¦ÀÕì §¸¡Î Á§¸¡¾Ãõ 
Å¡¾õ ¬¾¢Óò §¾¡¼ï ÍÃíÌÇ¢÷ 
¦ÀÕÁ¡¨ÄôÒÃ¢ §Á¸õ À¢¼¸Óõ 
§ÀÕó ¾¢ôÀ¢Ä¢ô §ÀÃíÌ¨Ãì¸§Å. 
 
¬ºÉ§¿¡ö ¦¾¡ñ¨¼§¿¡ö ¬ÅÃ½ À¢ò¾Ó¾ø 
¿¡º¢Å¢Æ¢ ¸¡¾¢¨Å§¿¡ö ¿¡ðÒØ§¿¡ö- Å£º¢ÎÅ¢ 
Âí¸Ä¡ïº Éïº¢¨¾Ôõ «õÀ¡ö «Æ¢Å¢óÐõ 
¦À¡í¸Ä¡ïº ¿í¨¸Â÷§¸¡ð §À¡ø. 
      -§¾.Ì. 
¸ðÊ ¦Â¾¢÷¿¢ýÚ ¸Î§¿¡¦Âø Ä¡õÀ½¢Ôõ 
¾¢ðÊ Å¢¨ÉÂ¸Öõ §¾¸¦Áò¾- ÒðÊÂ¡õ 
Á¡ÁÛìÌ Á¡Á¦ÉÉ ÁüÈÅ÷ìÌ ÁüÈÅÉ¡í 
¸¡Á¦ÁÛó ¾¢ôÀ¢Ä¢ìÌõ ¨¸. 
 
®¨Ç Â¢ÕÁ Ä¢¨ÃôÒô ÀºôÀ¢½¢¸û 
Á¡Ç ¦Å¡Æ¢Â¡Áø Å¡ðÎ§Á- Â¡ÙÓ¨È 
À¡í¸¡ ÂüóÐ¦ºöÅ£÷ ÀñÊ¾ò¨¾ô ÀñÊ¾§Ã 
§Åí¨¸Å¡öô À¡ý¸¨½ ¦Áö. 
      -§¾Ãñ ¦ÅñÀ¡. 
Botanical Name            :  Piper longum, Linn 
Family             :  Piperaceae 
Suvai     :   Kaarppu 
Thanmai    :  Veppam 
Pirivu    :  Enippu 
Part Used    : Dried fruit 
Properties    : Stimulant, carminative. 
19.þÄÅí¸õ 
À¢ò¾ ÁÂì¸õ §À¾¢¦Â¡Î Å¡ó¾¢Ôõ§À¡õ 
Íò¾Å¢Ãò ¾¸ÎôÒó §¾¡ýÚ§Á¡- ¦Áò¾ 
þÄÅí¸í ¦¸¡ñ¼ÅÕì §¸ü Í¸Á¡Ìõ 
ÁÄÁí§¸ ¸ðÎ¦ÁÉ Å¡úòÐ. 
 
Íì¸¢Ä¿ð ¼í¸÷ñ Ý÷Å¢Âí¸ Ä¡ïºÉó¾¡ð 
º¢ì¸øÅ¢¼¡î º÷Å¡ º¢ÂôÀ¢½¢Ôó- Áì¸¢ìÌð 
¼í¸ô â§Å¡Îù ¾Ã¢À¼Õó §¾¡ýÈ¢Ä¢ø 
Åí¸ôâ §Å¡Î¨ÃòÐ Å¡. 
      -«.Ì. 
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Botanical Name            :  Syzygium aromaticum, (Linn) Merrill & Perry 
Family             :  Myrtaceae 
Suvai     :   Kaarppu viruviruppu 
Thanmai    :  Veppam 
Pirivu    :  Kaarppu 
Part Used    : Dried bud 
Properties    : Antispasmodic, carminative, stomachic 
 
20.§¸¡¨Ãì ¸¢ÆíÌ 
º£¾ ÍÃó¾£÷Ìï ¦ºõÒÉøÀ¢ò ¾õ§À¡Ìõ 
Å¡¾ ÍÃó¾½¢ìÌõ ¨ÅÂ¸ò¾¢ø- §Å¨¾¦ºö 
Åó¾ À¢½¢¨Â¦ÂøÄ¡õ Å¡ðÎÓò ¾ì¸¡Í 
¦¸¡óÐÄ×õ Å¡÷ÌÆ§Ä! ÜÚ. 
 
«¾¢º¡Ãõ À¢ò¾õ «ÉüÈ¡¸õ ³Âí 
Ì¾¢Å¡¾ï §º¡Àí ¦¸¡ÊÂ- Ó¾¢÷Å¡ó¾¢ 
Â¡¨Ãò ¦¾¡¼÷ó¾¡Öõ «ùÅÅ÷ì¦¸ Ä¡íÌÇòÐì 
§¸¡¨Ãì ¸¢Æí¨¸ì ¦¸¡Î. 
      -«.Ì. 
Botanical Name            :  Cyperus rotundus, Linn 
Family             :  Cyperaceae 
Part Used    : Root tuber 
Properties    : Astringent, stimulant, tonic, diuretic, diaphoretic,  
     demulcent, emmenagogue, vermifuge. 
 
21.¦ÀÕí¸¡Âõ 
¾ó¾§Å ¾ó¾ ãÄò¦¾ØõÀ¢½¢ 
ºÕÅ¸¡Çõ Å¢Õîº¢¸í¸£¼õÁ¡ 
Áó¾õÅ¡¾õ ¯¾¡Å÷ò¾õ «øÌø§¿¡ö 
Á¡÷À½í¸ð¼ ÌýÁõÁ§¸¡¾Ãõ 
¯óÐ¦¸÷ôÀò¾¢ý Å¢ò¾¢ÃïÝ¨ÄîÝ÷ 
¯¾¢Ãôâîº¢ º¢§ÄòÐÁòÐÚõÅÄ¢ 
Åó¾¦Áöì¸Îô §À¡Ê¨ÅÓüÚ§Á 
Á¡Ô¿¡Ú¿ü ¸¡Âí¸¢¨¼¸¢§É. 
      -§¾.Ì. 
Botanical Name            :  Ferula asafoetida, Linn 
Family             :  Apiaceae 
Suvai     :   Kasappu, karakarappu 
Thanmai    :  Veppam 
Pirivu    :  Kaarppu 
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Part Used    : Gum-oleoresin 
Properties    : Stimulant, carminative, antispasmodic, expectorant,  
     laxative, anthelmintic, diuretic, aphrodisiac,  
     emmenagogue 
 
22.º¡¾¢ôÀò¾¢Ã¢ 
º¡¾¢¾Õõ Àò¾¢Ã¢ìÌò ¾¡Àî ÍÃó¾½¢Ôõ 
µÐ¸¢ýÈ À¢ò¾õ ¯ÂÕí¸¡ñ- ¾¡ÐÅ¢÷ò¾¢ 
Ôñ¼¡í ¸¢Ã¡½¢§Â¡ §¼¡¾ì ¸Æ¢îºÄÚõ 
Àñ¼¡í Ì¨È§Â À¸÷. 
      -«.Ì. 
Botanical Name            :  Myristica fragrans, Houtt 
Family             :  Myristicaceae 
Suvai     :   Kaarppu, thuvarppu 
Thanmai    :  Veppam 
Pirivu    :  Kaarppu 
Part Used    : Aril 
Properties    : Aphrodisiac, carminative, stimulant, hypnotic. 
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RAW DRUG PHOTOS 
Atthi - Ficus recemosa Kondrai - Cassia fistula Aavarai - Cassia 
auriculata 
Kadalalinjil - Salacia 
reticulate 
Iluppai - Madhuca 
longifolia 
Puli - Tamarindus indica 
Maruthu - Terminalia 
arjuna 
Nathaisoori - Spermacoce 
hispida 
Naarathai - Citrus medica 
Nannaari - Hemidesmus 
indicus 
Sirukeerai - Amaranthus 
tricolor 
Neerpoola - Phyllanthus 
reticulates 
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Kattralai - Aloe 
barbadensis 
Korai - Cyperus rotundus Seenthil - Tinospora 
cordifolia 
sukku - Zingiber officinale Milaku - Piper nigrum Thippili - Piper longum 
Thalisa pathri - Abies 
spectabilis 
Saathi pathri - Myristica 
fragrans 
Kirambu - Syzygium 
aromaticum 
Perungaayam - Ferula 
asafoetida 
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STANDARD OPERATING PROCEDURE 
SOURCE OF RAW DRUGS: 
           The required raw drugs for preparation of ATTHIPPATTAIYATHI   KASAYAM 
are purchased from a well reputed country shop. The raw drugs will be authenticated by the 
Botanist, Medicinal Botany Department of NIS. The raw drugs are purified and medicine is 
prepared in Gunapadam lab of National Institute of Siddha. The prepared medicine is 
again authenticated by the HOD of Gunapadam department, NIS. 
PURIFICATION METHODS: 
1. Roots: (General method) 
a. Wash the roots with running water and dry it. 
2. Barks: (General method) 
a. Clean the barks with cotton cloth and remove the peel with small knife and 
dry it. 
3. Kadalazhinjil - Salacia reticulate, Wight 
a. Dry it in sunlight. 
4. Korai kizhangu – Cyperus rotundus,Linn.  
a. Dry it in sunlight. 
5. Seenthil - Tinospora cordifolia (Willd) 
a. Remove the peel and dry it. 
6. Sukku – Zingiber officinalis,Rosc 
a. Double the proportion of lime stone [calcium carbonate] solution is poured 
and boiled for three hours, then wash it, dry and remove the peel. 
7. Milagu – Piper nigrum,Linn. 
a. Soak it in sour butter milk for three hours. 
8. Thippili – Piper longum,Linn. 
a. Soak it in plumbago zeylanica,Linn leaf(Ceylon lead wort- Venkodiveli) 
juice for twenty four minutes (1 Nazhigai) and dry it in sunlight. 
9. Thalisa pathri - Abies spectabilis, (D.Don) Mirb 
a. Dry it in sunlight. 
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10. Saathi pathri - Myristica fragrans, Houtt 
a. Dry it in sunlight. 
11. Kirambu- Syzygium aromaticum, (Linn) Merrill & Perry 
a. Dry it in sunlight. 
12. Perungaayam - Ferula asafoetida,Linn 
a. Cut into small pieces and roasted it or Soak it in Nelumbo nucifera, Gaertn 
leaf(Lotus- Thamarai) juice for twenty four minutes (1 Nazhigai) and dry 
it. 
METHOD OF PREPARATION 
Kasayam powder preparation method: 
All the purified drugs are ground into a coarse powder by using iron mortar & pestle. 
Kasayam preparation method: 
Take 5gm (verukadi) of Atthippattaiyathi kasayam powder and add 1.3 lit (nazhi) of 
water, boil it to reduce 1/4th of the part, ie 336ml (uzhakku). 
 DRUG STORAGE: 
 The trial drug, Atthippattaiyathi   kasayam powder is stored in clean and dry wide 
mouthed glass bottles. 
DISPENSING:  
The study drug packages will contain 150gm of ATTHIPPATTAIYATHI   
KASAYAM   powder sachets. At each visit (once in 10 days for 40 days) the patients will 
be given the above drug packages for 10 days of treatment. At each visit the patients will 
be advised to bring back the unconsumed drugs and return to the research scholar. 
DOSAGE:  
· Kasayam powder -5gm (verukadi) 
· Kasayam- 336ml (uzhakku) 3 times per day.  
COURSE: 40 days 
INDICATIONS: Neerizhivu (Mathumeagm) 
 
REFERENCE: Agathiyar 2000- 3rd volume, Author: Dr.S.Venkattarajan, L.I.M, 5th 
Edition- Oct 2002. Page No: 4, 5. Publisher: Saraswathy Mahal Library, Thanjavur. 
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ATTHIPPATTAIYATHI KASAYAM PHOTOS 
 
Atthippattaiyathi kasayam powder 
 
Atthippattaiyathi kasayam (Decoction) 
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CLINICAL STUDY 
STUDY DESIGN & CONDUCT OF STUDY 
Study Type: An open clinical trial. 
Study place: OPD and IPD of Ayothidoss Pandithar Hospital, National Institute of 
siddha, Tambaram sanatorium, Chennai-47. 
Study period: 12 months 
Sample size: 40 patients  
SUBJECT SELECTION 
                As and when patients’ reporting at OPD of Ayothidass Pandithar Hospital with 
symptoms of inclusion criteria was subjected to screening test & documented using 
screening proforma. 
INCLUSION CRITERIA 
· Age : 30-55Yrs 
· Sex: Male & Female 
Symptoms: 
· Polyuria  
· Nocturia 
· Polydipsia 
· Polyphagia 
· Body pain  
· Weight gain (obesity), Tiredness, Burning feet and genital pruritus. 
 
Blood glucose level: 
Ø Fasting plasma glucose level- 126 to180 mg/dl 
Ø 2 hours postprandial plasma glucose level- 200 to 300 mg/dl 
 
Asymptomatic individuals fulfilling the following criteria may be screened  
Ø Previously identified Impaired Fasting Glucose (IFG) or Impaired Glucose 
Tolerance (IGT).  
o IFG- FPG >110 and <126mg/dl 
o IGT- 2h PG >140 and <200mg/dl 
Ø Over weight – Body mass index  ≥ 23kg/m² 
Ø Family history of diabetes 
Ø Sedentary lifestyle 
Ø History of gestational diabetes mellitus, recurrent fetal loss or delivery of large 
baby ≥ 3.5kg  
Ø Dyslipidemia 
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Ø Hypertension (>140/90 mm hg in adults) 
Ø Urine test – glycosuria, microalbuminuria 
Ø Acanthosis nigricans 
Ø Patient willing to sign the informed consent stating that he  will conscientiously 
stick to the treatment during 40 days but can opt out of the trial of his  own 
conscious discretion. 
Ø Patients who are willing to provide blood and urine for lab investigation. 
 
EXCLUSION CRITERIA 
· IDDM (Insulin Dependent Diabetes Mellitus) 
· Diabetic complications like microvascular and macrovascular complications etc. 
· Cardiac diseases 
· Pulmonary diseases 
· Renal diseases 
· Thyroid dysfunctions 
· Gestational diabetes 
· Other endocrine abnormalities 
· Patient who are not willing to give blood sample 
 
WITHDRAWAL CRITERIA 
· Intolerance to the drug & development of any serious adverse reactions during 
drug trial. 
· Poor patient compliance & defaulters. 
· Patient turned unwilling to continue in the course of clinical trial. 
· Increase in severity of symptoms. 
· Uncontrolled blood sugar level 
 
TEST & ASSESSMENTS 
1. CLINICAL ASSESSMENT 
2. SIDDHA ASSESSMENT 
3. ROUTINE INVESTIGATION 
4. SPECIFIC INVESTIGATION 
1. CLINICAL ASSESSMENT 
· Increased frequency of Urination (polyuria) 
· Thirst (polydipsia) 
· Excessive hunger (polyphagia) 
74 
 
· Body pain  
· Tiredness  
· Burning feet   
· Generalized/genital pruritus 
· Dull pain in the testis 
· Yellow coloured urine 
 
2. SIDDHA ASSESSMENT 
Thinai (Living Place) 
Paruvakaalam (Season) 
Gnanenthiriyam and Kanmenthiriyam: 
1. Vaai (Buccal Cavity) 
2. Kaal (lower limb) 
3. Kai (upper limb) 
4. Eruvaai (anorectal region) 
5. Karuvaai (uro- genital region) 
 
Ezhu Udal Kattugal: 
1. Saram 
2. Senneer 
3. Uoon 
4. Kozhuppu 
5. Enbu 
6. Moolai 
7. Sukkilam/Suronitham 
 
Enn Vagai Thervu (Eight types of Examination): 
1. Nadi (Pulse perception) 
2. Naa (Tongue) 
3. Niram (Complexion) 
4. Mozhi (Voice) 
5. Vizhi (Eyes) 
6. Parisam (Palpatory perception) 
7. Malam (Bowel habits) 
8. Moothiram (Urine){Neerkuri& Neikuri} 
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3. ROUTINE INVESTIGATION 
HAEMATOLOGY 
Ø Hb (gms %) 
Ø Total WBC Count(cells/cumm) 
Ø DC 
· Polymorphs (%) 
· Lymphocytes (%) 
· Eosinophils (%) 
· Monocytes (%) 
· Basophils (%) 
Ø Total RBC count (cells/cu.mm) 
Ø ESR (mm/hr) 
 
CLINICAL BIOCHEMISTRY 
RENAL FUNCTION TEST 
· Blood urea (mg/dl) 
· S. total creatinine (mg/dl) 
· Uric acid (mg/dl) 
 
LIPID PROFILE 
· S. Total cholesterol (mg/dl) 
· HDL (mg/dl) 
· LDL  (mg/dl) 
· VLDL (mg/dl) 
· TGL (mg/dl) 
 
LIVER FUNCTION TEST 
· S. Total bilirubin (mg/dl) 
· S. Direct bilirubin (mg/dl) 
· S. Indirect bilirubin (mg/dl)  
· SGOT (U/dl) 
· SGPT (U/dl) 
· S. Alkaline phosphatase (U/dl)  
· S. Total protein (g/dl) 
· S. Albumin (g/dl) 
· S. Globulin (g/dl) 
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OTHER TEST 
· S. Calcium (mg/dl) 
· S. Phosphorous (mg/dl) 
URINE EXAMINATION  
· Neerkuri & Neikuri  
· Albumin  
· Sugar (Fasting & postprandial) 
· Deposits  
SIDDHA PARAMETERS 
· Neerkuri and Neikuri 
· Malam  
4. SPECIFIC INVESTIGATION 
· OGTT 
· Fasting (over night fast) 
· 2 Hours after glucose load 
 
STUDY ENROLLMENT  
· In this clinical trial, patients reporting at NIS OPD with the clinical symptoms 
of Polyuria, Polydipsia, Polyphagia, General body pain and tiredness was 
examined clinically for enrolling in the study based on the inclusion and 
exclusion criteria. 
· The patients who are to be enrolled in this study was informed (Form IV) 
about the objective of the study, trial drug, possible outcomes in their own 
language and terms understandable to them. 
· After ascertaining the patient’s willingness, informed consent was obtained in 
the consent form (Form IV A). 
· All these patients was given unique registration card in which patients’ 
Registration number of the study, Address, Phone number and Doctors phone 
number etc. so as to report adverse reaction. 
· Complete clinical history, complaints and duration, examination findings all 
was recorded in the prescribed Proforma in the history and clinical assessment 
forms separately. Screening Form- I was filled up; Form I-A, Form –II and 
Form –III was used for recording the patient’s history, clinical examination of 
symptoms and signs and laboratory investigations respectively. 
· Patients were advised to take the trial drug and appropriate dietary advice 
(Form IV-E) would be given according to the patients’ perfect understanding. 
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CONDUCT OF THE STUDY: 
          The trial drug ATTHIPPATTAIYATHI   KASAYAM was given continuously for 
40 days for OP patients, they should visit the hospital once in 10 days.  At each clinical 
visit clinical assessment was done and prognosis was recorded. For IP patients the drug is 
provided daily and prognosis was noted. For IP patients’ also clinical assessment was 
done daily.  Laboratory investigations were done 0th day & 40th day of the trial. For IP 
patients, who was not in a situation to stay in the hospital for 40 days were advised to 
attend the OPD for further continuation of course of treatment. After the end of the 
treatment also, the patient was advised to visit the OPD for another 2 months for follow-
up. If any trial patient who fails to collect  the trial drug on the prescribed day but wants 
to continue in the trial from the next day or two, he/she was allowed, but defaulters of one 
week and more was not allowed to continue and withdrawn from the study with fresh 
case being inducted. 
DATA MANAGEMENT 
· After enrolling the patient in the study, a separate file for each patient was opened 
and all forms was filed in the file. Study Number and Patient Number were 
entered on the top of file for easy identification. Whenever the study patient visits 
OPD during the study period, the respective patient file was taken and necessary 
recordings were made at the assessment form or other suitable form. 
· The screening forms were filed separately. 
· The Data recordings were monitored for completion by HOD and adverse event 
by Pharmacovigilance Department of National Institute of Siddha. All forms were 
further scrutinized in presence of Investigators by Senior Research Officer 
(Statistics) for logical errors and incompleteness of data to avoid any bias. No 
modification in the results is permitted for unbiased reports. 
OUTCOME: 
Primary outcome:     
  The outcome is mainly assessed by comparing the pre and post treatment blood glucose 
level of the trial patient. 
Secondary outcome: 
Secondary outcome is assessed by comparing the following parameters, pre and post 
treatment. 
Ø Changes in siddha and clinical parameters 
Ø Changes in investigation parameters 
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ADVERSE EFFECT/SERIOUS EFFECT MANAGEMENT: 
If the trial patient develops any adverse reaction, it was recorded in Adverse Reaction 
Form and he/she was referred to the member of the Pharmacovigilance Department of 
NIS, and proper management was given by the investigator in OPD of NIS. 
STATISTICAL ANALYSIS 
        All collected data were entered into computer using MS access / MS excel software 
by the investigator. The data was analyzed using STATA software under the guidance of 
SRO (stat), NIS. The level of significance was 0.05 Descriptive analyses were made and 
necessary tables/graphs generated to understand the profile of the patients included in the 
study. Student‘t’ test and chi-square test were proposed to be performed for quantitative 
and qualitative data. 
 
ETHICAL ISSUES 
1. Informed consent was obtained from the patient explaining in the 
understandable language to the patient. 
2. After the consent of the patient (through consent form) they were enrolled 
in the study.  
3. Treatment was provided free of cost.  
4. No other external or internal medicines were used. There was no 
infringement on the rights of patient.    
5. To prevent any infection, while collecting blood sample from the patient, 
only disposable syringes, disposable gloves, with proper sterilization of lab 
equipments was used. 
6. The data collected from the patient was kept confidentially. The patient 
was informed about the diagnosis, treatment and follow-up.  
7. In conditions of treatment failure, adverse reactions, Patients was given   
alternate treatment at National Institute of Siddha with full care throughout 
the end. 
8. The patient who are excluded (as per exclusion criteria) are given proper 
treatment with full care at National Institute of Siddha. 
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ASSESSMENT FORMS 
FORM l     SCREENING & SELECTION PROFORMA 
FORM l A     HISTORY PROFORMA ON ENROLLMENT 
 FORM ll      CLINICAL ASSESSMENT ON ENROLLMENT 
FORM ll A      CLINICAL ASSESSMENT DURING & AFTER TRIAL 
FORM lll      LABORATORY INVESTIGATION ON ENROLLMENT & 
CONCLUSION OF TRIAL 
FORM IV      INFORMATION SHEET 
FORM IV A     CONSENT FORM 
FORM IV B     WITHDRAWAL FORM 
FORM IV C       DRUG COMPLIANCE FORM 
FORM IV D     DIETARY ADVICE FORM 
FORM IV E       ADVERSE REACTION FORM 
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Observations and Results are tabulated under the following headings 
1. Age incidence. 
2. Sex distribution  
3. Socio-economic status  
4. Family history  
5. Food habits  
6. Thinai  
7. Paruva Kaalam  
8. Yaakai 
9. Mukkutrangal  
9.a) Derangement in Vatham 
9.b) Derangement in Pitham 
9.c) Derangement in Kabam 
10. Ezhu udal thaathukkal  
11. a) Enn vagai thervugal 
b) Niram 
c) Manam 
d) Nurai 
e) Edai 
f) Enjal 
g) Neikuri 
h) Naadi 
12. Clinical features 
13. Chronicity of illness 
14. Gradation of result 
15. Prognosis of Clinical features 
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OBSERVATION AND RESULTS 
Table-1 
Age incidence 
S.no Age in year No of cases Percentage (%) 
 
1. 
2. 
3. 
4. 
 
30-40 
41-45 
46-50 
51-55 
 
3 
13 
6 
18 
 
7.5% 
32.5% 
15% 
45% 
 Total 40 100% 
 
 
 
Observation:  
As per table 1 & fig 1: The prevalence of the disease was found to be higher in 18 cases 
(45 %) in the age group of 51 - 55 years, 13 cases (32.5%) in the age group of 41 – 45 
years, 6 cases (15 %) in the age group of 46 - 50 years and 3 cases (7.5 %) in the age 
group of 30 - 40 years. 
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Table-2 
Sex incidence 
S.no Sex No of cases Percentage (%) 
1 
2 
Male 
Female 
22 
18 
55% 
45% 
 Total 40 100% 
 
 
 
 
 
 
Observation: 
As per table 2 and fig 2: Among the 40 patients selected, prevalence of the disease was 
found to be higher in males i.e. 22 cases (55%) then the Female cases of 18 (45%). 
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Table-3 
Economic status 
S.no Economic status No of cases Percentage (%) 
1. 
2. 
3. 
Poor 
Middle class 
Rich 
20 
14 
6 
50% 
35% 
15% 
 Total 40 100% 
 
 
 
 
Observation:   
As per table 3 and Fig 3: The incidence of the disease was found to be higher in 20 (50 
%) cases belonging to poor class, medium in 14 (35 %) cases belonging to middle class 
and lower in 6 (15) cases belonging to high class. 
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 Table-4 
Family history 
S.no Family history No. of cases Percentage (%) 
1. 
2. 
Positive 
Negative 
24 
16 
60% 
40% 
 Total 40 100% 
 
 
 
 
 
 
Observation:  
As per table 4 and Fig 4. Among the 40 cases, Positive familial history  was seen in 24 
(60 %)  patients and no history of family involvement was found in 16 cases(40 %).   
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Table-5 
Food habits 
S.no Food habits No. of cases Percentage (%) 
1. 
2. 
Vegetarians 
Non-vegetarians(Mixed) 
7 
33 
17.5% 
82.5% 
 Total 40 100% 
 
 
 
 
 
Observation:  
 As per table 5 and fig 5: Among 40 cases the incidence of the disease was higher in 33 
(82.5%) cases, which were non vegetarians and lower in vegetarians 7 cases (17.5%). 
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Table-6 
Distribution of Thinai (Land) 
S. No Thinai No. of cases Percentage (%) 
 
1. 
 
2. 
 
3. 
 
4. 
 
5. 
 
 
Kurinji 
 
Mullai 
 
Marutham 
 
Neidhal 
 
Paalai 
 
1 
 
1 
 
7 
 
31 
 
0 
 
2.5% 
 
2.5% 
 
17.5% 
 
77.5% 
 
0% 
 Total 40 100% 
 
 
 
 
Observation:  
 As per table 6 and fig 6: Among 40 cases 31 (77.5%) cases belongs to Neidhal, 7 
(17.5%) cases were from Marutham, and only one (2.5%) case was from Kurunji and 
Mullai. 
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Table-7 
Paruva kaalangal (Season) 
S.no Paruva kaalam Months No. of cases Percentage(%) 
1. 
 
2. 
 
3. 
 
4. 
 
5. 
 
6. 
Kaar kaalam 
 
Koothir kaalam 
 
Mun pani kaalam 
 
Pin pani kaalam 
 
Elavenil kaalam 
 
Mudhuvenil kaalam 
Aavani- Puratasi 
(Aug. 17 - Oct 17) 
Aipasi-karthigai 
(Oct. 18 - Dec. 15) 
Margazhi-Thai 
(Dec. 16 - Feb. 12) 
Masi- panguni 
(Feb.13 - Aprl. 13) 
Chithirai- Vaigasi 
(Aprl. 14 - June 14) 
Aani- Aadi 
(June 15 - Aug. 16) 
23 
 
0 
 
0 
 
0 
 
0 
 
17 
57.5% 
 
0 
 
0 
 
0 
 
0 
 
42.5% 
  Total 40 100% 
 
 
 
Observation:  
As per table 7 and fig 7: Among the 40 cases, in 23 cases (57.5%) the incidence of the 
disease seems to be higher in Kaar kaalam (Avani-Puratasi), 17 cases (42.5%) in 
Muthuvenil kaalam (Aani-Aadi). 
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Table-8 
Yaakkai 
S. no Yakkai No. of cases Percentage (%) 
 
1. 
 
2. 
 
3. 
 
4. 
 
Vaatham Thegi 
 
Pittham Thegi 
 
Kapham Thegi 
 
Thontham Thegi 
 
12 
 
7 
 
11 
 
10 
 
30% 
 
17% 
 
28% 
 
25% 
 Total 40 100% 
 
 
 
 
 
Observation:  
As per table 8 and fig 8: Among the 40 cases, 12 cases (30%) were vaatha thegi, 7cases 
(17%) were pitha thegi, 11 cases (28%) were kappa thegi and 10 cases (25%) were 
thontha thegi. 
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Incidence according to Mukkutrangal 
Table-9a (i) Derangement in Vaatham 
Sl. No Vaatham No. of cases  Percentage (%) 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Praanan 
 
Abaanan 
 
Udhaanan 
 
Viyaanan 
 
Samaanan 
 
Naagan 
 
Koorman 
 
Kirukaran 
 
Devathaththan 
 
Thananjeyan 
 
0 
 
23 
 
2 
 
28 
 
28 
 
0 
 
0 
 
2 
 
34 
 
0 
 
0 
 
57.5% 
 
5% 
 
70% 
 
70% 
 
0 
 
0 
 
5% 
 
85% 
 
0 
 
 
Observation:  
As per table 9a and Fig 9a: Among 40 cases, Samanan and viyanan were affected in 28 
(70%) cases. In 34 (85 %) cases Devathathan was affected. Abanan was affected in 23 
(57.5%) cases and Udhanan was affected in 2 (5%) cases. 
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Table-9b (ii) Derangement in Piththam 
 
S.no Piththam No. of cases out of 40 Percentage (%) 
 
1. 
 
2. 
 
3. 
 
4. 
 
5. 
 
Anarpitham 
 
Ranjagam 
 
Pirasagam 
 
Saathagam 
 
Aalosagam 
 
14 
 
0 
 
0 
 
31 
 
0 
 
35% 
 
0 
 
0 
 
77.5% 
 
0 
 
 
 
 
Observation:  
As per table 9b and Fig 9b: Among the 40 cases, Sathagam was affected in 31 (77.5%) 
cases and Anarpitham was affected in 14 (35%) cases. 
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Table-9c (iii) Derangement in Kabam 
S.no Kapham No. of cases out of 40 Percentage (%) 
 
1. 
 
2. 
 
3. 
 
4. 
 
5. 
 
Avlambagam 
 
Kilethagam 
 
Pothagam 
 
Tharpagam 
 
Santhigam 
 
2  
 
0 
 
0 
 
0 
 
14 
 
5% 
 
0 
 
0 
 
0 
 
35% 
 
 
Observation: 
As per table 9c and Fig 9c: Among 40 cases Avalambagam was affected in 2 (5%) cases 
and Santhigam was affected in 14 (35 %) as a result of pain in both lower limbs. 
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Table-10   
Ezhu udal thaathukkal 
S.no Udal thaathukkal No .of cases out of 40 Percentage (%) 
 
1. 
 
2. 
 
3. 
 
4. 
 
5. 
 
6. 
 
7. 
 
Saaram 
 
Chenneer 
 
Oon 
 
Kozhuppu 
 
Enbu 
 
Moolai 
 
Sukilam/Suronitham 
 
40 
 
5 
 
0 
 
17 
 
10 
 
0 
 
0 
 
100% 
 
12.5% 
 
0 
 
42.5% 
 
25% 
 
0 
 
0 
 
 
 
 Observation:  
As per table 10 and Fig 10: A mong 40 cases, Saaram was affected in all the 40 (100%) 
cases, Senner was affected in 5 (12.5 %) cases, Kozhuppu affected in 17 cases (42.5%) 
and Enbu affected in 10 cases (25%). 
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Table-11a  
Envagai thervugal 
 
S.no Enn vagai thervugal No. of cases out of 40 Percentage (%) 
1. 
 
2. 
 
3. 
 
4. 
 
5. 
 
6. 
 
7. 
 
8. 
Sparisam 
 
Naa 
 
Niram 
 
Mozhi 
 
Vizhi 
 
Malam 
 
Moothiram 
 
Naadi 
29 
 
18 
 
0 
 
0 
 
0 
 
7 
 
40 
 
40 
72.5% 
 
45% 
 
0 
 
0 
 
0 
 
17.5% 
 
100% 
 
100% 
 
 
 
Observation  
As per table 11a and Fig 11a: Naa was affected in 18 (45%) cases, Sparism was affected 
in 29 (72.5%) cases, Malam was affected in 7 (17.5%). Naadi and moothirakuri noted in 
all (100%) cases. 
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Neerkuri 
Table-11b  
Niram (colour): 
S.No Niram Before Trt  After Trt 
 
1. 
 
2. 
 
3. 
 
4. 
 
 
White 
 
Yellowish 
 
Straw coloured 
 
Crystal clear 
 
0 
 
2(5%) 
 
38 (95%) 
 
0 
 
0 
 
0 
 
40 (100%) 
 
0 
Total  40 40 
 
 
 
 
 
Observation:   
As per table 11b and Fig 11b: Among the total of 40 patients before treatment straw 
coloured urine noted in 38 (95%) cases and yellow colour urine noted in 2 patients. In 
after treatment straw coloured noted in all (100%) cases. 
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Table-11c 
Manam (Odour): 
S.No Manam Before Trt After Trt 
 
1. 
 
2. 
 
 
Present 
 
Absent 
 
0 
 
40 (100%) 
 
0 
 
40 (100%) 
Total  40 (100%) 40 (100%) 
 
 
 
  
 
 
 
 
Observation:   
As per table 11c and Fig 11c: Among the total of 40 patients Manam absent in all 
(100%) patients in before and after treatment. 
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Table-11d 
Nurai (Froth): 
S.No Nurai Before Trt After Trt 
 
1. 
 
2. 
 
3. 
 
4. 
 
 
Normal 
 
Reduced 
 
Increased 
 
Absent 
 
37 (92.5%) 
 
3 (7.5%) 
 
0 
 
0 
 
40 (100%) 
 
0 
 
0 
 
0 
Total  40 40 
 
 
 
 
 
 
 
Observation:   
As per table 11d and Fig 11d: Among the total of 40 patients before treatment Nurai 
normal in 37 (92.5%) cases and reduced in 3 (7.5%) cases. After treatment normal in all 
(100%) cases. 
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Table-11e 
Edai (volume): 
S.No Edai Before Trt After Trt 
 
1. 
 
2. 
 
3. 
 
 
Normal 
 
Increased 
 
Reduced 
 
 
20 (50%) 
 
16 (40%) 
 
4 (10%) 
 
 
39 (97.5%) 
 
1 (2.5%) 
 
0 
Total  40 (100%) 40 (100%) 
 
 
 
 
 
 
Observation:   
As per table 11e and Fig 11e: Among the total of 40 patients before treatment Edai 
increased in 16 (40%) cases, reduced in 4 (10%) cases and normal in 20 (50%) cases. 
After treatment Edai normal in 39 (97.5%) cases and increased in 1 (2.5%) case. 
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Table-11f 
Enjal (Deposits): 
S.No Enjal No. of cases out of 40 Percentage (%) 
 
1. 
 
2. 
 
 
Present 
 
Absent 
 
 
40 
 
0 
 
 
100% 
 
0 
 
 
 
 
 
 
Observation:   
As per table 11f and Fig 11f: Among the total of 40 patients Enjal noted in all (100%) 
patients’ urine like pus cells and epithelial cells. 
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Table-11g 
Neikuri: 
S.No Neikuri No. of cases out of 40 Percentage (%) 
 
1. 
 
2. 
 
3. 
 
4. 
 
5. 
 
Serpentine like 
 
Ring like 
 
Pearl like 
 
Mixed pattern 
 
Other pattern 
 
12 
 
0 
 
4 
 
18 
 
6 
 
30% 
 
0 
 
10% 
 
45% 
 
15% 
 
  
 
 
 
 
Inference:   
As per table 11g and Fig 11g: Among the total of 40 patients Serpentine fashion is noted 
in 12 (30%) of cases, Pearl beaded fashion was noted in 4 (10%), Mixed fashion noted in 
18 cases (45%) and other fashion noted in 6 cases (15%). 
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Table-11h 
Naadi: 
S.No Naadi No. of cases out of 40 Percentage (%) 
 
1. 
 
2. 
 
3. 
 
4. 
 
5. 
 
Vaatha piththam 
 
Piththa vaatham 
 
Piththa kapham 
 
Kapha vatham 
 
kappa pitham 
 
16 
 
15 
 
2 
 
5 
 
2 
 
40% 
 
37.5% 
 
5% 
 
12.5% 
 
5% 
 
 
 
 
Inference:  
As per table 11h and Fig 11h: Among 40 cases, 16 (40%) cases revealed Vatha pitha 
naadi and 15 (37.5%) cases with Pitha vatha naadi. Other 5 (12.5%) cases with Kaba 
vatham, 2 (5%) cases with Pitha kabam and 2 (5%) cases with Kaba pitham naadi. 
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Table-12 
Showing the clinical features 
S. 
no 
Clinical features No. of cases 
out of 40 
Percentage 
(%) 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
Polyuria  
Nocturia  
Polydipsia  
Polyphagia  
Body pain  
Weight gain(obesity) 
Tiredness 
Burning feet 
Genital pruritus 
16 
31 
20 
15 
24 
5 
28 
28 
4 
40% 
77.5% 
50% 
37.5% 
60% 
12.5% 
70% 
70% 
10% 
 
 
Inference:  
As per table 12 and Fig 12: Among 40 cases, 16 cases (40%) patients complained of 
polyuria and 20 cases (50%) complained of Polydipsia. 15 cases (37.5%) complained of 
polyphagia, 31 cases (77.5%)   complained nocturia, 28 cases (70%) complained 
tiredness, 24 cases (60%) complained body pain. 28 cases (70%) complained burning 
feet, and 4 cases (10%) complained genital pruritis, 5 cases (12.5%) complained weight 
gain. 
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Table-13 
Chronicity of illness: 
S.no Duration of illness No. of cases Percentage (%) 
1. 
2. 
3. 
4. 
1-6 Months 
7-12 Months 
1-5 years 
6-10 years 
22 
5 
11 
2 
55% 
12.5% 
27.5% 
                    5% 
 Total 40 100% 
 
 
 
Inference:  
As per table 13 and Fig 13: The chronicity of illness before recruitment for the study 
was more in 22 (55%) cases with 1-6 months of illness then 11 (27.5%) cases in the 
category  with 1-5 years, 5 (12.5%) cases with 7-12 months and 2 (5%) cases with 6-10 
years. 
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Table-14a    Gradation of results 
Blood sugar: 
S.No Gradation of results No of cases Percentage (%) 
1. Good 25 62.5% 
2. Moderate 6 15% 
3. Poor 9 22.5% 
Total  40 100% 
 
 
Inference: As per table 14 a,c,d,e and Fig 14a: Among 40 cases, 25 (62.5%) cases had 
Good clinical improvement, 6 (15%) cases had Moderate and 9 (22.5%) cases had Poor 
improvement. 
 
Good result range: Fasting 70-126mg%, Postprandial-120-200mg% in 25 cases (62.5%) 
Moderate result range: Fasting 127-140mg%, Postprandial-180-220mg% in 6 cases 
(15%) 
Poor result range: Fasting above 140mg%, Postprandial- above 220mg% in 9cases 
(22.5%) 
 
Note: Inclusion blood glucose range 
· Fasting: 126 – 180mg% 
· Postprandial: 200 – 300mg% 
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Table-14b    Gradation of results 
Urine sugar: 
S.No Gradation of results No of cases Percentage (%) 
1. Good 25 62.5% 
2. Moderate 6 15% 
3. Poor 9 22.5% 
Total  40 100% 
 
 
Inference: As per table 14 b,c,d,e and Fig 14b: Among 40 cases, 25 (62.5%) cases had 
Good clinical improvement, 6 (15%) cases had Moderate and 9 (22.5%) cases had Poor 
improvement. 
 
Good result range: Fasting - Nil, Postprandial- Nil or + in 25 cases (62.5%) 
Moderate result range: Fasting - Nil, Postprandial - + or Trace in 6 cases (15%) 
Poor result range: Fasting – Nil or +, Postprandial- +, ++ in 9cases (22.5%) 
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Table-14c  
Blood sugar and urine sugar before and after treatment results: 
                                                                    GOOD RESULTS 
S.No OP/IP 
No 
Age/ 
Sex 
Before 
treatment 
After 
treatment 
before 
treatment 
after 
treatment 
B.Sugar 
mg/dl 
B.Sugar 
mg/dl 
urine sugar urine sugar 
FA PP FA PP F PP F PP 
1 C79506 52/F 135 210 115 161 Nil ++ Nil  Nil 
2 C93762 48/F 140 235 118 170 Trace ++ Nil + 
3 C29305 50/F 160 230 125 154 Trace ++ Nil Nil 
4 C98043 40/F 138 210 121 174 Nil + Nil Nil 
5 C28386 50/F 131 212 120 196 Nil + Nil + 
6 C41076 44/F 176 278 121 198 Nil ++ Nil + 
7 C61757 45/F 131 266 122 161 Nil N Nil Nil 
8 4244 45/F 126 219 115 170 Nil ++ Nil Nil 
9 4151 55/F 142 272 126 152 Nil N Nil Nil 
10 4182 53/F 156 252 112 167 Nil + Nil Nil 
11 4210 40/F 127 226 112 123 Nil N Nil Nil 
12 4203 55/F 127 210 122 136 Nil N Nil Nil 
13 4129 48/F 138 261 110 135 N N Nil Nil 
14 4236 55/F 134 300 107 191 + ++ Nil Nil 
15 C77100 50/M 136 239 126 146 Nil + Nil Nil 
16 C93323 40/M 136 254 112 164 Nil + Nil Nil 
17 C77872 33/M 117 257 110 190 Trace + Nil + 
18 C76014 43/M 157 245 120 170 Nil + Nil Trace 
19 C73821 43/M 124 200 118 177 Nil N Nil Nil 
20 C77322 53/M 134 236 121 177 Nil ++ Nil Nil 
21 C84379 40/M 173 265 123 195 Trace ++ Nil + 
22 C75253 36/M 128 237 116 199 Nil Trace Nil + 
23 B95665 42/M 145 213 122 164 N + Nil Nil 
24 C92670 46/M 160 270 126 177 + ++ Nil Nil 
25 C99837 41/M 128 268 112 187 N + Nil + 
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Table-14d 
                                                                 MODERATE  RESULTS 
S.No OP/IP 
No 
Age/ 
Sex 
Before 
treatment 
After treatment before 
treatment 
after treatment 
B.Sugar mg/dl B.Sugar mg/dl urine sugar urine sugar 
FA PP FA PP F PP F PP 
1 4272 54/F 138 233 130 192 + ++ Nil + 
2 C81031 53/M 172 260 140 211 Trace + Nil + 
3 C92864 38/M 162 258 139 198 Nil + Nil + 
4 C42893 43/M 131 278 130 196 Nil ++ Nil + 
5 C85416 42/M 160 220 139 180 Nil + Nil Trace 
6 C89234 50/M 159 298 140 182 Trace + Nil Trace 
 
Table-14e 
                                                                       POOR RESULTS 
S.No OP/IP 
No 
Age/ 
Sex 
Before 
treatment 
After treatment  before 
treatment 
after treatment 
B.Sugar mg/dl B.Sugar mg/dl urine sugar urine sugar 
FA PP FA PP F PP F PP 
1 4125 50/F 191 234 160 174 + ++  Nil + 
2 4035 52/F 169 239 185 336 Nil ++ Nil ++ 
3 B53440 42/F 168 295 143 225 Nil ++ Nil ++ 
4 C77041 51/M 132 262 154 220 Nil ++  Nil ++ 
5 C91330 53/M 148 300 148 220 Nil + Nil ++ 
6 C86489 55/M 146 278 156 280 Nil + Nil ++ 
7 B95283 50/M 132 300 149 248 Nil + Nil ++ 
8 C78746 42/M 160 290 252 300 Nil ++ + ++ 
9 C90731 45/M 180 295 147 191 + ++ Trace ++ 
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Table-15 Prognosis of Clinical features results: 
Clinical features 
 
 Prognosis Result 
  Before treatment After treatment  Percentage  
Polyuria 16 15 93.8% 
Nocturia 31 26 83.9% 
Polydipsia  20 18 90% 
Polyphagia 15 12 80% 
Body pain  24 12 50% 
Weight gain (obesity) 5 0 0% 
Tiredness 28 18 64.3% 
Burning feet 28 17 60.7% 
Genital pruritus 4 2 50% 
 
 
Inference:  
As per table 15 and Fig 15: After treatment there was a considerable reduction in all 
symptoms except obesity. Good reduction in Polyuria (93.8%), Polydipsia (90%), 
Polyphagia (80%) and Nocturia (83.9%), Moderate reduction in Tiredness (64.3%) and 
burning feet (60.7%) and then poor reduction in Genital Pruritis (50%) and  Body pain 
(50%). 
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Statistical Analysis 
All collected data were entered into MS Excel software using different columns as 
variables and rows as patients. SPSS software was used to perform statistical analysis. 
Basic descriptive statistics include frequency distributions and cross-tabulations were 
performed. The quantity variables were expressed as Mean ± Standard Deviation and 
qualitative data as percentage. A probability value of <0.05 was considered to indicate as 
statistical significance. Paired‘t’ test was performed for determining the significance 
between before and after treatment. 
 
Blood Glucose at fasting Mean ± Std t value and p value 
Before trt. 146.18 ± 18.22 T = 3.81, p < 0.0001 
 After trt 131.6 ± 25.7 
The mean ± standard deviation of glucose at fasting before and after treatment were 
146.18 ± 18.22 and 131.6 ± 25.7 respectively which is statistically significant (t= 3.81 
p<0.0001). 
 
Blood Glucose at 
Postprandial 
Mean ± Std t value and p value 
Before trt. 250.00 ± 33.965 T = 9.044, p < 0.0001 
 After trt 191.70 ± 43.439 
The mean ± standard deviation of glucose at postprandial before and after treatment were 
250.00 ± 33.965and 191.70 ± 43.439 respectively which is statistically significant (T = 
9.044, p < 0.0001). 
 
Serum total cholesterol Mean ± Std t value and p value 
Before trt. 195.83 ± 43.974 T = 3.572, p < 0.001 
 After trt 170.98 ± 27.647 
The mean ± standard deviation of serum total cholesterol before and after treatment were 
195.83 ± 43.974 and 170.98 ± 27.647respectively which is statistically significant (T = 
3.572, p < 0.001). 
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HDL Mean ± Std t value and p value 
Before trt. 38.70 ± 8.064 T = 2.666, p < 0.011 
 After trt 35.70 ± 4.968 
The mean ± standard deviation of HDL before and after treatment were 38.70 ± 8.064 and 
35.70 ± 4.968 respectively which is statistically significant (T = 2.666, p < 0.011). 
 
LDL Mean ± Std t value and p value 
Before trt. 108.80 ± 28.776 T = 3.799, p < 0.0001 
 After trt 93.40 ± 16.375 
The mean ± standard deviation of LDL before and after treatment were 108.80 ± 28.776 
and 93.40 ± 16.375 respectively which is statistically significant (t= 3.799 p<0.0001). 
 
VLDL Mean ± Std t value and p value 
Before trt. 41.93 ± 15.698 T = 3.479, p < 0.001 
 After trt 33.78 ± 11.939 
The mean ± standard deviation of VLDL before and after treatment were 41.93 ± 15.698 
and 33.78 ± 11.939 respectively which is statistically significant (t= 3.479 p<0.001). 
 
TGL Mean ± Std t value and p value 
Before trt. 198.95 ± 81.305 T = 3.272, p < 0.002 
 After trt 159.05 ± 51.591 
The mean ± standard deviation of TGL before and after treatment were 198.95 ± 81.305 
and 159.05 ± 51.591 respectively which is statistically significant (t= 3.272 p<0.002). 
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DISCUSSION 
Diabetes Mellitus is a heterogeneous group of metabolic disorders characterized 
by hyperglycemia resulting from defects in insulin secretion, insulin action or both. Type 
2 Diabetes is one of the major health problems all over the world.  
Mathumegam mentioned in siddha literature may be correlated to “Diabetes 
mellitus” having the symptoms of polyuria (frequent urination), polydipsia (increased 
thirst), polyphagia (increased hunger). Yoogimuni, author of Yoogi Vaithiya Chinthamani 
has described the signs and symptoms of Mathumegam as “Gunam and Avathaigal". They 
are also may be correlated to sign and symptoms of Diabetes mellitus.   
In the siddha literature Agathiyar 2000- 3rd volume, the drug Atthippattaiyathi   
kasayam is indicated for Mathumegam (type-2 Diabetes Mellitus). Atthippattaiyathi   
kasayam comprises of twenty two Herbs. There are 12 herbs of this formulation having 
potential Antidiabetic activity and 12 herbs have potential Antioxidant activity and other 
herbs have Hypolipidemic, Hepatoprotective, Cardioprotective, Nephroprotective action. 
So the formulation is may be a preventable medicine for development of diabetes and its 
complications. 
The raw drugs were purchased from reputed country drugs stores and 
authenticated by the concerned department. The trial drug was prepared by the standard 
operating procedure as mentioned in the protocol in the Dept of Gunapadam, National 
Institute of Siddha under the direct supervision of lecturers. 
The safety of the trial drug usage and standardization of the trial drug through 
biochemical analysis were also ensured during the study. 
The preclinical toxicity studies (Acute and long term toxicity) for the above said 
trial drug was carried out at National Institute of Siddha after getting the proper 
acceptance and permission from the Institutional Animal Ethical Committee. The trial 
drug was proved to be safe for human beings from the observations made from the study. 
The biochemical qualitative and quantitative analysis were done at the 
biochemistry lab of NIS and SAIF, IIT Chennai respectively. It revealed the presence of 
effective minerals and the existence of the drug molecules at micro level. 
111 
 
Before initiating the trial, Institutional Animal Ethical Committee (IAEC: 
1248/ac/09/ CPCSEA/4-07/2011 - Dt. 20.12.2011) and Institutional Ethical Committee 
(IEC: NIS/IEC/ 2011/3/07 - Dt. 24.12.2011) of NIS, approval was obtained for this study. 
After the approval of the Institutional Ethical Committee of NIS, the clinical study 
was conducted with a well defined protocol with a proper proforma under the direct 
supervision of faculties of Dept of Maruthuvam. After screening 60 cases reporting at the 
OPD, 40 cases were selected for induction to the trial. The patient who satisfied the 
Inclusion and Exclusion criteria as per the protocol were admitted to the trial. The 
patients were well explained about the clinical trial and informed consent was obtained 
from the patient. 
Then the enrolled patients were subjected to lab investigations before and after 
treatment. From the 1stday onwards the patients were treated with the trial drug 
Atthippattaiyathi   kasayam 336ml internal 3 times daily for a period of 40 days. 
For OP patients, they should visit the hospital once in 10 days. At each clinical 
visit clinical assessment was done and prognosis was noted. For IP Patients clinical 
assessment was done daily and prognosis was noted. 
 For IP patients who were not in a situation to stay in the hospital for a long time 
were advised to attend the OPD for the continuation of the treatment. All the patients 
were put under observation for 2 months as follow up period without the trial drug 
treatment. The observations are summarized below. 
Incidence with reference to Age distribution: 
The prevalence of the disease was found to be higher in 18 cases (45 %) in the age 
group of 51 - 55 years, 13 cases (32.5%) in the age group of 41 – 45 years, 6 cases (15 %) 
in the age group of 46 - 50 years and 3 cases (7.5 %) in the age group of 30 - 40 years. 
Incidence with reference to Sex distribution: 
Among the 40 patients selected, prevalence of the disease was found to be higher 
in males i.e. 22 cases (55%) then the Female cases of 18 (45%). 
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Incidence with reference to Socio-economic status: 
The incidence of the disease was found to be higher in 20 (50 %) cases belonging 
to poor class, medium in 14 (35 %) cases belonging to middle class and lower in 6 (15) 
cases belonging to high class. Affected cases were mostly from poor and middle class. 
Incidence with reference to Family history: 
Among the 40 cases, Positive familial history was seen in 24 (60 %) patients and 
no history of family involvement was found in 16 cases(40 %). From the above study 
hereditary plays an important role in this disease.  
Incidence with reference to Food habits: 
Among 40 cases the incidence of the disease was higher in 33 (82.5%) cases, 
which were non vegetarians and lower in vegetarians 7 cases (17.5%). It clearly showed 
that non-vegetarians is more prone to Mathumegam. 
Incidence with reference to Thinai: 
Among 40 cases 31 (77.5%) cases belongs to Neidhal, 7 (17.5%) cases were from 
Marutham, and only one (2.5%) case was from Kurunji and Mullai. 
Incidence with reference to Paruva kaalangal: 
Among the 40 cases, in 23 cases (57.5%) the incidence of the disease seems to be 
higher in Kaar kaalam (Avani-Puratasi), 17 cases (42.5%) in Muthuvenil kaalam (Aani-
Aadi). 
Incidence with reference to Yakkai: 
Among the 40 cases, 12 cases (30%) were vaatha thegi, 7cases (17%) were pitha 
thegi, 11 cases (28%) were kappa thegi and 10 cases (25%) were thontha thegi. 
Incidence with reference to Vatham: 
Among 40 cases, Samanan and viyanan were affected in 28 (70%) cases. In 34 (85 
%) cases Devathathan was affected. Abanan was affected in 23 (57.5%) cases and 
Udhanan was affected in 2 (5%) cases. 
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Incidence with reference to Pitham: 
Among the 40 cases, Sathagam was affected in 31 (77.5%) cases and Anarpitham 
was affected in 14 (35%) cases. 
Incidence with reference to Kabham: 
Among 40 cases Avalambagam was affected in 2 (5%) cases and Santhigam was 
affected in 14 (35 %) as a result of pain in both lower limb joints. 
Incidence with reference to Ezhu udal thathukkal: 
 A mong 40 cases, Saaram was affected in all the 40 (100%) cases, Senner was 
affected in 5 (12.5 %) cases, Kozhuppu affected in 17 cases (42.5%) and Enbu affected in 
10 cases (25%). 
Incidence with reference to Envagai thervugal: 
In enn vagai thervugal Naa was affected in 18 (45%) cases, Sparism was affected 
in 29 (72.5%) cases, Malam was affected in 7 (17.5%). Naadi and moothirakuri noted in 
all (100%) cases. 
Neerkuri: 
· Niram: 
o Among the total of 40 patients before treatment straw coloured urine noted 
in 38 (95%) cases and yellow colour urine noted in 2 patients. In after 
treatment straw coloured noted in all (100%) cases. 
· Manam: 
o Among the total of 40 patients Manam absent in all (100%) patients in 
before and after treatment. 
· Nurai: 
o Among the total of 40 patients before treatment Nurai normal in 37 
(92.5%) cases and reduced in 3 (7.5%) cases. After treatment normal in all 
(100%) cases. 
· Edai (volume): 
o Among the total of 40 patients before treatment Edai increased in 16 
(40%) cases, reduced in 4 (10%) cases and normal in 20 (50%) cases. 
After treatment Edai normal in 39 (97.5%) cases and increased in 1 (2.5%) 
case. 
· Enjal: 
o Among the total of 40 patients Enjal noted in all (100%) patients’ urine 
like pus cells and epithelial cells. 
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Neikuri: 
Among the total of 40 patients Serpentine pattern is noted in 12 (30%) of cases, 
Pearl pattern was noted in 4 (10%), Mixed pattern noted in 18 cases (45%) and other 
pattern noted in 6 cases (15%). 
Naadi: 
Among 40 cases, 16 (40%) cases revealed Vatha pitha naadi and 15 (37.5%) cases 
with Pitha vatha naadi. Other 5 (12.5%) cases with Kaba vatham, 2 (5%) cases with Pitha 
kabam and 2 (5%) cases with Kaba pitham naadi. 
Incidence with reference to clinical features: 
16 cases (40%) patients complained of polyuria and 20 cases (50%) complained of 
Polydipsia. 15 cases (37.5%) complained of polyphagia, 31 cases (77.5%)   complained 
nocturia, 28 cases (70%) complained tiredness, 24 cases (60%) complained body pain. 28 
cases (70%) complained burning feet, and 4 cases (10%) complained genital pruritis, 5 
cases (12.5%) complained weight gain. 
Chronicity of illness: 
The chronicity of illness before recruitment for the study was more in 22 (55%) 
cases with 1-6 months of illness then 11 (27.5%) cases in the category  with 1-5 years, 5 
(12.5%) cases with 7-12 months and 2 (5%) cases with 6-10 years. 
Gradation of results: 
Blood Glucose: 
The result obtained from the clinical case study, 25 (62.5%) cases had Good 
clinical improvement, 6 (15%) cases had Moderate and 9 (22.5%) cases had Poor 
improvement. 
Good result range:  
Fasting 70-126mg%, Postprandial-120-200mg% in 25 cases (62.5%) 
Moderate result range:  
Fasting 127-140mg%, Postprandial-180-220mg% in 6 cases (15%) 
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Poor result range:  
Fasting above 140mg%, Postprandial- above 220mg% in 9cases (22.5%) 
Note: Inclusion blood glucose range 
· Fasting: 126 – 180mg% 
· Postprandial: 200 – 300mg% 
Urine Glucose: 
The result obtained from the clinical case study, 25 (62.5%) cases had Good 
clinical improvement, 6 (15%) cases had Moderate and 9 (22.5%) cases had Poor 
improvement. 
Good result range:   Fasting-Nil, Postprandial- Nil or + in 25 cases (62.5%) 
Moderate result range:  Fasting-Nil, Postprandial - + or Trace in 6 cases (15%) 
Poor result range:   Fasting-Nil or +, Postprandial- +, ++ in 9cases (22.5%) 
Prognosis of Clinical features: 
After treatment there was a considerable reduction in all symptoms except obesity. 
Good reduction in Polyuria (93.8%), Polydipsia (90%), Polyphagia (80%) and Nocturia 
(83.9%), Moderate reduction in Tiredness (64.3%) and burning feet (60.7%) and then 
poor reduction in Genital Pruritis (50%) and  Body pain (50%). 
Statistical Analysis: 
With the evidence of statistical report, it shows the average fasting blood sugar 
before the treatment and after the treatment were 146 and 131 respectively, postprandial 
blood sugar respectively 250 and 191. There is a significant difference between before 
and after treatment in the level of blood sugar at Fasting and Postprandial [P < 0.0001]. 
The mean ± standard deviation of serum total cholesterol before and after 
treatment were 195.83 ± 43.974 and 170.98 ± 27.647respectively which is statistically 
significant (T = 3.572, p < 0.001). 
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SUMMARY 
Ø The aim of the study was to evaluate the safty and efficacy of the drug 
Atthippattaiyathi kasayam in the treatment of Mathumegam. 
Ø Before initiating the clinical trial, approval was got from the Institutional Animal 
Ethical Committee (IAEC: 1248/ac/09/CPCSEA/4-07/2011 - Dt. 20.12.2011) and 
Institutional Ethical Committee (IEC: NIS/IEC/2011/3/07 - Dt. 24.12.2011) for 
conducting the pre clinical studies and clinical studies respectively by submitting 
the well defined protocol and proforma. 
Ø The raw drugs were authenticated by the concerned department and the trial drug 
was prepared in the Gunapadam lab of National Institute of Siddha as per the 
Standard Operating Procedure mentioned in the protocol. 
Ø The medicine was then subjected to toxicity studies (Acute and long term toxicity 
studies) as per the protocol and the safety of the drug was ensured. 
Ø The qualitative and quantitative bio chemical studies were done at the bio 
chemistry lab of National Institute of Siddha. 
Ø  SEM analysis and trace metals detection were done at Sophisticated Analytical 
Instrument Facility, IIT, Chennai.  
Ø The Biochemical analysis of the trial drug was done in Biochemistry laboratory 
National Institute of Siddha. Biochemical analysis showed the presence of 
inevitable constituents like Calcium, Iron, Sulphate. 
Ø Oral toxicity studies conducted ensured the safety usage of the drug to animals up 
to a maximum dose of 270 mg/animal for mice and 2700 mg/animal for wister rat.  
Ø Histopathological studies was done in pathology lab, Vels University, it shows 
that there is no abnormalities in the studies.  
Ø Among the 60 cases screened at the OPD of Branch-I, Ayothidoss Pandithar 
Hospital, NIS, 40 cases were recruited for the trial as per the inclusion and 
exclusion criteria of the Protocol. 
Ø Clinical diagnosis of Mathumegam was made by Siddha and Modern 
methodology. 
Ø Before inducement into the trial informed consent was obtained from the patients. 
Out of the 40 cases 30 cases were treated in OPD and 10 cases in IPD in Branch-I 
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Ø The clinical trial was conducted with the trial medicine Atthippattaiyathi kasayam 
5g t.i.d for a period of 40 days, referred under the Siddha literature Yoogi Vaithiya 
Chinthamani. 
Ø Diet restriction was strictly followed during the period of drug administration as 
per noted in the form IV D (Dietary advice form).  
Ø Required lab investigations were carried out before and after the treatment and the 
concerned data was recorded in the proforma.  
Ø Clinical assessment was done daily in all the IP patients and in OP patients it was 
assessed once in 10 days. 
Ø During the study period, there was no event of any adverse reactions owing to the 
drug or disease. 
Ø The clinical and labarotary Obserevation in the Mathumegam patient treated with 
the trial drug Atthippattaiyathi kasayam showed significant control in their 
blood glucose level and upgrading with in general health. 
Ø Statistical analysis showed significant difference between before and after 
treatment in the level of blood sugar at Fasting and Postprandial [P < 0.0001]. 
Ø In these studies out of 40 cases, 25 cases (62.5%) had good clinical improvement, 
6 cases (15%) had moderate and 9 cases (22.5%) had poor improvement.  
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CONCLUSION 
Ø The safety studies (the acute toxicity and long term toxicity) studies conducted 
revealed that the trial drug was safe even at higher dosage of 270 mg/animal for 
mice and 2700 mg/animal for wister rat. There were no abnormalities found in 
histopathological examination. Hence it can be reasonably assumed that the drug 
is safe for human. 
Ø Clinical study revealed that the trial drug posses’ good clinical improvement in 25 
(62.5%) cases, 6 (15%) cases had moderate results and 9 (22.5%) cases had poor 
results. 
Ø The clinical and labarotary Obserevation in the Mathumegam patient treated with 
the trial drug Atthippattaiyathi kasayam showed significant control in their blood 
glucose level and upgrading with in general health. 
Ø It is undoubtedly marked that the Medicine used in the siddha system do not have 
any harmful side effects. 
Ø Because of the hopeful results clinically, the study may be undertaken with the 
same drug for a prolonged period of time in more number of cases and it may 
throw new lights in the management of Mathumegam. 
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BIO -CHEMICAL ANALYSIS OF ATTHIPPATTAIYATHI KASAYAM -
ANALYSED AT NATIONAL INSTITUTE OF SIDDHA 
S.No EXPERIMENT OBSERVATION INFERENCE 
1. Appearance of sample Brown in 
colour 
 
2. Solubility: 
a.A little(500mg) of the sample is 
shaken well with distilled water. 
b.A little(500mg) of the sample is 
shaken well with con. HCl/Con. H2So4 
Sparingly 
soluble 
 
 
Presence of Silicate 
3. Action of Heat: 
A small amount(500mg) of the sample 
is taken in a dry test tube and heated 
gently at first and then strong. 
White fumes   
evolved 
Presence of Carbonate 
 
4. Flame Test: 
A small amount(500mg) of the sample 
is made into a paste with con. HCl in a 
watch glass and introduced into non-
luminous part of the Bunsen flame. 
No Bluish 
green flame 
appeared. 
Absence of Copper 
5. Ash Test: 
A filter paper is soaked into a mixture 
of sample and dil. cobalt nitrate 
solution and introduced into the 
Bunsen flame and ignited. 
Yellow colour 
flame 
Presence of sodium 
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Preparation of Extract 
 5 gm of Atthippattaiyathi Kasayam powder is weighed accurately and placed in a 
250 ml clean beaker and added with 50 ml of distilled water. Then it is boiled well for 
about 10 minutes. Then it is cooled and filtered in a 100ml volumetric flask and made up 
to 100ml with distilled water. 
S.No EXPERIMENT OBSERVATION INFERENCE 
 I. Test For Acid Radicals   
1.  Test For Sulphate: 
a.2ml of the above prepared extract is taken 
in a test tube to this added 2ml of 4% dil 
ammonium oxalate solution. 
Cloudy 
appearance present 
Presence of Sulphate 
 
 
 
2. Test For Chloride: 
2ml of the above prepared extracts is added 
with 2ml of dil-HCl is added until the 
effervescence ceases off.. 
No cloudy 
appearance present 
Absence of Chloride 
3. Test For Phosphate: 
2ml of the extract is treated with 2ml of 
dil.ammonium molybdate solution and 2ml 
of con.HNo3 
Mild Yellow 
appearance present 
Presence  of Phosphate 
4.  Test For Carbonate: 
2ml of the extract is treated with 2mldil. 
magnesium sulphate solution 
Cloudy 
appearance present 
Absence of carbonate 
C Test For Nitrate: 
1gm of the substance is heated with copper 
turning and concentrated H2So4 and viewed 
the test tube vertically down. 
 
No Brown gas is 
evolved 
 
Absence of Nitrate 
6. Test For Sulphide: 
1gm of the substance is treated with 2ml of 
con. HCL 
NoRotten Egg 
Smelling eggs 
evolved 
Absence of Sulphide 
7. Test For Fluoride & Oxalate: 
2ml of extract is added with 2ml of dil. 
No Cloudy 
appearance 
Absence of fluoride and 
oxalate 
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Acetic acid and 2ml dil.calcium chloride 
solution and heated. 
8. Test For Nitrite: 
3drops of the extract is placed on a filter 
paper, on that-2 drops of dil.acetic acid and 
2 drops of dil.Benzidine solution is placed. 
No Characteristic 
changes 
Absence of Nitrite 
9. Test For Borate: 
2 Pinches(50mg) of the substance is made 
into paste by using dil.sulphuric acid and 
alcohol (95%) and introduced into the blue 
flame. 
Bluish green 
colour flame not 
appeared 
Absence of borate 
 II. Test For Basic Radicals   
1. Test For Lead: 
2ml of the extract is added with 2ml of 
dil.potassium iodine solution. 
NoYellow 
Precipitate is 
obtained. 
Absence of Lead 
2. Test For Copper: 
a.One pinch(50mg) of substance is made 
into paste with con. HClin a watch glass and 
introduced into the non-luminuous part of 
the flame. 
No Blue colour 
flame 
No Blue colour 
precipitate formed. 
 
Absence of copper 
 
 
3. Test For Aluminium: 
To the 2ml of extract dil.sodium hydroxide 
is added in 5 drops to excess. 
Yellow colour 
appeared 
Presence of aluminium 
4. Test For Iron: 
a.To the 2ml of extract add 2ml of 
dil.ammonium solution 
b.To the 2ml of extract 2ml  thiocyanate 
solution and 2ml  of con HNo3 is added 
mild red colour 
appear 
 
 
Presence of Iron 
 
 
5. Test For Zinc:  
To 2ml of the extract dil.sodium hydroxide 
solution is added in 5 drops to excess and 
dil.ammonium chloride is added.  
 
White precipitate 
is   not formed 
Absence of Zinc 
6. Test For Calcium:    
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2ml of the extract is added with 2ml of 4% 
dil.ammonium oxalate solution  
Cloudy 
appearance and 
white precipitate is 
obtained 
Presence of calcium 
7. Test For Magnesium:  
To 2ml of extract dil.sodium hydroxide 
solution is added in drops to excess. 
 
White precipitate 
is  obtained 
Absence of Magnesium 
8. Test For Ammonium: 
To 2ml of extract 1 ml of Nessler's reagent 
and excess of dil.sodium hydroxide solution 
are added. 
 
Brown colour 
appeared 
Presence of ammonium 
9. Test For Potassium:  
A pinch(25mg) of substance is treated of 
with 2ml of dil.sodium nitrite solution and 
then treated with 2ml of dil.cobalt nitrate in 
30% dil.glacial acetic acid 
 
No Yellowish 
precipitate is 
obtained. 
 
Absence of Potassium 
10. Test For Sodium: 
2 pinches(50mg) of the substance is made 
into paste by using HCl and introduced into 
the blue flame of Bunsen burner. 
yellow colour 
flame appeared 
Presence of sodium 
11. Test For Mercury:   
2ml of the extract is treated with 2ml of 
dil.sodium hydroxide solution.  
 
No yellow 
precipitate is 
obtained 
Absence of mercury 
12. Test For Arsenic:  
2ml of the extract is treated with 2ml of 
dil.sodium hydroxide solution. 
 
No brownish red 
precipitate is 
obtained 
Absence of arsenic 
 III. Miscellaneous   
1.
  
Test For Starch:  
2ml of extract is treated with weak dil iodine 
solution  
 
Red colour 
developed 
 
Absence of starch 
2. Test For Reducing Sugar:   Presence of  reducing 
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  5ml of Benedict's qualitative solution is 
taken in a test tube and allowed to boil for 2 
minutes and added 8 to 10 drops of the 
extract and again boil it for 2 minutes. The 
colour changes are noted. 
Brick red colour 
not developed 
sugar 
3.
  
Test For The Alkaloids: 
a) 2ml of the extract is treated with  2ml of 
dil.potassium lodide solution. 
b)  2ml of the extract is treated with  2ml of 
dil.picric acid. 
c)  2ml of the extract is treated with 2ml of 
dil.phosphotungstic acid. 
 
. 
 
Yellow colour 
developed 
 
Presence of Alkaloid 
4.
  
Test For Tannic Acid:  
2ml of extract is treated with 2ml of 
dil.ferric chloride solution  
 
No block 
precipitate is 
obtained 
Presence of Tannic acid 
5.
  
Test For Unsaturated Compound: 
To the 2ml of extract 2ml of dil.Potassium 
permanganate solution is added.  
 
Potassium 
permanganate is 
not decolourised 
 
Presence of unsaturated 
compound 
6.
  
Test For Amino Acid: 
2 drops of the extract is placed on a filter 
paper and dried well. 20ml of  Biurette 
reagent is added. 
violet colour 
developed 
Absence of amino acids 
7. Test For Type Of Compound: 
2ml of the extract is treated with 2 ml of 
dil.ferric chloride solution.  
No colour change 
Presence of Type of 
Compound 
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Preliminary Qualitative phytochemical tests procedure and interpretation of results 
S.NO PROCEDURE INFERENCE 
1. Calcium Presence of calcium 
2. Sulphate presence of Sulphate 
3. Chloride absence of Chloride 
4. Carbonate presence of carbonate 
5. Starch absence of starch 
6. Iron  Presence of iron  
7. Phosphate Presence of phosphate 
8. Tannic acid Presence of Tannic acid 
9. Aluminium Presence of Aluminium 
10. Magnesium absence of Magnesium 
11. Ammonium presence of Ammonium 
12. Mercury Absence of  Mercury 
13. Alkaloids Presence of Alkaloids 
14. Reducing 
Sugar 
Presence of reducing sugar 
15. Silicate Presence of Silicate 
16. Copper Presence of Copper 
17. Sodium Absence of Sodium 
18. Lead Absence of Lead 
    19. Fluoride And 
Oxalate 
Absence of Fluoride and Oxalate 
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QUANTITATIVE ANALYSIS REPORT 
SOPHISTICATED ANALYTICAL INSTRUMENT FACILITY 
IITM, CHENNAI-36 
PERKIN ELMER OPTIMA 5300DV ICP-OES 
 
 Sample ID- Atthippattaiyathi Kasayam 
 
Analyte             Mean 
As193.696  BDL 
 
Al 308.215 BDL 
 
Ca 317.933 246.249 mg/L 
 
Cd 226.502  BDL 
 
Cu 324.754   8.255 mg/L 
 
Fe 238.204 16.985 mg/L 
 
Hg253.652  BDL 
 
K 766.491 120.159 mg/L 
 
Mg 257.610 19.578 mg/L 
 
Na 588.995 376.412 mg/L 
 
P 214.914  77.995 mg/L 
 
Pb 230.204 BDL 
 
S 181.975  64.654 mg/L 
 
Si 251.611 17.249 mg/L 
 
Zn 213.856 23.756 mg/L 
 
 
(BDL= below detection limit) 
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TOXICOLOGICAL EVALUVATION  
ACUTE TOXICITY STUDY OF ATTHIPPATTAIYATHI KASAYAM 
 [WHO GUIDELINES, 1993] 
Principle: 
   Acute toxicity was carried out in Swiss albino mice with a single exposure of 10 
times of the recommended therapeutic dose of test compound the study duration will be 
14 days. 
Animal species  : Swiss albino mice 
Age / Weight / Size  :  6 weeks.  Mice-20-25 gms. 
Gender   :   Both male and female 
Number of Animals   : Mice: 20 
Acclimatization Period : 7 Days 
Clinical dose   : 15000 mg\day 
 
S.No Group No of mice 
1 Vehicle control  10  (5 male, 5 female) 
2 Toxic dose (10 X therapeutic dose) 
(Single dose) (270 mg) 
10  (5 male, 5 female) 
 
Test Animals  
     Test animals were obtained from the animal laboratory of the King institute, Chennai 
and stocked at aninal house, National institute of siddha Chennai. All the animals were 
kept under standard environmental condition (27+ or – 2 degree c). The animals had free 
access to water and standard pellet diet (Sai meera foods pvt.ltd, Bangalore).The 
principles of laboratory animal care were followed and the Institutional Ethical 
Committee approved the use of animals and the study design. (1248/ac/09/CPCSEA/4-
07/ 2011) 
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Route of administration: oral route was selected, because it is the normal route of 
clinical administration. 
Test substance and vehicle 
      The Atthippattaiyathi kasayam powder is brown in colour with mild astringent taste. 
The test substance is soluble in water, in order to obtain and ensure the uniformity in drug 
distribution, the drug is extracted by decoction preparation method.  
Administration of doses 
Atthippattaiyathi kasayam decoction was administered to the group’s in a single oral 
dose. The control groups were received equal volume of the vehicle. The animals were 
weighed before giving the drug. The dose level was calculated according to body weight, 
and surface area. Since the clinical dose was 15000mg\day It was converted to animal 
dose (270mg) and then administered. The principle of laboratory animal care was 
followed. 
Observations 
Observations were made and recorded systematically and continuously observed as per 
the guideline after substance administration. Animals were observed individually visual 
observations included skin changes, alertness, grooming, aggressiveness, sensitivity to 
sound, touch and pain, restlessness, tremors, convulsion, righting reflex, gripping reflex, 
pinna reflex, corneal reflex, writhing reflex, papillary reflex, urination, salivation, 
lacrimation for first 4 hrs, then periodically during the first 24 hrs. Animals were 
observed for body weight and mortality for 14 days. If animals dying during the period of 
study the animals were sacrificed. At the end of the 14th day all animals were sacrificed 
and necropsy was done. 
Body Weight 
Individual weight of animals was determined before the test substance was 
administered and daily for 14 days. Weight changes were calculated and recorded. At the 
end of the test surviving animals were weighed and sacrificed. 
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Results:  
Atthippattaiyathi kasayam at the dose 270mg/kg/bw did not exhibit any mortality in mice. 
No behavior changes were noted for the first 4 hours and for the next 24 hours and 
throughout the study period of 14 days. No weight reduction was noted before and after 
the acute study duration. Reflexes were found to be normal before and after the study. All 
other observations were found to be normal before and after the study. In Necropsy, the 
organs of the animal such as, Liver, Heart, Lungs, Pancreas,  Spleen, Stomach, Intestine, 
Kidney, Urinary bladder, Uterus all appeared normal. 
SUBACUTE TOXICITY STUDY OF ATTHIPPATTAIYATHI KASAYAM 
[WHO GUIDELINES, 1993] 
Animals             : Male and Female wistar albino rats 
Age                     : 6-8 weeks 
Weight   : 150-200 gms 
Gender   :   Both male and female 
Number of animals   : Rat: 40 
Acclimatization period : 7 Days 
Clinical dose   : 15000mg\day 
Clinical duration  : 28 days 
 
 
S.No Group No of Rats 
       1 Vehicle control  10 (5male,5 female) 
       2 1XTherapeutic dose (270mg) 10 (5male,5 female) 
       3 5XTherapeutic dose (1350mg) 10 (5male,5 female) 
       4 10XTherapeutic dose(2700mg) 10(5male, 5 female) 
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Animal source: 
Test animals were obtained from the animal laboratory of the King Institute, Chennai, and 
stocked at animal house National Institute of Siddha, Chennai. All the animals were kept 
under standard environmental condition (27+ or – 2 degree c). The animals had free 
access to water and standard pellet diet(Sai meera foods pvt.ltd, Bangalore). The 
principles of laboratory animal care were followed and the Institutional Ethical 
Committee approved the use of animals and the study design. (1248/ac/09/CPCSEA/4-
07/ 2011) 
Identification of animal: By cage number, animal number and individual marking on 
fur. 
Housing & Environment:  The animals were housed in polypropylene cages provided 
with bedding of husk. Dark and light cycle each of 12 hours. 
Administration period: 
The period of administration of the test substance to animals are depending on the 
expected period of clinical use. Since the clinical dose of the test drug is 28 days and as 
per WHO guidelines the administration period is reported to be 6 months. 
 Dose selection: 
The results of acute toxicity studies in swiss albino mice indicated that Atthippattaiyathi 
kasayam was non toxic and no behavioral changes, mortality was observed. On the basis 
of these results, the doses were selected for the study as per WHO guidelines.  
Preparation and administration of dose:        
Atthippattaiyathi kasayam was extracted by decoction preparation method. It was 
administered to animals at dose levels of 1X therapeutic dose (270mg), 5X Therapeutic 
dose (1350mg) and 10X Therapeutic dose (2700mg). The control animals were 
administered vehicle only. Administration was by Oral Gavage once a day for 28 days. 
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METHODOLODY: 
Randomization, numbering and grouping of animal: 
The animals were randomly divided into four groups for dosing up to 28 days. Each 
group consist of 10 animals (5 per sex in each group) were allowed acclimatization period 
of 7 days to laboratory conditions prior to the initiation of treatment. Each animal was fur 
marked with picric acid. The females were nulliparous and non pregnant. 
OBSERVATION: 
Experimental animals were kept under observation throughout the course of study for the 
following,      
Body weight:  
Weight of each rat was recorded on day 1 and at weekly intervals throughout the course 
of study and at termination to calculate relative organ weights. From the data mean body 
weights and percent body gain were calculated. 
 Food and water consumption: 
The quantity of food consumed by groups consisting of an animal for different doses was 
recorded at weekly intervals. Food consumed per animal was calculated for control and 
the treated dose groups 
Clinical sings 
All animals were observed daily for clinical sings. The time of onset intensity and 
duration of this symptom if any were recorded 
Mortality: 
All animals were observed twice daily for mortality during entire course of study. 
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TERMINAL STUDIES: 
NECROPSY:  
All the animals were sacrificed on day 91 under ether anesthesia. Necropsy of all 
animals was carried out and the weights of the organs including liver, kidneys, brain, 
heart, and lungs were recorded.  
HISTOPATHOLOGY: 
  Tissue samples of organs from control and treated animals were preserved in 10% 
formalin for preparation of sections using microtome. The organs included liver, kidneys, 
heart, lungs and stomach of the animals were preserved and they were subjected to 
histopathological examination. 
   The organ pieces (3-5 micron ) were fixed in 10% formalin for 24 hours and 
washed in running water for 24 hours. Samples were dehydrated in tissue processor and 
then cleaned in benzene to remove absolute alcohol. Embedding was done by passing the 
cleared sample through three cups containing molten paraffin at 50 degree Celsius and 
then a cubical block of paraffin made by the L moulds it was followed by microtome and 
the slides were stained with haematoxylin–eosin stain. Stained sections of each organ 
were examined under light microscope at high (40X) power magnification. All the 
histopathological slides were prepared at Dept of Pathology, Vels University, pallavaram, 
Chennai.  
Results: 
270MG TREATED (Low dose) 
Kidney: shows normal renal tissue with glomeruli and tubules.  
Spleen: shows normal spleen with lymphoid aggregation. 
Liver: shows almost normal hepatocytes and occasional binucleate cells. 
Stomach: shows normal mucosal glands. 
Lung: shows normal alveoli. 
Heart: shows normal cardiac muscle bundles. 
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Pancrea: shows normal acini with islets of β-cells 
1350MG TREATED (Mid dose) 
Kidney: shows renal tissue with focal tubular damage, interstitial inflammatory 
collection. Glomeruli shows epithelial proliferation.  
Liver: shows hepatocytes with focal mild fatty change.  
Spleen: shows congestion with lymphoid hyperplasia.  
Stomach: shows near normal mucosal gland with mild exudates. 
Lung: shows congested alveolar wall with mild thickening and mild emphysematous 
changes.  
Pancreas: shows pancreas with acini and normal islets.  
Heart: shows congestion and mild inflammatory infiltration in between cardiac muscle 
bundles. 
2700MG TREATED (High dose) 
Stomach: shows stomach with superficial erosion and congestion.  
Heart: shows hypertrophic cardiac muscle bundles.  
Spleen: shows lymphoid hyperplasia. 
Liver: shows marked dilatation of sinusoids, degeneration of hepatocytes, necrosis.   
Kidney: shows renal tissue with tubular epithelial damage.  
Pancreas: shows atrophic islet cells. 
Lung: shows congestion, narrowed alveolar space and thickened alveolar wall. 
Impression: Normal study 
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HISTOPATHOLOGY SLIDES 
Slides Control Group 5x Group 10x Group 
Heart 
   
Lung 
   
Liver 
   
Spleen 
   
Pancreas 
   
Stomach 
   
Kidney 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASA PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “MATHUMEGAM” (TYPE-2 
DIABETES MELLITUS) AND THE DRUG OF CHOICE IS 
“ATTHIPPATTAIYATHI KASAYAM” (INTERNAL) 
FORM-l (SCREENING & SELECTION PROFORMA) 
IEC NO: NIS/IEC/2011/3/07 
1. SI NO: _______ 2.OP/IP NO: _________ 
3.NAME:________________________________ 
 
4.RELIGION: H/C/M/O  5. AGE: ________  6.GENDER: 
____________  
 
7. OCCUPATION:______________ 8. INCOME: _______ 9. CONTACT NO: 
___________ 
 
 10. ADDRESS: 
_______________________________________________________________ 
INCLUSION CRITERIA EXCLUSION CRITERIA 
· Age : 30-55Yrs  – Yes/No 
· Sex:  Male/Female 
Symptoms: 
· Polyuria   – Yes/No 
· Nocturia   – Yes/No 
· Polydipsia   – Yes/No 
· Polyphagia   – Yes/No 
· Body pain    – Yes/No 
· Weight gain (obesity)  – Yes/No 
· Tiredness  – Yes/No 
· Burning feet   – Yes/No 
· Genital pruritus                – Yes/No 
Blood glucose level: 
· Fasting plasma glucose level- 126 
to180 mg/dl                – Yes/No 
· 2 hours plasma glucose level- 200 to 
300 mg/dl               – Yes/No 
 
· IDDM (Insulin Dependent Diabetes Mellitus)       – Yes\No 
· Diabetic complications like micro and macrovascular 
complications etc                                                       -Yes\No 
· Cardiac diseases                            – Yes\No 
· Pulmonary diseases               – Yes\No 
· Renal diseases                             – Yes\No 
· Thyroid dysfunctions              – Yes\No 
· Gestational diabetes               – Yes\No 
· Other endocrine abnormalities                      – Yes\No 
· Patient who are not willing to give blood sample    – Yes\No 
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Asymptomatic individuals fulfilling the following criteria may be screened  
· Previously identified Impaired Fasting Glucose (IFG) or Impaired Glucose Tolerance 
(IGT).  
IFG- FPG >110 and <126mg/dl   – Yes/No 
IGT- 2h PG >140 and <200mg/dl   – Yes/No 
· Family history of diabetes    – Yes/No 
· Sedentary lifestyle     – Yes/No 
· History of gestational diabetes mellitus, recurrent fetal loss or delivery of large baby ≥ 
3.5kg       – Yes/No 
· Dyslipidemia      – Yes/No 
· Hypertension (>140/90 mm Hg in adults)  – Yes/No 
· Urine test – glycosuria, microalbuminuria  – Yes/No 
· Acanthosis nigricans     – Yes/No 
· Patient willing to sign the informed consent stating that he  will conscientiously stick 
to the treatment during 40 days but can opt out of the trial of his  own conscious 
discretion        – Yes/No 
· Patients who are willing to provide blood and urine for lab investigation  
– Yes/No 
Admited to trail  1.Yes   2.No   
   If Yes, Serial NO:  _____ 
DATE:        STATION: 
SIGNATURE OF THE INVESTIGATOR                                
 
 
SIGNATURE OF THE LECTURER 
 
 
SIGNATURE OF THE HOD 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASA PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “MATHUMEGAM” (TYPE-2 
DIABETES MELLITUS) AND THE DRUG OF CHOICE IS 
“ATTHIPPATTAIYATHI KASAYAM” (INTERNAL) 
FORM I-A  HISTORY PROFORMA 
IEC NO: NIS/IEC/2011/3/07 
 
1. Serial No of the patient:   _______________ OP.NO/IP.NO:________________ 
       
2. Name: _____________________________________    3. Gender: F/M 
 
4. Age (years): _________   DOB            
      Date       Month            Year 
5. Address: _______________________________________________________________ 
 
6. Occupation: ____________________ 
 
7. Educational Status:   A) Illiterate                  B) Literate          
 
8. Height:         ____cms                9.Weight:         _____kg        10. BMI: ________ kg/m² 
 
11. Marital status: 1.Married   2.Unmarried 
 
10. Complaints and Duration:   
_________________________________________________________________________ 
_________________________________________________________________________ 
_________________________________________________________________________ 
_________________________________________________________________________ 
 
11. History of present illness: 
_________________________________________________________________________ 
_________________________________________________________________________ 
_________________________________________________________________________ 
_________________________________________________________________________ 
 
12. Past History: 
_________________________________________________________________________ 
_________________________________________________________________________ 
_________________________________________________________________________ 
_________________________________________________________________________ 
 
13. Socio economic status: 
Income group  1.lower   2.middle   3.higher 
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14. Treatment History: 
Had the patient been treated before with Allopathy drug? Yes  No 
 
 
1.Yes  2.No 
 
Insulin injection 
 
Oral antidiabetic drugs 
 
How long: 
____________________________________________________________________ 
 
15. Family history: 
 
Whether diabetes mellitus runs this family? 
 1) Yes           2) No 
 
If yes, mention the relationship of affected person(s) 
1. ______________ 
2. ______________ 
3. ______________ 
16. Habit of 
 
A) Smoking                   1. Yes; duration ________ years; Quantity _____ ___ 2.No 
B) Tobacco chewing     1. Yes; duration ________ years       2.No                
C) Betel chewing          1. Yes; duration ________ years      2.No 
D) Alcoholism              1. Yes; duration ________ years; Quantity     ______ml 2.No 
 
17.Dietry style:  A.) Pure vegetarian        B.) Non-vegetarian    C.) Mixed diet 
 
 
DATE:         STATION: 
SIGNATURE OF THE INVESTIGATOR                                
 
SIGNATURE OF THE LECTURER      
SIGNATURE OF THE HOD 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASA PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “MATHUMEGAM” (TYPE-2 
DIABETES MELLITUS) AND THE DRUG OF CHOICE IS 
“ATTHIPPATTAIYATHI KASAYAM” (INTERNAL) 
FORM-II AND II-A    CLINICAL ASSESSMENT ON ENROLLMENT AND ON 
VISITS 
IEC NO: NIS/IEC/2011/3/07 
 
         1. S NO: _______________      2. OP/IP NO: __________________            
         3.  NAME: _____________________________________________      4.GENDER: M/F                         
         5. DATE OF ASSESSMENT   : ________________ 
          Initial (0th day)                10th day               20th day              30th day             40th day  
 SIDDHA SYSTEM OF EXAMINATION 
1. ENVAGAI THERVU: [EIGHT-FOLD EXAMINATION] 
 I. NAADI: [PULSE PERCEPTION] 
     
 II. NAA:[TONGUE] 
 0th Day 10th Day 20th Day 30th Day 40th Day 
Colour Dark / Yellow/Red 
/ Pale/Normal 
Dark/Yellow/ 
Red/Pale/Normal 
Dark/Yellow/ 
Red/Pale/Normal 
Dark/Yellow/ 
Red/Pale/Normal 
Dark/Yellow/ 
Red/Pale/Normal 
Taste Sweet/Bitter/Sour 
Pungent/None 
Sweet/Bitter/Sour 
Pungent/None 
Sweet/Bitter/Sour 
Pungent/None 
Sweet/Bitter/Sour 
Pungent/None 
Sweet/Bitter/Sour 
Pungent/None 
Coating Present/Absent Present/Absent Present/Absent Present/Absent Present/Absent 
Fissure Present/Absent Present/Absent Present/Absent Present/Absent Present/Absent 
Saliva Normal/Increased/ 
Decreased 
Normal/Increased 
Decreased 
Normal/Increased/ 
Decreased 
Normal/Increased/ 
Decreased 
Normal/Increased/ 
Decreased 
 0th  
day 
10th 
day 
20th 
day 
30th 
day 
40th  
day 
 0th  
day 
10th 
day 
20th  
day 
30th 
day 
40th  
day 
Vali      Iyya vali      
Azhal      Vali Iyyam      
Iyyam      Azhal Iyyam      
Vali Azhal      Iyya Azhal      
Azhal vali            
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Dryness Present/Absent Present/Absent Present/Absent Present/Absent Present/Absent 
Glossitis Present/Absent Present/Absent Present/Absent Present/Absent Present/Absent 
Baldness Present/Absent Present/Absent Present/Absent Present/Absent Present/Absent 
 
III.NIRAM: [COMPLEXION]    
0th Day  10th day  20th day  30th day 40th Day 
Dark/Yellow 
tinted/Whitish 
brown / Pale 
Dark/Yellow tinted  / 
Whitish brown / Pale 
Dark/Yellow tinted  / 
Whitish brown/ Pale 
Dark/Yellow tinted  / 
Whitish brown/ Pale 
Dark/Yellow tinted/       
Whitish brown / Pale 
 
IV.MOZHI: [VOICE] 
0th Day  10th day 20th Day 30th Day 40th Day 
Medium/High 
Low pitched 
Medium/High/ 
Low pitched 
Medium/High/ 
Low pitched 
Medium/High/ 
Low pitched 
Medium/High/ 
Low pitched 
 
V.VIZHI: [EYES] (Lower palpabrel conjunctiva)   
0th Day  10th day 20th Day 30th Day 40th Day 
Yellow 
Red/ Pale/Normal 
Yellow 
Red/ Pale/Normal 
Yellow 
Red/ Pale/Normal 
Yellow 
Red/ Pale/Normal 
Yellow 
Red/ Pale/Normal 
   
VI. MALAM; [BOWEL HABITS / STOOLS] 
Malam 0th Day 10th Day 20th Day 30th Day 40th Day 
Colour Dark/ Yellow/ 
Pale/Others 
Dark/ Yellow/ 
Pale 
Dark/ Yellow 
Pale 
Dark/ Yellow 
Pale 
Dark/ Yellow 
Pale 
Consistency Solid/Semisolid 
Watery 
Solid/Semisolid 
Watery 
Solid/Semisolid 
Watery 
Solid/Semisolid 
Watery 
Solid/Semisolid 
Watery 
Stool  bulk                         Normal/Reduced 
 
Normal/Reduced Normal/Reduced Normal/Reduced Normal/Reduced 
Constipation   Present/Absent 
 
Present/Absent 
 
Present/Absent 
 
Present/Absent 
 
Present/Absent 
 
Diarrhoea Present/Absent Present/Absent Present/Absent Present/Absent Present/Absent 
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VII. URINE EXAMINATION:    
 
 
VIII. SPARISAM: [PALPATORY  PERCEPTION] 
0th Day 10th Day 20th Day 30th Day 40th Day 
Warmth/Cold/Normal 
 Sweat 
Warmth/ Cold/Normal 
Sweat 
Warmth/ Cold/Normal 
Sweat 
Warmth/ Cold/Normal 
Sweat 
Warmth/ Cold/Normal 
Sweat 
 
5. THEGI: [ TYPE OF BODY CONSTITUTION]    
Vatham predominant  Kabam predominant  
Pitham predominant  Thondha udal  
 
 
NEERKURI 0th Day 10th Day 20th Day 30th Day 40th Day 
Niram 
[Colour]   
White/Yellowish/ 
Straw coloured/ 
Crystal clear 
White/Yellowish/ 
Straw coloured 
Crystal clear 
White/Yellowish/ 
Straw  coloured/ 
Crystal clear 
White/Yellowish/ 
Straw  coloured/ 
Crystal clear 
White/Yellowish/ 
Straw  coloured/ 
Crystal clear 
Manam 
[Odour] 
Present  
Absent 
 Present  
Absent 
Present  
Absent 
Present  
Absent 
Present  
Absent 
Nurai 
[Froth] 
Nil 
Reduced/Increased 
Nil 
Reduced/Increased 
Nil 
Reduced/Increased 
Nil 
Reduced/Increased 
Nil 
Reduced/Increased 
Edai 
[Sp.gra]                               
Normal 
Increased/Reduced 
Normal 
Increased/Reduced 
Normal 
Increased/Reduced 
Normal 
Increased/Reduced 
Normal 
Increased/Reduced 
Enjal 
[Deposits] 
Present/ Absent Present/ Absent Present/ Absent Present/ Absent Present/ Absent 
Volume   Normal 
Increased/Reduced 
Normal 
Increased/Reduced 
Normal 
Increased/Reduced 
Normal 
Increased/Reduced 
Normal 
Increased/Reduced 
NEIKURI 0th day 10th day 20th day 30th day 40th day 
Serpentine fashion      
Annular/Ringed fashion      
Pearl beaded fashion         
Mixed fashion      
Other fashion      
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6.NILAM: [ LAND WHERE PATIENT LIVED MOST ] 
  Kurinji                         Mullai                  Marutham              Neithal                  Palai 
(Hilly terrain)              (Forest range)          (Plains)                  (Coastal belt)        (Arid regions)  
 7. KAALAM 
Kaarkalam-                                 Pinpanikalam      
Koothirkalam-                            Ilavenil 
Munpanikalam -                         Muthuvenil 
8. GUNAM 
Sathuvam                        Rasatham                       Thamasam 
9. AIMPORIGAL (SENSORY ORGANS) 
10.KANMENDRIYAM ( MOTOR ORGANS) 
 
 
AIMPORIGAL 0th day 10th day 20th day 30th day 40th day 
Mei (Skin)      
Vai (Buccal Cavity)      
Kann (Eye)      
Mooku (Nose)      
Sevi  (Ear)      
 0th day 10th day 20th day 30th day 40th day 
Kai (upper limb)      
Kaal (lower limbs)      
Vai  (buccal cavity)      
Eruvai (excretory 
organs) 
     
Karuvai (reproductive 
organs) 
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11. KOSANGAL (Sheath)   
 0th day 10th day 20th day 30th day 40th day 
Annamaya Kosam      
Pranamaya kosam       
Manomaya kosam       
Vignanamaya kosam       
Ananthamaya kosam       
 
12. MUKKUTRAM: [AFFECTION OF THREE HUMORS] 
A)VATHAM: 
 0th day 10th day 20th day 30th day 40th day 
Praanan      
Abaanan      
Samaanan      
Udhaanan      
Viyaanan      
Naagan      
Koorman      
Kirukaran      
Devathathan      
Dhananjeyan      
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B) PITHAM:   
 0th day 10th day 20th day 30th day 40th day 
Anarpitham      
 Prasakam      
Ranjakam      
Aalosakam      
Saathakam      
C) KABAM: 
 0th day 10th day 20th day 30th day 40th day 
Avalambagam      
Kilethagam      
Pothagam      
Tharpagam      
Santhigam      
  
13. SEVEN DHATHUS: (7 SOMATIC COMPONENTS)  
 0th day 10th day 20th day 30th day 40th day 
Saaram [Chyme]      
Senneer [Blood]       
Oon [Muscle]      
Kozhuppu [Fat]      
Enbu [Bones]      
Moolai [Bonemarrow]      
Sukkilam/Suronitham 
[Genital discharges] 
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14. SYSTEMIC EXAMINATION: 
 0th day 10th day 20th day 30th day 40th day 
LOCOMOTOR 
SYSTEM 
     
CARDIO 
VASCULAR  
SYSTEM 
 
 
    
RESPIRATORY 
SYSTEM 
 
 
    
GASTRO 
INTESTINAL 
 SYSTEM    
 
 
    
CENTRAL  
NERVOUS  
SYSTEM        
 
 
    
UROGENITAL 
SYSTEM 
     
ENDOCRINE  
SYSTEM 
     
 
15. GENERAL EXAMINATION: 
 0th day 10th day 20th day 30th day 40th day 
Height (cms)      
Weight (kg)      
Temperature(°F)         
Pulse rate (per min)      
Heart rate (per min)      
Respiratoryrate(per min)      
Blood pressure(mm/Hg)      
Pallor      
Jaundice      
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Cyanosis      
Lymphadenopathy      
Pedal edema      
Clubbing      
Jugular vein pulsation      
 
16. CLINICAL SYMPTOMS 
S.NO CLINICAL  SYMPTOMS  0th day       10th day                              20th day     30th day         40th day         
1. POLYURIA      
2. NOCTURIA      
3. POLYDIPSIA      
4. POLYPHAGIA      
5. BODY PAIN      
6. WEIGHT GAIN (obesity)      
7. TIREDNESS      
8. BURNING FEET      
9. GENITAL PRURITUS      
DATE: 
STATION: 
SIGNATURE OF THE INVESTIGATOR                                
 
 
 
SIGNATURE OF THE LECTURER 
 
 
 
SIGNATURE OF THE HOD 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASA PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “MATHUMEGAM” (TYPE-2 
DIABETES MELLITUS) AND THE DRUG OF CHOICE IS 
“ATTHIPPATTAIYATHI KASAYAM” (INTERNAL) 
FORM-III LABORATORY PARAMETERS-CHART 
IEC NO: NIS/IEC/2011/3/07 
 
1. OP/IP No: _____________    2.S. No:                           
3. Name: _________________________      4. Age:   _______ years 5.Gender: M/F    
 
 
BLOOD INVESTIGATION NORMAL VALUES 
BEFORE 
TMT 
Date: 
AFTER  TMT 
Date: 
HB( gms%) M:13-18 W:11-16   
 
T.RBC(milli/cu.mm) 
M:4.5-6.5 
W:3.5-5.5   
 
ESR (mm) 
½ hr. -   
1 hr. M:0-10 W:0-20   
T.WBC (/cu.mm)       4000-11000   
DIFFERENTIAL 
COUNT (%) 
Polymorphs 40-75   
Lymphocytes 20-35   
Monocytes 2-10   
Esonophils 1-6   
Basophils 0-1   
Blood Investigation Normal Values 
Before TMT 
Date: 
After TMT  
Date: 
Lipid 
profile 
(mg/dl) 
Serum cholesterol 150-250   
HDL 30-60   
LDL Upto 130   
VLDL 40   
TGL Upto 160   
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RFT 
(mg/dl) 
Blood urea 16-50   
Serum creatinine 0.6-1.2   
Serum Uric acid M:3-9 W: 2.5-7.5   
LFT 
(mg/dl) 
Total bilirubin 0.3-1   
Direct bilirubin 0.1-0.3   
Indirect bilirubin 0.2-0.8   
Serum total protein 6-8   
Serum Albumin 3.5-5.5   
Serum globulin 2-3.5   
Serum calcium 9-11   
Serum phosphorous 2-5   
SGOT (IU/L) 6-18   
SGPT (IU/L) 3-26   
Alkaline 
phosphatase (IU/L) 80-290   
URINE INVESTIGATION Before TMT(with Date) After TMT (With Date) 
Albumin   
Fasting sugar   
PP sugar   
Deposits   
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SPECIFIC  INVESTIGATION: 
OGTT  
 
 
DATE:        STATION: 
 
SIGNATURE OF THE INVESTIGATOR                                
 
 
 
SIGNATURE OF THE LECTURER 
 
 
SIGNATURE OF THE HOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BLOOD GLUCOSE TEST 
NARMAL VALUE BEFORE TMT AFTER TMT 
OGTT  
FASTING (OVER NIGHT 8-10hr) 
 
 
 
<126  mg/dl 
  
2 HOURS AFTER GLUCOSE 
LOAD 
 
<200 mg/dl   
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASA PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “MATHUMEGAM” (TYPE-2 
DIABETES MELLITUS) AND THE DRUG OF CHOICE IS 
“ATTHIPPATTAIYATHI KASAYAM” (INTERNAL) 
FORM IV –C (DRUG COMPLIANCE FORM) 
IEC NO: NIS/IEC/2011/3/07 
 
Name:___________________ OP/IP No: Serial No: DRUG NAME: ____________    
On  0th   day-Date:  Drugs issued:           DOSE:___________ (before 
food) 
On 10th day-Date:                   Drugs issued:   Drugs returned:  
On 20th day-Date:                Drugs issued:   Drugs returned:  
On 30th day-Date:                Drugs issued:   Drugs returned: 
On 40th day-Date:      Drugs returned:  
   
Day  Date Morning (7-8 am)  After noon (1-2 pm) Evening (7-8 pm) 
Day 1     
Day2     
Day3     
Day4     
Day5     
Day6     
Day7     
Day8     
Day9     
Day10     
Day11     
Day12     
Day13     
Day14     
Day15     
Day16     
Day17     
Day18     
Day19     
Day20     
Day 21     
Day22     
Day23     
Day24     
Day25     
154 
 
Day26     
Day27     
Day28     
Day29     
Day30     
Day31     
Day32     
Day33     
Day34     
Day35     
Day36     
Day37     
Day38     
Day39     
Day40     
 
DATE: 
STATION: 
 
SIGNATURE OF THE INVESTIGATOR                                
 
 
 
SIGNATURE OF THE LECTURER 
 
 
SIGNATURE OF THE HOD 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASA PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “MATHUMEGAM” (TYPE-2 
DIABETES MELLITUS) AND THE DRUG OF CHOICE IS 
“ATTHIPPATTAIYATHI KASAYAM” (INTERNAL) 
 
FORM IV-D  DIETARY ADVICE FORM 
IEC NO: NIS/IEC/2011/3/07 
 
DIET ADVICE: 
 
Don’t 
· Avoid sugar, honey, jaggery, sweets, very sweet fruits, fruit juices, roots, 
tubers, ghee, milk, curd, oily foods, chicken, mutton, egg yolk.  
· Avoid alcohol, smoking, tobacco, betel nut. 
 
 
Do’s 
· Main source should be cereals, mixed coarse grains, whole pulses, salads 
and soybeans. 
· Take Protein from vegetables sources like tender fresh vegetables, fiber 
content vegetables, greens and butter milk, sea fish, lean meat. 
· Fiber rich food include whole grains, whole pulses, soybean, green leafy 
vegetables and fenu-greek seeds. 
· Ground nut, sesame, cotton seed, rice bran and safflower oils should be 
used. 
· Salt up to 6g/day is permitted. Restrict pickles, papad, chatni and salty 
processed foods, 
· Brisk walking for 45 minutes daily. 
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§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ, ¦ºý¨É-47 
«§Â¡ò¾¢¾¡º÷ ÀñÊ¾÷ ÁÕòÐÅÁ¨É 
¦À¡ÐÁÕòÐÅò Ð¨È 
ÁÐ§Á¸õ (Å¨¸-2 ¼ÂÀ¢ÊŠ ¦ÁøÄ¢¼Š) §¿¡öì¸¡É º¢ò¾ ÁÕó¾¢ý 
(«ò¾¢ôÀð¨¼Â¡¾¢ ¸º¡Âõ) ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É 
ÀÊÅõ IV-D ¯½× ÀÃ¢óÐ¨Ã ÀÊÅõ 
IEC NO: NIS/IEC/2011/3/07 
¾Å¢ì¸ §ÅñÊÂ¨Å: 
 
· º÷¸¨Ã, §¾ý, À¨É¦ÅøÄõ, þÉ¢ôÒ Å¨¸¸û, Á¢Ì þÉ¢ôÀ¡É 
ÀÆí¸û, ÀÆîº¡Ú Å¨¸¸û, ¸¢ÆíÌ Å¨¸¸û, ¦¿ö, À¡ø, ¾Â¢÷, 
±ñ¦½ö ÀÄ¸¡Ãí¸û, §¸¡Æ¢, ¬Î, Óð¨¼ Áïºû¸Õ ¬¸¢ÂÅü¨È 
¾Å¢÷¸×õ. 
· ÁÐ, Ò¨¸, ¦ÅüÈ¢¨Ä, À¡ìÌ þÅü¨È ¾Å¢÷¸×õ. 
 
§º÷ì¸ §ÅñÊÂ¨Å: 
 
· ¾¡É¢Â ¸Ä¨Å, Ó¨Æ¸ðÊÂ ¾É¢Âõ, ÀÕôÒ Å¨¸¸û, ÀîºÊ Å¨¸, 
§º¡Â¡À£ý ¬¸¢Â¨Å Óì¸¢Â ¯½×¸û ¬Ìõ. 
· Àî¨º þÇõ¸¡ö¸û, ¿¡÷ºòÐì ¸¡ö¸û, ¸£¨Ã¸û ÁüÚõ §Á¡÷, 
¸¼øÁ£ý, ¦¸¡ØôÀüÈ Á¡Á¢ºõ ¬¸¢ÂÅüÈ¢Ä¢ÕóÐ ÒÃ¾í¸¨Ç ¦ÀÚÅÐ 
¿ýÚ. 
· ÓØ¾¡É¢Âí¸û, ÓØÀÕôÒ Å¨¸¸û, §º¡Â¡À£ý, Àî¨º 
þ¨Äì¸¡ö¸È¢¸û ÁüÚõ ¦Åó¾Âõ ¬¸¢Â¨Å ¿¡÷ºòÐÁ¢ì¸ ¯½×¸û. 
· ¸¼¨Ä ±ñ¦½ö, ¿ø¦Äñ¦½ö, ÀÕò¾¢Å¢¨¾ ±ñ¦½ö, ¨ÃŠÀ¢Ãý 
±ñ¦½ö, º¡À¢Ç¡÷ ±ñ¦½ö ¬¸¢Â ±ñ¦½ö Å¨¸¸¨Ç 
ÀÂýÀÎò¾×õ. 
· ¾¢ÉºÃ¢ 6¸¢ ¯ôÒ ÁðÎ§Á ±ÎòÐì¦¸¡ûÇ×õ, °Ú¸¡ö, «ôÀÇõ, 
ºðÊÉ¢ ÁüÚõ ¯ôÀ¢ø °È¢Â ¾Â¡Ã¢ôÒ ¯½×¸¨Ç ¾Å¢÷¸×õ. 
· ¾¢ÉºÃ¢ 45 ¿¢Á¢¼õ §Å¸ ¿¨¼ ¿¼ôÀÐ ¿ýÚ. 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASA PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “MATHUMEGAM” (TYPE-2 
DIABETES MELLITUS) AND THE DRUG OF CHOICE IS 
“ATTHIPPATTAIYATHI KASAYAM” (INTERNAL) 
FORM IV-B WITHDRAWAL FORM 
IEC NO: NIS/IEC/2011/3/07 
 NAME:  _______________________________      OPD/ IPD NUMBER: _____________ 
AGE: _________                                       SERIAL NO: _____________________ 
DATE OF TRIAL COMMENCEMENT:  
DATE OF WITHDRAWAL FROM TRIAL:  
REASONS FOR WITHDRAWAL: 
· Long absence at reporting :                 Yes/ No 
· Irregular treatment:                           Yes/ No 
· Shift of locality :                                    Yes/No 
· Increase in severity of symptoms:    Yes/No 
· Development of severe adverse drug reactions:   Yes/No 
 
DATE: 
STATION: 
 
SIGNATURE OF THE INVESTIGATOR                                
 
 
 
SIGNATURE OF THE LECTURER 
 
 
SIGNATURE OF THE HOD 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASA PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “MATHUMEGAM” (TYPE-2 
DIABETES MELLITUS) AND THE DRUG OF CHOICE IS 
“ATTHIPPATTAIYATHI KASAYAM” (INTERNAL) 
 
FORM IV-E ADVERSE DRUG REACTION FORM 
IEC NO: NIS/IEC/2011/3/07 
NAME: ______________________________   OPD/ IPD NUMBER: 
___________________ 
AGE: ____________                                        SERIAL NO: 
_________________ 
DATE OF TRIAL COMMENCEMENT: 
DATE OF WITHDRAWAL FROM TRIAL: 
DESCRIPTION OF ADVERSE REACTION: 
___________________________________________________________________________
__ 
___________________________________________________________________________
__ 
___________________________________________________________________________
__ 
___________________________________________________________________________
__ 
DATE: 
STATION: 
 
SIGNATURE OF THE INVESTIGATOR                                
 
 
 
SIGNATURE OF THE LECTURER 
 
SIGNATURE OF THE HOD 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASA PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “MATHUMEGAM” (TYPE-2 
DIABETES MELLITUS) AND THE DRUG OF CHOICE IS 
“ATTHIPPATTAIYATHI KASAYAM” (INTERNAL) 
CONSENT FORM-IV A 
IEC NO: NIS/IEC/2011/3/07 
 
CERTIFICATE OF CONSENT 
“I have read the foregoing information, or it has been read to me. I have had the 
opportunity to ask question about it and any questions I have asked have been answered to my 
satisfaction. I consent voluntarily to participate as a participant in this study and understand that I 
have the right to withdraw from the study at any time without in any way it affecting my further 
medical care.” 
 
“I have received a copy of the information sheet/consent form.” 
 
 
Date:        Signature of the participant 
 
 
 
In case of illiterate participant 
 
“I have witnessed the reading of the consent form to the potential participant, and the individual 
has had the opportunity to ask question. I confirm that the individual has given consent freely.” 
 
 
Date: 
 
Signature of a witness       
 
 
Left thumb impression of participant 
(Selected by the participant bearing no connection with the project team) 
 
 
 
 
Date:        Signature of the Doctor 
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§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ, ¦ºý¨É-47 
«§Â¡ò¾¢¾¡º ÀñÊ¾÷ ÁÕòÐÅÁ¨É 
¦À¡ÐÁÕòÐÅò Ð¨È 
ÁÐ§Á¸õ (Å¨¸-2 ¼ÂÀ¢ÊŠ ¦ÁøÄ¢¼Š) §¿¡öì¸¡É º¢ò¾ ÁÕó¾¢ý 
(«ò¾¢ôÀð¨¼Â¡¾¢ ¸º¡Âõ) ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É 
 ´ôÒ¾ø ÀÊÅõ-IV A 
IEC NO: NIS/IEC/2011/3/07 
´ôÒ¾øÀÊÅ º¡ýÈ¢¾ø 
 
“¿¡ý §ÁüÜÈ¢Â ¾¸Åø ÀÊÅò¨¾ ÀÊòÐ «øÄÐ ÀÊì¸ §¸ðÎ 
¦¸¡ñ§¼ý. ­Ð ¦¾¡¼÷À¡É Å¢Çì¸í¸¨ÇÔõ §¸ðÎ ¦¾Ã¢óÐ ¦¸¡ñ§¼ý. 
±ó¾Å¢¾ ÅüÒÚò¾Ä¢ýÈ¢ ±ý ¦º¡ó¾ Å¢ÕôÀò¾¢ý §ÀÃ¢ø ±ý¨É ­ó¾ 
¬Ã¡öîº¢ìÌ ¯ðÀÎò¾ ±ý ÓØÁÉ§¾¡Îõ ÍÂ¿¢¨É§Å¡Îõ ºõÁ¾õ 
¦¾Ã¢Å¢ì¸¢§Èý. ¿¡ý þó¾ ÁÕòÐÅ ¬öÅ¢ý §À¡Ð ¸¡Ã½õ ±Ð×õ ÜÈ¡Áø 
±ô¦À¡ØÐ §ÅñÎÁ¡É¡Öõ þó¾ ¬öÅ¢Ä¢ÕóÐ ±ý¨É Å¢ÎÅ¢òÐì¦¸¡ûÙõ 
¯Ã¢¨Á¨Â ¦¾Ã¢ó¾¢Õì¸¢ý§Èý.” 
 
¿¡ý ¾¸Åø ÀÊÅõ/´ôÒ¾ø ÀÊÅ ¿¸¨Ä ¦ÀüÚì¦¸¡ñ§¼ý. 
 
 
§¾¾¢:                        ¨¸¦Â¡ôÀõ:  
 
 
±Ø¾ÀÊì¸ ¦¾Ã¢Â¡¾ §¿¡Â¡Ç¢Â¡¸ þÕìÌõ Àðºò¾¢ø 
 
“±ÉÐ ÓýÉ¢¨ÄÂ¢ø Ó¾ý¨Á ¬öÅ¡ÇÃ¡ø þó¾ ¬ö× ÌÈ¢òÐ «¨ÉòÐ 
¾¸Åø¸Ùõ §¿¡Â¡Ç¢ìÌ ¦¾Ç¢Å¡¸ Å¢Çì¸ôÀð¼Ð. ¬ö× ÌÈ¢ò¾ §¿¡Â¡Ç¢Â¢ý 
ºó§¾¸í¸ÙìÌ §¸ûÅ¢ ±ØôÀ Å¡öôÒ ÅÆí¸ôÀð¼Ð. §¿¡Â¡Ç¢ ÓØÁÉÐ¼ý 
±ó¾Å¢¾ ÅüÒÚò¾Ä¢ýÈ¢ þó¾ ¬öÅ¢ø Àí§¸üì¸¢È¡÷ ±ýÚ º¡ðº¢ÂÇ¢ì¸¢§Èý”. 
 
§¾¾¢:                      
 
 
º¡ðº¢ì¸¡Ã÷ ¨¸¦Â¡ôÀõ:  
 
§¿¡Â¡Ç¢Â¢ý þ¼Ð¨¸ ¦ÀÕÅ¢Ãø §Ã¨¸ 
 
 
 
 
§¾¾¢:        ÁÕòÐÅ÷ ¨¸¦Â¡ôÀõ 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASA PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “MATHUMEGAM” (TYPE-2 DIABETES MELLITUS) AND THE 
DRUG OF CHOICE IS “ATTHIPPATTAIYATHI KASAYAM” (INTERNAL) 
FORM IV – INFORMATION SHEET 
IEC NO: NIS/IEC/2011/3/07 
 
Name of the Principal Investigator: Dr.S.G.Senthil kumar 
 
Name of the Institution                  : National Institute of Siddha 
                                                        Tambaram Sanatorium 
                                                        Chennai-47. 
 
Ø I, Dr.S.G.Senthil kumar studying M.D(Siddha) in National Institute of Siddha, Chennai. 
The disease called Mathumegam (Type-2 Diabetes Mellitus) becomes heterogeneous 
group of metabolic disorders characterized by hyperglycemia resulting from defects in 
insulin secretion, insulin  resistance or both. It includes the symptoms like, frequent 
urination, increased thirst, increased hunger, general tiredness and burning feet. This 
condition is being treated in NIS with many siddha formulations. As a part of 
M.D(Siddha) research programme and developing new efficacious medicine, we propose 
to study the Atthippattaiyathi kasayam formulation for treating the condition. This 
formulation has been mentioned in siddha literature and empirical evidence with 
contemporary tools is required for documentation. You can receive medicines free of cost. 
The duration of treatment period is 40 days. You have to visit NIS every 10 days and 
collect drugs for 10 days. The diagnosis tests will be carried out free of cost. We will 
assess the effect of treatment after completion of 40 days of treatment using clinical and 
lab parameters. 
 
Ø In this regard, we need to ask you few questions. We will maintain confidentiality of your 
comments and data obtained from you. There will be no risk of disclosing your identity 
and no physical, psychological or professional risk is involved by taking part in this 
study. 
Ø Taking part in this study is voluntary. No compensation will be paid to you for taking part 
in this study. You can choose not to answer any specific question. There is no specific 
benefit for you if you take part in the study, but you will be under our clinical monitoring 
and specific attention will be given for your health. Taking part in the study may be of 
benefit to the community, as it may help us to develop medicine for Mathumegam (Type-2 
Diabetes Mellitus). You can withdraw from the study at the midst of treatment period, if 
you are not interested to continue and you will receive our usual treatment without 
condition. 
Ø The information we will collect in this study, will remain between you and the principal 
investigator. We will ask you a few questions through questionnaire. We will not write 
your name on different forms which sent to different investigating/analysis sections and 
we will use a code instead given by the principal investigator. Only the principal 
investigator will know the key to this code which will be kept in safe custody. If you agree 
to be a participant in this study, you will be screened as per the study protocol. 
  
Ø If you wish to find out more about this study before taking part, you can ask me all the 
questions you want or contact Dr.S.G.Senthil kumar, PG scholar cum principal 
investigator of this study, attached to the National Institute of Siddha, Chennai (Mobile 
phone no:9994172837). You can also contact the Chairman/Member-secretary of Ethics 
committee, National Institute of Siddha, Chennai – 600047, Tel no: 91-44-22411611, for 
rights and participation in the study. 
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§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ, ¦ºý¨É 47 
«§Â¡ò¾¢¾¡º ÀñÊ¾÷ ÁÕòÐÅÁ¨É 
¦À¡ÐÁÕòÐÅò Ð¨È 
ÁÐ§Á¸õ (Å¨¸-2 ¼ÂÀ¢ÊŠ ¦ÁøÄ¢¼Š) §¿¡öì¸¡É º¢ò¾ ÁÕó¾¢ý («ò¾¢ôÀð¨¼Â¡¾¢ ¸º¡Âõ) 
ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ. 
FORM IV B - ¾¸Åø ÀÊÅõ 
IEC NO: NIS/IEC/2011/3/07 
 
Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ¦ÀÂ÷  : Dr. º.§¸¡.¦ºó¾¢ø ÌÁ¡÷ 
 ¿¢ÚÅÉò¾¢ý ¦ÀÂ÷  : §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
                                                  ¾¡õÀÃõ º¡Éð§¼¡Ã¢Âõ 
                                                  ¦ºý¨É- 47 
 
              Dr.º.§¸¡.¦ºó¾¢ø ÌÁ¡÷ ¬ ¢¸Â ¿¡ý §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø Àð¼ §ÁüÀÊôÒ ÀÂ¢ýÚ 
ÅÕ¸¢§Èý. ÁÐ§Á¸õ (Å¨¸-2 ¼ÂÀ¢ÊŠ ¦ÁøÄ¢¼Š) ±ýÛõ ÅÇ÷º¢¨¾Á¡üÈ §¿¡Â¡ÉÐ ¸¨½Âõ 
±ýÛõ ¿¡ÇÁ¢øÄ¡ ÍÃôÀ¢Â¢ý þýÍÄ¢ý ±ýÛõ †¡÷§Á¡ý ÍÃôÀ¢ý ÀÂýÀ¡ðÎò ¾¨¼Â¢ý 
¸¡Ã½Á¡¸§Å¡, þýÍÄ¢ý Ì¨ÈÀ¡ðÊý ¸¡Ã½Á¡¸§Å¡ «øÄÐ þÃñÊý ¸¡Ã½Á¡¸§Å¡ ÌÕ¾¢Â¢ø 
º÷ì¸¨ÃÂ¢ý «Ç¨Å «¾¢¸ôÀÎòÐõ ´Õ §¿¡Â¡Ìõ. þó§¿¡ö «Êì¸Ê º¢Ú¿£Ã¢Æ¢¾ø, «¾¢¸Àº¢, 
«¾¢¾¡¸õ, ¯¼ø §º¡÷×, «º¾¢, ¸¡ø ±Ã¢îºø §À¡ýÈ ÌÈ¢Ì½í¸¨Çò §¾¡üÚÅ¢ìÌõ. þó§¿¡öìÌ 
§¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø ÀÄ º¢ò¾ ÁÕóÐ¸û ÀÂýÀÎò¾ôÀðÎ ÅÕ¸¢ýÈÉ. º¢ò¾ ÁÕòÐÅ 
Àð¼§ÁüÀÊôÀ¢ø, ¬öÅ¢ý ´Õ ÀÌ¾¢Â¡¸ Ò¾¢Â ÁÕóÐ¸¨Ç ÀÂýÀÎòÐõ §¿¡ì¸¢ø 
“«ò¾¢ôÀð¨¼Â¡¾¢ ¸º¡Âõ” ±ýÛõ ÁÕó¾¢¨É þó§¿¡öìÌ ÅÆí¸ ÀÃ¢óÐ¨Ã ¦ºö¸¢§È¡õ. þó¾ 
ÁÕó¾¢ý ¦ºöÓ¨È, «Ç× ÁüÚõ ÁÕòÐÅ ÀÂý¸û «¨ÉòÐõ «í¸£¸Ã¢ì¸ôÀð¼ º¢ò¾ ÁÕòÐÅ 
áÄ¢ø ÜÈôÀðÎûÇÐ. ±ó¾Å¢¾ ¸ð¼½ÓÁ¢ýÈ¢ ¾¡í¸û þó¾ ÁÕó¾¢¨É ¦ÀüÚì¦¸¡ûÇÄ¡õ. þó¾ 
¬öÅ¢ø ÁÕóÐ ¯ð¦¸¡ûÙõ ¸¡Äõ 40 ¿¡ð¸û ¬Ìõ. 10 ¿¡ð¸ÙìÌ ´ÕÓ¨È §¾º¢Â º¢ò¾ 
ÁÕòÐÅÁ¨ÉìÌ §¿Ã¢ø ÅóÐ 10 ¿¡ð¸Ùì¸¡É ÁÕó¾¢¨É ¦ÀüÚì¦¸¡ûÇ §ÅñÎõ. þó¾ ¬ö× 
ºõÀó¾Á¡É ¬öÅ¸ ÀÃ¢§º¡¾¨É¸û ¸ð¼½Á¢ýÈ¢ ¦ºöÂôÀÎõ. 40 ¿¡ð¸û ÁÕóÐ ¯ð¦¸¡ûÙõ 
¸¡Äõ ÓÊó¾ À¢ÈÌ §¿¡öì¸¡É ÌÈ¢Ì½í¸û ÁüÚõ ¬öÅ¸ ÀÃ¢§º¡¾¨É¸û þÅüÈ¢ý ÓÊ×¸Ç¢ý 
«ÊôÀ¨¼Â¢ø ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò¾¢Èý ¸ñ¼È¢ÂôÀÎõ.  
        
þó¾ ¬ö× ºõÀó¾Á¡¸ º¢Ä §¸ûÅ¢¸¨Ç ¾í¸Ç¢¼õ §¸ð¸ þÕì ¢¸§Èý. ¾í¸Ç¢¼Á¢ÕóÐ ¦ÀÈôÀÎõ 
¸ÕòÐì¸û ÁüÚõ ÌÈ¢ôÒ¸û «¨ÉòÐõ ¿õÀ¢ì¨¸Â¡¸ À¾¢× ¦ºöÂôÀÎõ. þó¾ ¬öÅ¢ø ¾í¸¨Ç 
¯ðÀÎò¾¢ì¦¸¡ûÅ¾¢ý ãÄõ ±ó¾ Å¨¸Â¢Öõ À¡¾¢ôÒìÌûÇ¡¸ Á¡ðË÷¸û ±É ¯Ú¾¢ «Ç¢ì¸¢§Èý. 
        
±ó¾Å¢¾ ÅüÒÚò¾ÖÁ¢ýÈ¢, þó¾ ¬öÅ¢ø Àí§¸ü¸×õ, þó¾ ¬ö× ºõÀó¾Á¡¸ §¸ð¸ôÀÎõ 
§¸ûÅ¢¸ÙìÌ À¾¢ø ÜÈ×õ ¾í¸ÙìÌ ÓØ Í¾ó¾¢Ãõ «Ç¢ì¸ôÀÎ¸¢ÈÐ. þó¾ ¬öÅ¢ø Àí§¸üÀ¾üÌ 
±ó¾ ºýÁ¡ÉÓõ ÅÆí¸ôÀ¼Á¡ð¼¡Ð.  ¬É¡ø, ¬ö× ÓØÅÐõ ±ÉÐ §ÁüÀ¡÷¨ÅÂ¢Öõ, ¾í¸û 
¯¼ø¿Äý ÌÈ¢ò¾ ¾É¢ ¸ÅÉò¾¢Öõ §Áü¦¸¡ûÇôÀÎõ. ÁÐ§Á¸õ §¿¡öì¸¡É Ò¾¢Â ÁÕó¾¢ý 
ÀÃ¢¸Ã¢ôÒò¾¢È¨É ºã¸ò¾¢üÌ ¯½÷òÐõ Å¨¸Â¢ø þó¾ ¬ö× §Áü¦¸¡ûÇôÀÎ¸¢ÈÐ. þó¾ 
¬öÅ¢¨Éò ¦¾¡¼Ã ¾í¸ÙìÌ Å¢ÕôÀõ þø¨Ä¦ÂÉ¢ø, ±ô¦À¡ØÐ §ÅñÎÁ¡ÉÖõ ¬öÅ¢ý 
þ¨¼Â¢ø Å¢Ä¸¢ì¦¸¡ûÇ×õ, ÁÕòÐÅÁ¨ÉÂ¢ø ÅÆí¸ôÀÎõ þó§¿¡öì¸¡É ÅÆì¸Á¡É ÁÕóÐ¸¨Ç 
¦ÀüÚì¦¸¡ûÇ×õ «È¢×Úò¾ôÀÎ ¢¸È£÷¸û. 
        
þó¾ ¬öÅ¢ø §º¸Ã¢ì¸ôÀÎõ Å¢ÀÃí¸û «¨ÉòÐõ ¾í¸ÙìÌõ Ó¾ý¨Á ¬Ã¡öîº¢Â¡ÇÃ¡É ±ÉìÌõ 
þ¨¼Â¢ø þÃ¸º¢ÂÁ¡¸ ¨Åì¸ôÀÎõ. §¸ûÅ¢ À¾¢ø ÅÊÅò¾¢ø ¾í¸Ç¢¼õ §¸ûÅ¢¸û §¸ð¸ôÀÎõ. 
«¨ÉòÐô ÀÊÅí¸Ç¢Öõ ¾í¸Ç¢ý ¦ÀÂ÷ ¾Å¢÷ì¸ôÀðÎ ¬öÅ¡ÇÃ¡ø ¾í¸Ùì¦¸É ¾É¢ì ÌÈ¢Â£Î 
ÅÆí¸ôÀÎõ. «ó¾ì ÌÈ¢Â£Î ¬öÅ¡ÇÕìÌ ÁðÎ§Á ¦¾Ã¢ó¾¾¡¸ þÕìÌõ. ¿£í¸û þó¾ ¬öÅ¢ø 
Àí§¸ü¸ Å¢ÕôÀôÀð¼¡ø, ¾¢ð¼Å¨Ã×ÀÊ §¾÷× ¦ºöÂôÀÎÅ£÷¸û. 
         
¿£í¸û þó¾ ¬öÅ¢ø Àí§¸üÌõ Óý, þó¾ ¬öÅ¢¨Éô ÀüÈ¢Â §ÁÖõ Å¢ÀÃí¸û ¦ÀÈ §ÅñÎ¦ÁÉ 
Å¢ÕôÀôÀð¼¡ø, þó¾ ¬öÅ¢ý Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ÁüÚõ §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨É, Àð¼ 
§ÁüÀÊôÒòÐ¨È Á¡½Å÷ Dr.º.§¸¡.¦ºó¾¢ø ÌÁ¡÷ ¬¸¢Â ±ý¨É 9994172837 ±ýÈ ±ñ½¢ø 
¦¾¡¼÷Ò ¦¸¡ûÇÄ¡õ. §ÁÖõ, ¿£í¸û þó¾ ¬öÅ¢ø, ¯í¸ÇÐ Àí§¸üÒ ÁüÚõ ¯Ã¢¨Á ÀüÈ¢ 
¦¾Ã¢óÐ ¦¸¡ûÇ §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨É, ¾¨ÄÅ÷/¦ºÂüÌØ ¯ÚôÀ¢É÷ «Å÷¸¨ÇÔõ  
91-44-22411611 ±ýÈ ±ñ½¢ø ¦¾¡¼÷Ò ¦¸¡ûÇÄ¡õ. 
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OBSERVATION OF CLINICAL LABORATORY EXAMINATIONS 
At the time of admission to the trial, in all the 40 patients the following parameters 
observed, 
Haematology 
· Hb (gms%) 
· Total WBC Count(cells/cumm) 
· DC 
Ø Polymorphs(%) 
Ø Lymphocytes (%) 
Ø Eosinophils (%) 
Ø Monocytes (%) 
Ø Basophils (%) 
· Total RBC count (cells/cu.mm) 
· ESR(mm/hr) 
Renal function test 
· Blood urea (mg/dl) 
· S. Creatinine (mg/dl) 
· Uric acid (mg/dl) 
Lipid profile 
· S. Total cholesterol (mg/dl) 
· HDL (mg/dl) 
· LDL  (mg/dl) 
· VLDL (mg/dl) 
· TGL (mg/dl) 
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Liver function test 
· S. Total bilirubin (mg/dl) 
· S. Direct bilirubin (mg/dl) 
· S. Indirect bilirubin (mg/dl)  
· SGOT (U/dl) 
· SGPT (U/dl) 
· S. Alkaline phosphatase (U/dl)  
· S. Total protein (g/dl) 
· S. Albumin (g/dl) 
· S. Globulin (g/dl) 
Other test 
· S. Calcium (mg/dl) 
· S. Phosphorous (mg/dl) 
Urine examination  
· Neerkuri & Neikuri  
· Albumin  
· Sugar (Fasting & postprandial) 
· Deposits  
Specific investigation 
· OGTT 
Ø Fasting (over night fast) 
Ø 2 Hours after glucose load
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Before treatment- Haematology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.No 
OP/IP 
No 
Age/ 
Sex 
B.Sugar mg/dl Hb 
gms% 
TC 
cu/m
m 
DC-% 
ESR 
mm/hr 
T.RBC
million 
FA PP P L E M 1/2 1 
1. C79506 52/F 135 210 13.6 7400 61 34 03 - 6 12 3.1 
2. C93762 48/F 140 235 14.6 8300 55 40 05 - 10 20 3.4 
3. C29305 50/F 160 230 15.5 7900 55 40 03 - 08 16 3.2 
4. C98043 40/F 138 210 13.5 6600 62 34 04 - 2 4 5.2 
5. C28386 50/F 131 212 13.3 7200 67 28 05 - 4 8 4.2 
6. C41076 44/F 176 278 12.9 6300 49 45 06 - 4 12 4.2 
7. C61757 45/F 131 266 12 7300 56 39 05 - 08 16 3.1 
8. 4244 45/F 126 219 13.3 10000 74 20 06 - 22 62 4.4 
9. 4151 55/F 142 272 12.5 9500 54 41 05 - 28 60 3.9 
10. 4182 53/F 156 252 11.6 7300 70 26 04 - 2 50 4.2 
11. 4210 40/F 127 226 13.3 6900 62 36 02 - 08 15 4.2 
12. 4203 55/F 127 210 10.0 7700 67 30 03 - 28 76 3.4 
13. 4129 48/F 138 261 13.7 6700 60 37 03 - 10 26 4.7 
14. 4236 55/F 134 300 11.3 10200 68 29 03 - 12 30 3.9 
15. C77100 50/M 136 239 14.9 4300 60 34 06 - 12 26 4.9 
16. C93323 40/M 136 254 14.5 6200 58 37 05 - 2 4 5.0 
17. C77872 33/M 117 257 14.8 8800 71 23 06 - 6 14 4.9 
18. C76014 43/M 157 245 14 5500 66 30 04 - 2 4 5.1 
19. C73821 43/M 124 200 16.8 7400 53 44 03 - 8 16 5.6 
20. C77322 53/M 134 236 15.5 7300 55 40 05 - 4 10 4.8 
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Before treatment- Haematology 
S.No 
OP/IP 
No 
Age/ 
Sex 
B.Sugar mg/dl Hb 
gms% 
TC 
cu/m
m 
DC-% 
ESR 
mm/hr T.RBC
million 
FA PP P L E M 1/2 1 
21 C84379 40/M 173 265   14.9                                                                                                                             7700 58 41 01 - 4 8 5.0
22. C75253 36/M 128 237 15.4 7800 53 39 08 - 4 8 5.5 
23. B95665 42/M 145 213 11.0 8000 66 32 04 - 04 08 4.8 
24. C92670 46/M 160 270 10.7 8200 52 44 03 01 20 40 3.5 
25. C99837 41/M 128 268 17.2 5900 69 25 05 - 2 4 5.6 
26 4272 54/F 138 233 9.3 10100 73 22 05 - 6 20 3.5 
27. C81031 53/M 172 260 18 6400 48 45 07 - 2 4 5.8 
28. C92864 38/M 162 258 15 7300 68 27 05 - 4 20 5 
29. C42893 43/M 131 278 13.5 6100 50 44 06 - 2 6 4.4 
30 C85416 42/M 160 220 15.3 5500 60 36 04 - 2 4 5.1 
31. C89234 50/M 159 298 16.1 7500 60 35 03 02 4 8 5.3 
32. 4125 50/F 191 234 13.3 6500 56 39 05 - 2 4 4.5 
33. 4035 52/F 169 239 14.3 8500 64 30 06 - 2 4 4.9 
34. B53440 42/F 168 295 13.6 10800 65 28 05 02 6 14 5.2 
35. C77041 51/M 132 262 14.4 8700 60 34 05 - 2 4 4.3 
36. C91330 53/M 148 300 14.5 6800 47 48 05 - 2 8 4.7 
37. C86489 55/M 146 178 16.7 10300 54 31 15 - 2 8 5.8 
38. B95283 50/M 132 300 15.9 10700 74 23 03 - 6 12 5.1 
39. C78746 42/M 160 290 14.6 7600 59 37 03 - 4 10 5.5 
40. C90731 45/M 180 295 7.5 8000 64 30 05 01 08 16 2.5 
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After treatment- Haematology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.No OP/IP 
No 
Age/ 
Sex 
B.Sugar mg/dl Hb 
gms% 
TC 
cu/m
m 
DC-% ESR 
mm/hr 
T.RBC
million 
FA PP P L E M 1/2 1 
1. C79506 52/F 115 161 12.8 7200 58 32 01 - 05 11 3.0 
2. C93762 48/F 118 170 13.0 8200 54 43 03 - 07 13 3.2 
3. C29305 50/F 125 154 15.0 8300 56 42 03 - 05 12 3.1 
4. C98043 40/F 121 174 13.5 7600 63 38 02 - 09 18 3.3 
5. C28386 50/F 120 196 11.5 7400 64 32 04 - 6 14 4.2 
6. C41076 44/F 121 198 11.5 6300 40 55 05 - 4 8 4.2 
7. C61757 45/F 122 161 12.2 8500 53 45 02 - 8 26 4.4 
8. 4244 45/F 115 170 12.4 8100 53 47 03 - 11 22 3.2 
9. 4151 55/F 126 152 11.8 7300 52 41 01 - 03 06 3.7 
10. 4182 53/F 112 167 13.7 8500 65 36 03 - 04 08 4.1 
11. 4210 40/F 112 123 11.7 7800 66 32 02 - 02 06 4.4 
12. 4203 55/F 122 136 9.2 9300 69 27 04 - 30 72 3.9 
13. 4129 48/F 110 135 12.1 11500 65 30 05 - 2 4 4.7 
14. 4236 55/F 107 211 9.8 7400 64 31 05 - 16 36 3.6 
15. C77100 50/M 126 146 13.4 4500 55 40 05 - 6 14 5.1 
16. C93323 40/M 112 164 11.8 7600 52 45 02 - 06 12 3.2 
17. C77872 33/M 110 190 12.7 11200 80 18 02 - 2 4 4.9 
18. C76014 43/M 120 170 15.1 6700 57 40 03 - 4 8 5.0 
19. C73821 43/M 118 177 15.5 7300 61 33 06 - 10 22 5.3 
20. C77322 53/M 121 177 15.9 7900 58 37 05 - 2 4 4.8 
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After treatment - Haematology 
S.No OP/IP 
No 
Age/ 
Sex 
B.Sugar mg/dl Hb 
gms% 
TC 
cu/m
m 
DC-% ESR 
mm/hr 
T.RBC
million 
FA PP P L E M 1/2 1 
21 C84379 40/M 123 248 15.0 8200 52 45 03 - 2 6 5.1 
22. C15253 36/M 116 207 14.9 8800 53 43 04 - 4 6 5.3 
23. B95665 42/M 122 164 12.6 9000 62 37 05 - 04 08 4.2 
24. C92670 46/M 126 177 10.2 8500 57 41 06 - 10 20 3.8 
25. C99837 41/M 112 187 15.1 5700 62 33 05 - 2 8 5.6 
26 4272 54/F 130 192 11.6 7400 58 37 02 - 08 16 4.2 
27. C81031 53/M 140 211 16.4 5600 60 37 03 - 4 8 5.8 
28. C92864 38/M 139 198 13.9 8200 68 30 02 - 4 8 5.8 
29. C42893 43/M 130 196 14 4600 45 50 05 - 2 4 4.6 
30 C85416 42/M 139 180 15.4 7100 65 29 06 - 4 8 5.2 
31. C89234 50/M 140 182 14.7 7100 59 35 06 - 4 8 4.9 
32. 4125 50/F 185 336 14.8 9200 65 29 05 01 2 8 5.1 
33. 4035 52/F 92 126 12.6 1800 52 44 03 - 06 12 4.1 
34. B53440 42/F 143 225 13.4 9400 64 34 02 - 8 30 5.1 
35. C77041 51/M 154 220 14 8100 57 37 05 - 5 10 4.5 
36. C91330 53/M 148 220 15 7400 46 50 04 - 8 18 4.7 
37. C86489 55/M 156 280 14.6 9900 66 20 14 - 2 4 5.6 
38. B95283 50/M 149 248 15.3 7600 61 36 03 - 2 6 4.9 
39. C78746 42/M 252 300 13.2 9200 61 32 04 01 08 16 4.2 
40. C90731 45/M 147 191 9.8 8200 53 30 04 - 06 12 3.5 
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Before treatment- Haematology 
S. 
No 
OP/IP 
No 
Age/ 
Sex 
                 Lipid profile                                          Liver Function Test RFT 
T.Ch
o 
Mg/
dl 
HD
L 
Mg
/dl 
LD
L 
Mg/
dl 
VL
DL 
Mg
/dl 
TG
L 
Mg/
dl 
T.
Bm
g/d
l 
D.
Bm
g/d
l 
I.B
mg
/dl 
  
OT 
u/l 
PT 
u/l 
AL
K 
u/l 
T.P 
G
ms
% 
Al
b 
G
ms
% 
Gl
o 
G
ms        
% 
Cal 
Mg
/     
dl 
P 
Mg
/dl 
U.
A 
Mg
/dl 
U 
mg
/dl 
Cr 
Mg
/dl 
1. C79506 52/F 244 45 111 12 60 0.6 0.2 0.4 36 24 236 8.6 4.4 4.2 8.2 3.5 5.0 26 0.6 
2. C93762 48/F 288 50 142 68 342 0.5 0.3 0.2 30 26 216 8.2 4.6 3.6 8.4 3.6 4.9 38 0.6 
3. C29305 50/F 218 45 112 29 148 0.6 0.2 0.4 34 27 195 7.9 4.8 3.1 8.2 3.4 4.7 18 0.8 
4. C98043 40/F 288 50 142 68 342 0.4 0.2 0.2 25 27 142 6.4 3.7 2.8 10 2.9 3.1 16 0.5 
5. C28386 50/F 110 26 68 28 140 0.5 0.2 0.3 29 30 162 7.0 3.0 4.0 10 2.9 4.4 20 0.6 
6. C41076 44/F 206 37 152 44 220 0.4 0.2 0.2 20 22 160 6.4 3.9 2.5 11 3.5 4.6 20 0.7 
7. C61757 45/F 188 31 106 33 165 0.6 0.3 0.3 34 48 235 8.6 4.8 3.8 10 3.0 5.2 18 0.6 
8. 4244 45/F 169 33 77 32 163 0.7 0.3 0.4 12 14 155 6.6 3.7 2.9 10 2.8 4.0 15 0.4 
9. 4151 55/F 197 35 115 50 251 0.5 0.2 0.3 17 19 166 5.0 2.0 3.0 10 2.9 3.7 17 0.5 
10. 4182 53/F 179 36 92 46 234 0.7 0.3 0.4 16 18 163 6.5 4.0 2.5 11 3.1 3.4 20 0.6 
11. 4210 40/F 171 41 112 44 224 0.4 0.2 0.2 33 36 201 7.0 4.0 3.0 10 2.9 5.5 26 0.7 
12.. 4203 55/F 218 45 112 29 148 0.5 0.2 0.3 13 15 176 6.7 3.8 2.9 10 2.7 5.1 27 0.8 
13. 4129 48/F 227 42 107 45 229 0.5 0.2 0.3 20 22 172 6.5 3.2 3.3 10 3.0 3.5 15 0.5 
14. 4236 55/F 246 39 106 32 17 0.8 0.4 0.4 16 18 172 5.5 3.5 2.0 8.3 4.0 3.7 17 0.5 
15. C77100 50/M 212 36 102 41 209 0.6 0.2 0.4 43 44 196 6.0 4.0 2.0 10 3.1 6.9 14 0.4 
16. C93323 40/M 117 31 70 38 193 0.5 0.2 0.3 12 16 151 5 3 2 10 3.2 3.2 19 0.5 
17. C77872 33/M 154 58 92 38 193 0.6 0.2 0.4 23 25 232 7.8 3.2 4.6 11 3.1 4.7 20 0.7 
18. C76014 43/M 230 45 115 63 257 0.6 0.3 0.3 22 18 160 7.2 5.2 2.0 10 3.2 3.4 27 1.2 
19. C73821 43/M 168 39 114 28 54 0.6 0.2 0.4 28 29 178 6.8 4.0 2.8 10 3.2 7.4 15 0.4 
20. C77322 53/M 228 41 123 64 320 0.7 0.3 0.4 38 33 190 8.6 4.6 4.0 9.2 3.8 4.0 22 0.6 
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Before treatment- Haematology 
S. 
No 
OP/IP 
No 
Age/ 
Sex 
                 Lipid profile                                          Liver Function Test RFT 
T.Cho 
Mg/dl 
HDL 
Mg/d
l 
LD
L 
Mg/
dl 
VL
DL 
Mg
/dl 
TG
L 
Mg/
dl 
T.
Bm
g/d
l 
D
B
mg
/dl 
I.B
mg
/dl 
  
OT 
u/l 
PT 
u/l 
AL
K 
u/l 
T.
P 
G
ms
% 
Al
b 
G
ms
% 
Glo 
Gm
s        
% 
Cal 
Mg/     
dl 
P 
Mg/
dl 
U.A 
Mg/
dl 
U 
mg
/dl 
Cr 
Mg
/dl 
21. C84379 40/M 201 34 126 31 158 0.6 0.2 0.4 20 22 160 7.0 4.0 3.0 10 2.9 4.8 27 0.7 
22. C15253 36/M 198 35 150 43 218 0.6 0.2 0.4 30 32 204 6.0 4.0 2.0 10 3.0 3.6 23 0.7 
23. B95665 42/M 213 50 96 37 212 0.8 0.4 0.4 28 21 211 8.4 4.8 3.6 7.8 3.2 5.1 27 0.7 
24. C92670 46/M 189 40 146 60 219 0.6 0.3 0.3 26 19 270 7.4 4.3 3.1 9.2 3.6 4.5 26 0.6 
25. C99837 41/M 163 32 81 37 185 0.8 0.3 0.5 21 25 198 7.0 4.0 3.0 11 3.0 4.3 18 0.5 
26. 4272 54/F 102 22 50 46 234 0.4 0.2 0.2 13 16 190 6.1 3.8 2.3 10 2.7 6.5 45 1.0 
27. C81031 53/M 156 33 79 26 131 0.7 0.3 0.4 16 19 166 6.0 4.0 2.0 10 2.9 3.0 14 0.4 
28. C92864 38/M 146 32 86 24 121 0.7 0.2 0.5 17 19 174 6.5 4.2 2.3 11 3.1 3.3 30 1.0 
29. C42893 43/M 188 34 86 78 393 0.4 0.2 0.2 13 15 165 6.7 4.9 1.8 11 3.6 3.3 25 0.7 
30. C85416 42/M 247 50 135 60 300 0.5 0.2 0.3 22 23 155 7.2 5.2 2.0 10 3.2 8.2 22 0.6 
31. C89234 50/M 195 40 108 52 263 0.6 0.2 0.4 21 22 220 6.6 4.3 2.3 11 3.0 7.5 31 0.8 
32. 4125 50/F 172 35 48 45 225 0.5 0.2 0.3 22 26 188 7.3 4.3 3.0 10. 3.0 6.3 24 0.7 
33. 4035 52/F 171 45 95 31 187 0.5 0.3 0.2 33 42 213 8.9 4.8 4.1 7.6 3.8 5.8 21 0.9 
34. B53440 42/F 243 50 142 51 257 0.5 0.2 0.3 50 78 212 6.9 4.2 2.7 8.7 3.1 6.7 14 0.4 
35. C77041 51/M 149 32 94 23 119 0.7 0.3 0.4 14 15 130 6.6 4.2 2.4 11 3.0 5.1 14 0.5 
36. C91330 53/M 185 36 91 62 311 1.0 0.5 0.5 22 28 204 7.2 5.2 2.0 11 3.7 4.0 27 0.7 
37. C86489 55/M 155 30 89 44 222 0.6 0.2 0.4 24 25 188 7.0 5.0 2.0 10 3.0 6.3 19 0.5 
38. B95283 50/M 244 45 111 12 60 0.7 0.3 0.4 11 12 156 6.8 4.0 2.8 10 2.9 5.3 32 0.9 
39. C78746 42/M 192 23 166 25 125 0.6 0.2 0.4 24 26 238 7.0 4.8 2.2 9.3 3.5 4.9 20 0.6 
40. C90731 45/M 264 41 164 56 227 0.5 0.3 0.2 16 18 212 7.6 4.3 3.3 8.9 3.2 3.1 22 0.7 
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After treatment - Haematology 
S. 
No 
OP/IP 
No 
Age/ 
Sex 
                 Lipid profile                                          Liver Function Test RFT 
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1. C79506 52/F 169 40 98 37 186 0.8 0.6 0.2 36 22 240 8.4 4.2 4.2 8.0 3.2 5.1 26 0.6 
2. C93762 48/F 203 47 118 26 126 0.5 0.2 0.3 34 24 215 8.6 4.6 3.8 8.6 3.4 5.0 30 0.9 
3. C29305 50/F 186 35 100 40 166 0.6 0.3 0.3 28 26 210 8.0 4.8 3.2 8.2 3.2 5.1 20 0.6 
4. C98043 40/F 115 41 74 37 213 0.5 0.3 0.2 34 30 215 8.4 5.0 3.4 8.0 3.6 4.2 26 0.8 
5. C28386 50/F 139 30 70 33 169 0.4 0.2 0.2 16 17 156 6.0 3.7 2.3 10 2.9 4.4 20 0.6 
6. C41076 44/F 203 47 118 26 129 0.4 0.2 0.2 13 16 149 6.1 3.9 2.2 10 3.0 3.0 18 0.6 
7. C61757 45/F 165 40 94 35 175 0.4 0.2 0.2 20 21 182 5.7 2.9 2.8 10 2.9 3.0 26 0.7 
8. 4244 45/F 147 32 78 23 118 0.6 0.3 0.3 26 22 260 8.2 4.8 3.4 9.0 3.4 4.2 26 0.6 
9. 4151 55/F 126 30 88 35 176 0.8 0.4 0.4 32 36 210 8.4 4.6 3.8 8.2 3.4 5.0 20 0.6 
10. 4182 53/F 170 36 113 31 157 1.0 0.5 0.5 26 20 215 8.2 4.2 4.0 9.2 4.2 4.0 22 0.7 
11. 4210 40/F 200 34 120 76 322 0.7 0.3 0.4 20 21 163 6.8 4.0 2.8 10 3.0 5.0 19 0.6 
12.. 4203 55/F 201 44 120 36 166 0.5 0.2 0.3 14 15 151 7.0 4.0 3.0 8.6 2.9 5.4 24 0.8 
13. 4129 48/F 205 40 105 45 170 0.6 0.2 0.4 24 26 210 7.0 4.0 3.0 10 3.3 7.3 26 0.8 
14. 4236 55/F 229 42 108 22 111 0.7 0.3 0.4 22 24 170 5.5 3.5 2.0 10 3.2 4.5 20 0.6 
15. C77100 50/M 179 35 86 36 179 0.6 0.2 0.4 24 26 179 6.0 4.0 2.0 10 3.1 4.1 14 0.4 
16. C93323 40/M 156 31 74 30 122 0.6 0.3 0.3 26 18 210 8.4 4.6 3.8 8.4 3.9 4.7 16 0.8 
17. C77872 33/M 162 33 88 31 158 0.6 0.2 0.4 11 12 141 6.3 4.0 2.3 10 3.0 3.5 24 0.7 
18. C76014 43/M 190 41 98 55 212 0.5 0.2 0.3 22 23 155 7.0 5.0 2.0 10 3.5 4.1 21 1.2 
19. C73821 43/M 153 30 74 12 61 0.6 0.2 0.4 22 24 226 6.4 4.0 2.4 10 3.0 6.0 15 0.5 
20. C77322 53/M 176 31 101 47 236 0.8 0.3 0.5 18 20 145 5.0 3.0 2.0 10 3.1 3.9 22 0.6 
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After treatment - Haematology 
 
S. 
No 
OP/IP No Age/ 
Sex 
                 Lipid profile                                          Liver Function Test RFT 
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21. C84379 40/M 185 38 92 27 138 0.7 0.3 0.4 20 22 160 7.0 4.0 3.0 10 2.9 4.8 27 0.7 
22. C15253 36/M 170 36 113 31 157 0.7 0.3 0.4 20 23 155 5.0 3.0 2.0 10 3.1 5.3 20 0.6 
23. B95665 42/M 115 41 61 30 164 0.6 0.4 0.2 28 21 215 8.4 4.2 4.2 7.6 3.4 5.4 30 0.5 
24. C92670 46/M 164 31 116 39 166 0.6 0.3 0.3 30 26 280 8.6 5.0 3.0 8.3 3.4 5.4 24 0.7 
25. C99837 41/M 147 32 78 23 118 0.6 0.2 0.4 20 22 228 5.4 3.4 2.0 10 3.0 4.5 16 0.4 
26. 4272 54/F 154 30 74 37 129 0.8 0.4 0.4 30 34 250 8.2 4.2 4.0 8.5 3.0 5.1 36 0.6 
27. C81031 53/M 189 36 92 18 90 0.4 0.2 0.2 25 27 176 6.1 4.0 2.1 10 3.1 3.0 14 0.4 
28. C92864 38/M 192 36 100 16 81 0.9 0.3 0.6 20 22 187 5.1 3.0 2.1 10 3.0 5.1 20 0.6 
29. C42893 43/M 176 30 94 41 190 0.5 0.3 0.2 22 38 197 9.0 5.2 3.8 7.9 3.8 5.2 26 0.8 
30. C85416 42/M 180 40 96 37 170 0.6 0.2 0.4 20 21 160 6.4 4.2 2.2 10 3.1 4.1 18 0.5 
31. C89234 50/M 169 40 98 37 186 0.5 0.2 0.3 12 15 177 6.0 4.0 2.0 9.9 2.9 3.8 14 0.4 
32. 4125 50/F 186 35 100 40 203 0.5 0.2 0.3 12 15 137 7.0 5.0 2.0 9.8 2.6 4.3 21 0.6 
33. 4035 52/F 152 46 87 19 157 0.6 0.4 0.2 40 32 310 7.4 3.2 4.2 8.2 3.2 5.2 19 0.6 
34. B53440 42/F 193 40 98 55 279 0.6 0.2 0.4 28 30 315 7.5 4.3 3.2 8.5 3.1 4.8 19 0.7 
35. C77041 51/M 115 30 61 17 85 0.6 0.2 0.4 14 15 226 5.9 3.0 2.9 11 3.0 3.3 14 0.4 
36. C91330 53/M 155 31 75 37 185 0.4 0.2 0.2 12 14 166 7.5 4.8 2.7 11 3.1 3.6 22 0.6 
37. C86489 55/M 160 34 72 33 166 1.5 0.6 0.9 12 13 160 6.4 3.7 2.7 10 3.2 4.3 19 0.6 
38. B95283 50/M 189 33 100 24 121 0.5 0.2 0.3 20 22 167 5.8 3.0 2.8 9.8 2.7 2.9 20 0.6 
39. C78746 42/M 126 30 88 35 176 0.8 0.3 0.5 19 20 172 6.5 3.6 2.9 10 2.9 3.5 14 0.4 
40. C90731 45/M 197 30 111 43 116 0.6 0.3 0.3 26 22 222 7.4 4.6 3.4 9.0 4.6 3.6 18 0.7 
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Before treatment – Urine analysis 
S.NO OP/IP No Age/ 
Sex 
Alb Sugar Deposit Neerkkuri 
 
Neikkuri 
 F PP 
1. C79506 52/F Nil N ++ 1-2Pc,2-4Ec Straw color Slowly spread 
2. C93762 48/F Nil T ++ 1-2Pc,2-4Ec Straw color Slowly spread 
3. C29305 50/F Nil T ++ 2-3Pc,1-2Ec Straw color Slowly spread 
4. C98043 40/F Nil N + 2-4Pc,2-6Ec Straw color Slowly spread 
5. C28386 50/F Nil N + 2-4Pc,4-5Ec Straw color Slowly spread 
6. C41076 44/F Nil N ++ 1-2Pc,2-4Ec Straw color Slowly spread 
7. C61757 45/F Nil N N 1-2Pc,1-3Ec Straw color Slowly spread 
8. 4244 45/F Nil N ++ 4-5Pc,5-6Ec Straw color Slowly spread 
9. 4151 55/F Nil N N 3-5Pc,2-3Ec Straw color Slowly spread 
10. 4182 53/F Nil N + 8-9Pc,6-8Ec Straw color Slowly spread 
11. 4210 40/F Nil N N 2-4Pc,2-4Ec Straw color Fastly spread 
12.. 4203 55/F Nil N N 4-5Pc,4-5Ec Yellowish Slowly spread 
13. 4129 48/F Nil N N 1-3Pc,2-4Ec Straw color Slowly spread 
14. 4236 55/F Nil + ++ 3-5Pc,2-3Ec Straw color Fastly spread 
15. C77100 50/M Nil N + 2-4Pc,1-2Ec Straw color Slowly spread 
16. C93323 40/M Nil N + 2-3Pc,1-5Ec Straw color Slowly spread 
17. C77872 33/M Nil T + 1-2Pc,2-4Ec Straw color Slowly spread 
18. C76014 43/M Nil N + 2-3Pc,1-4Ec Straw color Slowly spread 
19. C73821 43/M Nil N N 1-2Pc,2-3Ec Straw color Slowly spread 
20. C77322 53/M Nil N ++ 4-5Pc,2-4Ec Straw color Slowly spread 
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Before treatment – Urine analysis 
S.NO OP/IP No Age/ 
Sex 
Alb Sugar Deposit Neerkuri 
 
Neikkuri 
F PP 
21. C84379 40/M Nil T ++ 1-4Pc,2-5Ec Straw color Slowly spread 
22. C15253 36/M Nil N T 2-3Pc,4-5Ec Straw color Slowly spread 
23. B95665 42/M Nil N + 4-6Pc,2-4Ec Straw color Fastly spread 
24. C92670 46/M Nil + ++ 2-4Pc,4-5Ec Straw color Slowly spread 
25. C99837 41/M Nil N + 1-5Pc,2-3Ec Straw color Slowly spread 
26. 4272 54/F Nil + ++ 3-6Pc,3-6Ec Straw color Slowly spread 
27. C81031 53/M Nil T + 2-3Pc,2-3Ec Straw color Slowly spread 
28. C92864 38/M Nil N + 1-2Pc,2-3Ec Straw color Slowly spread 
29. C42893 43/M Nil N ++ 2-4Pc,3-5Ec Straw color Fastly spread 
30. C85416 42/M Nil N + 1-2Pc,2-8Ec Straw color Slowly spread 
31. C89234 50/M Nil T + 2-3Pc,1-4Ec Straw color Fastly spread 
32. 4125 50/F Nil + ++ 3-4Pc,1-2Ec Straw color Slowly spread 
33. 4035 52/F Nil N ++ 5-6Pc,4-5Ec Straw color Slowly spread 
34. B53440 42/F Nil N ++ 2-4Pc,1-2Ec Straw color Slowly spread 
35. C77041 51/M Nil N ++ 2-5Pc,4-5Ec Straw color Slowly spread 
36. C91330 53/M Nil N + 4-5Pc,4-5Ec Yellowish Slowly spread 
37. C86489 55/M Nil N + 1-2Pc,2-6Ec Straw color Slowly spread 
38. B95283 50/M Nil N + 2-3Pc,1-2Ec Straw color Slowly spread 
39. C78746 42/M Nil N ++ 2-4Pc,8-9Ec Straw color Slowly spread 
40. C90731 45/M Nil + ++ 1-2Pc,2-4Ec Straw color Slowly spread 
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Afetr treatment – Urine analysis 
S.NO OP/IP No Age/ 
Sex 
Alb Sugar Deposit Neerkuri 
 
Neikkuri 
F PP 
1. C79506 52/F Nil N N 1-2Pc,1-2Ec Straw color Slowly spread 
2. C93762 48/F Nil N + 1-2Pc,1-2Ec Straw color Slowly spread 
3. C29305 50/F Nil N N 2-3Pc,2-4Ec Straw color Slowly spread 
4. C98043 40/F Nil N N 1-2Pc,2-5Ec Straw color Slowly spread 
5. C28386 50/F Nil N + 2-5Pc,4-5Ec Straw color Slowly spread 
6. C41076 44/F Nil N + 1-3Pc,2-4Ec Straw color Slowly spread 
7. C61757 45/F Nil N N 3-4Pc,1-3Ec Straw color Slowly spread 
8. 4244 45/F Nil N N 1-2Pc,2-4Ec Straw color Slowly spread 
9. 4151 55/F Nil N N 3-4Pc,2-5Ec Straw color Slowly spread 
10. 4182 53/F Nil N N 2-5Pc,2-3Ec Straw color Slowly spread 
11. 4210 40/F Nil N N 1-2Pc,2-5Ec Straw color Fastly spread 
12.. 4203 55/F Nil N N 2-4Pc,2-5Ec Straw color Slowly spread 
13. 4129 48/F Nil N N 1-3Pc,2-4Ec Straw color Slowly spread 
14. 4236 55/F Nil N N 1-2Pc,2-4Ec Straw color Fastly spread 
15. C77100 50/M Nil N N 2-3Pc,2-3Ec Straw color Slowly spread 
16. C93323 40/M Nil N N 4-5Pc,1-4Ec Straw color Slowly spread 
17. C77872 33/M Nil N + 4-5Pc,2-6Ec Straw color Slowly spread 
18. C76014 43/M Nil N T 1-4Pc,1-2Ec Straw color Slowly spread 
19. C73821 43/M Nil N N 1-2Pc,2-3Ec Straw color Slowly spread 
20. C77322 53/M Nil N N 4-5Pc,1-5Ec Straw color Slowly spread 
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Afetr treatment – Urine analysis 
S.NO OP/IP No Age/ 
Sex 
Alb Sugar Deposit Neerkuri 
 
Neikkuri 
F PP 
21. C84379 40/M Nil N + 1-4Pc,2-3Ec Straw color Slowly spread 
22. C15253 36/M Nil N + 2-4Pc,1-4Ec Straw color Slowly spread 
23. B95665 42/M Nil N N 3-5Pc,2-4Ec Straw color Slowly spread 
24. C92670 46/M Nil N N 2-4Pc,4-6Ec Straw color Slowly spread 
25. C99837 41/M Nil N + 4-6Pc,4-8Ec Straw color Slowly spread 
26. 4272 54/F Nil N + 2-8Pc,4-6Ec Straw color Slowly spread 
27. C81031 53/M Nil N + 1-2Pc,1-2Ec Straw color Slowly spread 
28. C92864 38/M Nil N + 4-5Pc,4-5Ec Straw color Slowly spread 
29. C42893 43/M Nil N + 2-5Pc,2-3Ec Straw color Slowly spread 
30. C85416 42/M Nil N T 1-2Pc,2-4Ec Straw color Slowly spread 
31. C89234 50/M Nil N T 1-4Pc,4-5Ec Straw color Fastly spread 
32. 4125 50/F Nil N + 2-4Pc,1-2Ec Straw color Slowly spread 
33. 4035 52/F Nil N ++ 5-6Pc,6-9Ec Straw color Slowly spread 
34. B53440 42/F Nil N ++ 3-5Pc,1-2Ec Straw color Fastly spread 
35. C77041 51/M Nil N ++ 2-5Pc,1-2Ec Straw color Slowly spread 
36. C91330 53/M Nil N ++ 2-4Pc,4-5Ec Straw color Slowly spread 
37. C86489 55/M Nil N ++ 1-4Pc,2-6Ec Straw color Slowly spread 
38. B95283 50/M Nil N ++ 2-5Pc,1-2Ec Straw color Slowly spread 
39. C78746 42/M Nil + ++ 1-2Pc,1-2Ec Straw color Slowly spread 
40. C90731 45/M Nil T ++ 2-4Pc,2-4Ec Straw color Slowly spread 
 




